

# CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "HONG KONG STOCK EXCHANGE")

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Hong Kong Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given that the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Hong Kong Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Hong Kong Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors (the "Directors") of Grand Brilliance Group Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "We") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Hong Kong Stock Exchange (the "GEM Listing Rules") for the purpose of giving information with regard to the Group. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this report is accurate and complete in all material respects and not misleading and deceptive; (2) there are no other matters the omission of which would make any statement in this report misleading; and (3) all opinions expressed in this report have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

# CONTENTS

Corporate Information	3
Chairman's Statement	4
Management Discussion and Analysis	5
Biographical Details of Directors and Senior Management	11
Corporate Governance Report	15
Environmental, Social and Governance Report	27
Directors' Report	55
Independent Auditor's Report	65
Consolidated Statement of Comprehensive Income	69
Consolidated Statement of Financial Position	70
Consolidated Statement of Changes in Equity	71
Consolidated Statement of Cash Flows	72
Notes to the Consolidated Financial Statements	73
Financial Summary	120

# **CORPORATE INFORMATION**

#### **BOARD OF DIRECTORS**

#### **Executive Director**

Ms. Wong Bik Kwan Bikie (Chairman and Chief Executive Officer)

#### **Non-executive Directors**

Dr. Miu Yin Shun Andrew

Mr. Chiu Man Wai

#### **Independent non-executive Directors**

Mr. Ng Leung Sing SBS, JP Mr. Wong Lung Wo James

Mr. Chow Ming Po Aaron (appointed on 21 June 2021)

Mr. Chan Ping Keung (retired on 17 September 2021)

#### **AUDIT COMMITTEE**

Mr. Wong Lung Wo James (Chairman)

Mr. Chow Ming Po Aaron (appointed on 21 June 2021)

Dr. Miu Yin Shun Andrew Mr. Chan Ping Keung

(ceased to act on 17 September 2021)

#### REMUNERATION COMMITTEE

Mr. Chow Ming Po Aaron (Chairman)
(appointed as member on 21 June 2021 and redesignated as Chairman on 17 September 2021)

Mr. Wong Lung Wo James Ms. Wong Bik Kwan Bikie

Mr. Chan Ping Keung (ceased to act as Chairman on 17 September 2021)

#### NOMINATION COMMITTEE

Mr. Ng Leung Sing SBS, JP (Chairman)

Mr. Chow Ming Po Aaron (appointed on 21 June 2021)

Mr. Chiu Man Wai

Mr. Chan Ping Keung (ceased to act on 17 September 2021)

#### **COMPANY SECRETARY**

Ms. Lee Ka Man

#### **AUTHORISED REPRESENTATIVES**

Ms. Wong Bik Kwan Bikie Ms. Lee Ka Man

#### **COMPLIANCE OFFICER**

Ms. Wong Bik Kwan Bikie

#### **AUDITOR**

BDO Limited

Certified Public Accountants

#### **REGISTERED OFFICE**

Cricket Square

**Hutchins Drive** 

P.O. Box 2681

Grand Cayman, KY1-1111

Cayman Islands

# PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Units 2901-2903 and 2905

29/F, The Octagon

6 Sha Tsui Road

Tsuen Wan

**New Territories** 

Hong Kong

# PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Conyers Trust Company (Cayman) Limited

Cricket Square

**Hutchins Drive** 

P.O. Box 2681

Grand Cayman, KY1-1111

Cayman Islands

# HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Tricor Investor Services Limited

Level 54, Hopewell Centre

183 Queen's Road East

Hong Kong

#### PRINCIPAL BANKER

Bank of China (Hong Kong) Limited

#### **STOCK CODE**

8372

#### **COMPANY WEBSITE**

www.grandbrilliancegroup.com

# **CHAIRMAN'S STATEMENT**

Dear Shareholders,

On behalf of the board (the "Board") of Directors of the Group, I am pleased to present this annual report of the Group for the year ended 31 March 2022.

The global market is full of challenges in the Coronavirus Disease 2019 ("COVID-19") outbreak, As challenges bring opportunities, we strived harder to prepare ourselves and actively leverage our strength to diversify product portfolio, broaden customer base and introduce technology advance.

We continue to be optimistic on the outlook of the medical and healthcare industry, attributable to the increase of aging population and rising healthcare awareness of the public in Hong Kong together with our automation solution to eliminate the medical manpower shortage crisis in Hong Kong. The Group is looking for suitable investment opportunities to diversify business and bring better investment return to the shareholders of the Company.

Last but not least, I wish to take this opportunity to express my sincere thanks to our customers, staff, business partners and shareholders for their unremitting confidence in and support for the Group. I would also like to extend by heartfelt appreciation to the Board for their efforts and contributions to the Group's expeditious business growth.

Wong Bik Kwan Bikie

Chairman and Chief Executive Officer

Hong Kong, 17 June 2022

We are an established medical device distributor and one-stop medical device solutions provider with over 20 years of experience in the medical device market in Hong Kong.

#### **BUSINESS REVIEW**

For the year ended 31 March 2022, the Group continued to implement our business strategy to solidify our position as a major medical device distributor in Hong Kong. We have recruited talented personnel in various business units in order to support and sustain the growth of our business and expand our business. The Group achieved its business growth through diversifying the product portfolio.

During the year ended 31 March 2022, Hong Kong's economy was significantly affected by the COVID-19 outbreak, the number of visitor to Hong Kong had greatly reduced. The spending plans of our customers have been disrupted or postponed by the outbreak of COVID-19. The above raise challenges on our customers' business. The Group will further expand the product portfolio and enhance the customer services to enhance our one-stop medical device solutions services.

#### **FINANCIAL REVIEW**

#### Revenue

The Group's revenue increased by approximately 2.5%, from approximately HK\$70.2 million for the year ended 31 March 2021 to approximately HK\$72.0 million for the year ended 31 March 2022. The increase was primarily attributable to the increase in revenue generated from medical consumables, resulting from increase in sales of medical glove and biopsy needles.

#### Gross profit and gross profit margin

The Group recorded gross profit of approximately HK\$36.3 million for the year ended 31 March 2022, representing an increase by approximately HK\$2.7 million or 8.1%, as compared to approximately HK\$33.6 million for the year ended 31 March 2021. Gross profit margin increased from approximately 47.9% for the year ended 31 March 2021 to approximately 50.5% for the year ended 31 March 2022. The increase in gross profit margin was mainly due to the increase in sales of medical consumables, which had a comparatively higher gross profit margin.

#### Administrative and other operating expenses

Administrative and other operating expenses mainly included auditor's remuneration, advertising and marketing expenses, depreciation, Directors' remuneration, legal and professional fee, rent, rates and management fee for office and warehouses, recruitment costs, staff costs, travelling and entertainment expenses and other miscellaneous expenses.

Administrative and other operating expenses for the year ended 31 March 2022 amounted to approximately HK\$29.2 million, representing an increase by approximately HK\$3.8 million or 15.2%, as compared to approximately HK\$25.4 million for the year ended 31 March 2021. The increase was primarily attributable to the increase of workforce of the Group for the year ended 31 March 2022.

#### **Income tax expenses**

Income tax expenses for the year ended 31 March 2022 amounted to approximately HK\$1.4 million (2021: approximately HK\$1.5 million).

#### Profit for the year

The Group's profit decreased by approximately HK\$3.9 million from approximately HK\$7.9 million for the year ended 31 March 2021 to approximately HK\$4.0 million for the year ended 31 March 2022. The decrease was primarily attribute to (i) increase of workforce and related staff costs during the year; and (ii) one-off employment support scheme government grant for the year ended 31 March 2021.

#### **DIVIDEND**

The Board has declared the payment of an interim dividend of HK0.3 cent (2021: HK0.45 cent) per ordinary share in lieu of final dividend for the year ended 31 March 2022. It is expected that the interim dividend will be paid on or before Monday, 15 August 2022 to the shareholders of the Company whose name appear on the register of members on Friday, 8 July 2022.

#### LIQUIDITY AND FINANCIAL RESOURCES

#### Liquidity

As at 31 March 2022, current assets amounted to approximately HK\$97.4 million (2021: approximately HK\$101.8 million). Current liabilities were approximately HK\$14.7 million (2021: approximately HK\$17.5 million).

#### **Financial Resources**

As at 31 March 2022, the Group had total cash and bank balances of approximately HK\$55.3 million (2021: approximately HK\$70.2 million).

As at 31 March 2022, the Group had trade receivables of approximately HK\$17.3 million (2021: approximately HK\$7.7 million).

#### **Gearing Ratio**

The gearing ratio of the Group as at 31 March 2022 was nil (2021: nil) as the Group had no material debt financing.

#### **CAPITAL STRUCTURE**

There has been no change in the capital structure of the Company since the listing. The share capital of the Group only comprises of ordinary shares.

As at 31 March 2022, the Company's issued share capital was HK\$8,000,000 and the number of issued ordinary shares was 800,000,000 of HK\$0.01 each. Details of the Group's share capital are set out in note 26 to the consolidated financial statements in this annual report.

#### COMMITMENTS

As at 31 March 2022, the Group did not have any significant capital commitments (2021: nil).

#### **SEGMENT INFORMATION**

Segment information is disclosed in note 6 to the consolidated financial statements.

#### FUTURE PLANS FOR MATERIAL INVESTMENTS AND CAPITAL ASSETS

Save as disclosed in the prospectus of the Company dated 19 March 2018 (the "Prospectus") and as set out in the announcement of the Company dated 24 November 2021, the Group did not have other plans for material investments and capital assets.

# MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES AND AFFILIATED COMPANIES

The Group did not have any material acquisitions or disposals of subsidiaries and affiliated companies during the year ended 31 March 2022.

#### SIGNIFICANT INVESTMENTS

As at 31 March 2022, there was no significant investment held by the Group (2021: nil).

#### **CONTINGENT LIABILITIES**

As at 31 March 2022, the Group had no material contingent liabilities (2021: nil).

#### FOREIGN EXCHANGE EXPOSURE

The Group operates in Hong Kong with certain business transactions being settled in HK\$, United States dollars ("US\$") or Euro. As HK\$ is pegged to US\$, the Directors do not expect any significant movement in the US\$/HK\$ exchange rate. The Group monitors its foreign currency exposure closely and will consider undertake foreign exchange hedging activities to reduce the impact of foreign exchange rate movements on the Group's operating result.

#### **CHARGE OF GROUP'S ASSETS**

No pledged bank deposits was placed in bank to secure the banking facilities of the Group as at 31 March 2022 and 2021.

#### **EMPLOYEES AND REMUNERATION POLICIES**

As at 31 March 2022, the Group has a total of 41 employees (2021: 34 employees). Staff costs, including Directors' remuneration, of the Group were approximately HK\$18.2 million for the year ended 31 March 2022 (2021: approximately HK\$15.6 million). Remuneration is determined with reference to factors such as comparable market salaries and work performance, qualification and experience of individual employees. In addition to a basic salary, year-end discretionary bonuses are offered to employees with outstanding performance to attract and retain eligible employees to contribute to the Group.

# **COMPARISON OF BUSINESS STRATEGIES AND ACTUAL BUSINESS PROGRESS**

The following is a comparison of the Group's business plan as set out in the Prospectus with actual business progress up to 31 March 2022.

Business objectives as stated in the Prospectus	Actual business progress up to 31 March 2022
Further penetrate the medical device market and enhance the market share	The Group has been participating in various local and international trade shows, exhibitions including Hospital Authority Convention, Hong Kong International Medical and Healthcare Fair and Pediatric Society Annual Scientific Meeting.
	The Group has re-designed and enhanced our website to include an e-commerce platform to serve our retail customers online.
	The Group has purchased samples of medical devices for display in our showroom for our customers' inspection before ordering.
Expand the workforce	The Group has recruited and retained seven product representatives, two engineers, one warehouse staff, two R&D staff, one administration staff, two marketing staff and one accounting staff.
Selectively pursue opportunities for strategic acquisitions	The Group is in the process of identifying potential acquisition target with prudence.
Enhance the research and development and product development effort	The Group has recruited two software engineer to strengthen our product research and development capability and researching certain medical and healthcare automation solutions.
	The Group has purchased some new hardware and software for research and development purpose.
Upgrade the information technology systems	The Group has purchased some new hardware and software and engaged an independent consultant to implement an enterprise resources planning system and upgrade the information technology infrastructure.
Maximise the warehouse space, establish the showroom and upgrade the functionality of office space	The Group has established a new showroom and installed racks to fully utilise the vertical space of our warehouses.

#### **USE OF PROCEEDS**

The actual net proceeds from the Share Offer, after deducting the listing-related expenses, were approximately HK\$31.2 million, compared to the estimated net proceeds of approximately HK\$33.1 million as disclosed in the Prospectus. The difference of HK\$1.9 million between the actual and estimated amount of the net proceeds has been adjusted in the same manner as stated in the Prospectus.

As set out in the announcement of the Company dated 24 November 2021 ("the announcement"), the Board resolved to change in the use of unutilised Net Proceeds as of 24 November 2021.

As at 31 March 2022, the net proceeds had been applied and utilised as follows:

Intended use of proceeds	Actual net proceeds from the Share Offer HK\$ million	Utilised proceeds as at 31 March 2021	Unutilised proceeds as at 31 March 2021 HK\$ million	Utilised proceeds from 1 April 2021 to 24 November 2021 HK\$ million	Unutilised proceeds as at 24 November 2021	Change in use of unutilised net proceeds after 24 November 2021	Utilised proceeds from 25 November 2021 to 31 March 2022 HK\$ million	31 March	Expected timeline of full utilisation of the balance
Further penetrate the medical device market and enhance the market share	6.1	0.6	5.5	0.5	5.0	(5.0)	-	-	N/A
Expand the workforce	9.7	9.7	-	-	-	-	-	-	N/A
Selectively pursue opportunities for strategic acquisitions	7.7	-	7.7	-	7.7	(7.7)	-	-	N/A
Enhance the research and development and product development effort	1.3	0.1	1.2	-	1.2	(1.2)	-	-	N/A
Upgrade the information technology systems	2.5	0.4	2.1	0.5	1.6	(1.6)	-	_	N/A
Maximise the warehouse space, establish the showroom and upgrade the functionality of office space	2.1	0.4	1.7	0.4	1.3	(1.3)	-	-	N/A
General working capital	1.8	1.8	-	_	-	6.0	1.5	4.5	By end of 30 June 2024
Develop own brand autonomous mobile robot solution to reduce the medical manpower shortage	-	-	-	-	-	8.0	1.0	7.0	By end of 30 June 2024
The Subscription and formation of the joint venture in the JV Company	_	-	-	-	-	2.8	2.8	-	N/A
	31.2	13.0	18.2	1.4	16.8	-	5.3	11.5	

The business objectives, future plans and planned use of proceeds as stated in the Prospectus and the announcement were based on the best estimation and assumption of the future market conditions made by the Group at the time of preparing the Prospectus, while the proceeds were applied based on the actual development of the Group's business and the market.

The discrepancy between the planned use of the net proceeds and the actual use mainly arose as a result of the actual market conditions affecting the Group after the listing. The continuing trade conflict between the U.S. and the PRC, the PRC's gradual economic slowdown and the recent outbreak of coronavirus (COVID-19) epidemic have presented the Group with uncertainties and multiple challenges, rendering the need for the Group to be prudent in implementing its future plans as set out in the Prospectus and the announcement.

The Group intends to apply the net proceeds in the manner as stated in the Prospectus and the announcement. However, the Directors will constantly evaluate the Group's business objectives and may change or modify plans against the changing market condition to attain sustainable business growth of the Group.

The unused net proceeds have been deposited in licensed banks in Hong Kong.

#### **EXECUTIVE DIRECTOR**

Ms. Wong Bik Kwan Bikie (黃碧君女士) ("Ms. Wong"), aged 53, is the Chairman, chief executive officer ("CEO") and executive Director. Ms. Wong is also a member of the Remuneration Committee and compliance officer of the Company. Ms. Wong founded the Group in November 1997. Ms. Wong was appointed as the Director on 5 July 2017 and was redesignated as the executive Director on 18 September 2017 and appointed as the Chairman and the CEO on 1 March 2018. Ms. Wong also serves as a director of all of the subsidiaries of the Company. Ms. Wong is responsible for overseeing management and strategic planning and development of the Group's business operations. Ms. Wong is the spouse of Dr. Miu Yin Shun Andrew, the non-executive Director.

Ms. Wong has over 28 years of experience in the medical device industry in Hong Kong. She obtained a Diploma in General Nursing from The Hong Kong Hospital Services Department School of General Nursing in July 1990. She subsequently obtained a degree of Master of Business Administration in September 1999 from the University of South Australia.

Ms. Wong was bestowed with the "GBA Outstanding Women Entrepreneur Awards 2018" by the Hong Kong Small and Medium Enterprises Association and Metro Finance in December 2018, "Junzi Corporation Award" by The Hang Seng University of Hong Kong in October 2019 and was granted the "Chinese Role Model • 2019 Outstanding Women" by the Central Newsreel & Documentary Film Studio of China Central Television.

#### NON-EXECUTIVE DIRECTORS

**Dr. Miu Yin Shun Andrew (苗延舜醫生) ("Dr. Miu")**, aged 55, was appointed as the non-executive Director on 18 September 2017. He is also a member of the Audit Committee. Dr. Miu is responsible for providing consultation on technical information on medical devices.

Dr. Miu obtained a degree of Bachelor of Medicine and Bachelor of Surgery from the Chinese University of Hong Kong in December 1990. He was awarded a fellowship by the Royal College of Surgeons of Edinburgh in July 1995, a fellowship in orthopaedic surgery by the Royal College of the Surgeons of Edinburgh in February 2000, a fellowship by the Hong Kong College of Orthopaedic Surgeons in March 2000, a fellowship in orthopaedic surgery by the Hong Kong Academy of Medicine (in orthopaedics) in May 2000, a first fellowship in rehabilitation of the Hong Kong College of Orthopaedic Surgeons in October 2004. He then obtained a degree of Master of Science in Sports Medicine and Health Science from the Chinese University of Hong Kong in November 2015.

Dr. Miu has extensive experience of over 30 years in the medical industry. He is the spouse of Ms. Wong. Dr. Miu has been practising as an orthopaedic specialist in Elite Clinic Limited since November 2011.

Mr. Chiu Man Wai (趙文煒先生) ("Mr. Chiu"), aged 53, was appointed as the non-executive Director on 18 September 2017. He is also a member of the Nomination Committee. Mr. Chiu is responsible for advising on matters relating to investors' relations to the Group.

Mr. Chiu obtained a degree of Bachelor of Arts in Mathematics from Oxford University in June 1990. He also obtained a degree of Master of Science in Mathematical Modelling and Numerical Analysis from Oxford University in October 1991.

Mr. Chiu has extensive experience of over 27 years in the financial industry. Prior to joining the Group, Mr. Chiu was an investment analyst of the research department of Worldsec International Limited from March 1993 to April 1996 and served as a director of the research department of BNP Paribas Equities Hong Kong Limited from April 1996 to March 2004.

Moreover, Mr. Chiu has served as a director of Abridge Enterprises Company Limited since April 2007, which is mainly engaged in the provision of financial and investment services. He has also been a director of Technic Investment Company Limited since February 2004, a company whose principal business is investment. In addition, he has been a director of United Builders Insurance Company Limited since May 1996, a company whose principal business is insurance advisory services.

#### INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Ng Leung Sing sas, JP (吳亮星先生) ("Mr. Ng"), aged 72, was appointed as the independent non-executive Director on 1 March 2018. He is also the chairman of the Nomination Committee.

Mr. Ng has served as a director in Bank of China (Hong Kong) Trustees Limited since August 2009, an organisation whose principal business is in the provision of trust services. He has also served as a director in Hong Kong Mortgage Corporation Limited from April 2014 to April 2018. He is also an independent non-executive director of SmarTone Telecommunications Holdings Limited (stock code: 315), Nine Dragons Paper (Holdings) Limited (stock code: 2689) and Hanhua Financial Holding Company Limited (stock code: 3903), all of which the shares are listed on the Hong Kong Stock Exchange.

In addition, he has served as a Hong Kong deputy to the 10th, 11th, 12th and 13th National People's Congress of the People's Republic of China ("PRC") since March 2003. He was previously a member of the Legislative Council of Hong Kong from 1998 to 2004 and 2012 to 2016, and a member of the Provisional Legislative Council of Hong Kong from 1996 to 1998. Moreover, he held the position of the trustee in the Hong Kong Government Land Fund from 1988 to 1997. He served as a Chinese representative in Sino-British Land Commission from 1988 to 1997. Mr. Ng obtained a Diploma in Chinese Law from the University of East Asia, Macau (currently known as the University of Macau) in May 1987.

Mr. Wong Lung Wo James (黃龍和先生) ("Mr. Wong"), aged 67, was appointed as the independent non-executive Director on 1 March 2018. He is also the chairman of the Audit Committee and a member of the Remuneration Committee.

Mr. Wong obtained a Higher Diploma in Accountancy from the Hong Kong Polytechnic (currently known as the Hong Kong Polytechnic University) in October 1977. Mr. Wong is currently a member of the Hong Kong Institute of Certified Public Accountants and The Association of Chartered Certified Accountants and a fellow of The Hong Kong Chartered Governance Institute (former known as Hong Kong Institute of Chartered Secretaries). He was admitted an associate of The Association of Certified Accountants in May 1980, The Hong Kong Society of Accountants in January 1982, The Taxation Institute of Hong Kong in June 1982 and a fellow of the Chartered Association of Certified Accountants in May 1985. Mr. Wong was also admitted an associate of The Institute of Chartered Secretaries and Administrators in September 1980 and was subsequently elected its fellow in October 2013.

From June 1980 to November 2005, Mr. Wong has served as various roles in HSBC Holdings plc (stock code: 005), of which the share is listed on the Hong Kong Stock Exchange, for credit, syndications, project finance, securities custody, corporate banking and branches management. Mr. Wong worked in Computershare Hong Kong Investor Services Limited ("Computershare Hong Kong") from December 2005 to December 2017 with his last position as chief executive officer Asia. He has been appointed as a senior executive advisor by Computershare Hong Kong from January 2018 to June 2018. Computershare Hong Kong is currently a subsidiary of Computershare Limited (stock code: CPU) which is listed on the Australian Securities Exchange Limited and whose principal business is in the provision of registry service, employee share plan managers, shareholder identification and proxy solicitation solutions, governance services and global solutions.

Mr. Chow Ming Po Aaron (周明寶先生) ("Mr. Chow"), aged 49, was appointed as an independent non-executive Director on 21 June 2021. He is also the chairman of the Remuneration Committee, a member of the Audit Committee and Nomination Committee.

Mr. Chow is a practicing solicitor in Hong Kong. Mr. Chow obtained his Bachelor of Laws degree and Postgraduate Certificate in Laws from the University of Hong Kong respectively in 1995 and 1996. Mr. Chow was admitted as a solicitor of the High Court of Hong Kong in 1998. Mr. Chow is one of the founders of Hau V. & Chow, a firm of solicitors in Hong Kong, and has been a partner of the firm since 2006. Mr. Chow currently serves as the legal adviser for the Hong Kong Pui Ching Alumni Association Limited and an honorary legal adviser for the Hong Kong Chinese Civil Servants' Association.

#### SENIOR MANAGEMENT

Ms. Ho Hoi Yin (何海燕小姐) ("Ms. Ho"), aged 41, General Manager of the Group. Ms. Ho joined the Group in March 2020 as Sales Manager and responsible to lead a consumables sales team to achieve the company targets. In 2021, Ms. Ho became general manager of Group and responsible for overseeing the daily sales operation with her direct subordinates in sales and operations teams. She is also responsible for developing sales strategies, data analysis, sales forecasting, hiring, training, and troubleshooting day to day issues. Ms. Ho obtained her Bachelor of Commerce in Marketing and Advertising from the Curtin University of Technology. Prior to joining the Group, Ms. Ho has over 10 years' work experience in medical device industry. She worked as a Product Manager at Synapse Therapeutics Limited from 2011 to 2018.

Mr. Cheung Chong Chi (張創智先生) ("Mr. Cheung"), aged 44, Financial Controller of the Group. Mr. Cheung joined the Group on 12 August 2019. He is primarily responsible for overseeing accounting, financial management, company secretarial and internal control matters of the Group.

Mr. Cheung graduated from the Chinese University of Hong Kong with a Degree of Bachelor of Business Administration in May 1999. He is a fellow member of the Hong Kong Institute of Certified Public Accountants and a fellow member of The Association of Chartered Certified Accountants.

Mr. Lee Chun Sing (李春成先生) ("Mr. Lee"), aged 52, is the business development manager of the Group. Mr. Lee joined the Group as a business operation manager in January 1998 and is primarily responsible for the overall management of business development and formulation of business strategies. Mr. Lee obtained a Victorian Certificate of Education from the Victorian Curriculum and Assessment Board in January 1990. He has over 23 years of working experience in the medical equipment industry. Prior to joining the Group, Mr. Lee worked as an electrical engineer in Shell Electric Manufacturing (Holdings) Company Limited (a company listed on the Main Board (stock code: 81), currently known as China Overseas Grand Oceans Group Limited) from November 1994 to June 1995.

Mr. Lau Wai Man (劉偉民先生) ("Mr. Lau"), aged 35, is the manager in marketing, project and service engineering of the Group. Mr. Lau joined the Group in February 2015 and is primarily responsible for developing new business opportunities, and invention of new technology and marketing. Mr. Lau obtained a degree of Bachelor of Engineering in Medical Engineering from the University of Hong Kong in November 2008 and a degree of Master of Science in Biomedical Engineering from the Chinese University of Hong Kong in December 2009. Before joining the Group, Mr. Lau worked in AML Health Plus Limited, a company engaged in the manufacturing and export of medical and health care devices, from April 2010 to December 2014 where his last position was assistant marketing and project manager. Mr. Lau worked as a research assistant in the Prenatal Diagnostic Laboratory at Tsan Yuk Hospital under the University of Hong Kong from October 2009 to April 2010. He also worked as a junior research assistant in the Department of Medicine and Therapeutics of the Chinese University of Hong Kong from August 2008 to August 2009.

#### CORPORATE GOVERNANCE PRACTICE

The Board is committed to maintaining robust corporate governance.

The Board believes that high standard of corporate governance is essential for the Group to enhance corporate value and accountability, safeguard shareholders' interests, set forth business development direction, develop internal controls and policies, and enhance transparency.

The Group has adopted the code provisions of the Corporate Governance Code (the "CG Code") as set out in the Appendix 15 to the GEM Listing Rules. The Board considers that the Group has complied with the all code provisions, except for code provision A.2.1 of the CG Code as mentioned below, for the financial year ended 31 March 2022.

The CG Code was amended on 1 January 2022 (the "New Code"), with majority of the amendments applying to financial year beginning on or after 1 January 2022. Major amendments of the New Code includes the alignment of the Company's culture with its purpose, values, and strategy, establishment of anti-corruption and whistleblowing policies, board independence and diversity of its members, communication with shareholders, publication of environmental, social and governance reports at the same time as publication of annual reports, and rearrangement of the code provisions and disclosure requirements of the corporate governance code. As this report relates to the financial year ended 31 March 2022, the numbering of code provision in the report follow the code provisions of the CG Code before the New Code came into effect.

#### **Directors' Securities Trading Transactions**

The Group has adopted a code of conduct set out in the "required standard of dealings" in Rules 5.48 to 5.67 of the GEM Listing Rules.

The Group has made specific enquiries of all the Directors and the Directors have confirmed that they have been complying with the required standard of dealings and the related code of conduct regarding director's securities transactions.

As far as the Group is aware, the Directors and employees of the Group have not breached the required standard of dealings and the code of conduct.

#### **Board of Directors**

There are currently six Directors, responsible for formulating the overall business development targets and long-term company strategies, assessing results of management policies and monitoring performance of the management. The Board currently comprises the following Directors:

Ms. Wong Bik Kwan Bikie Chairman, Chief Executive Officer and Executive Director

Dr. Miu Yin Shun Andrew
Mr. Chiu Man Wai
Non-executive Director
Non-executive Director

Mr. Ng Leung Sing SBS, JP Independent non-executive Director
Mr. Wong Lung Wo James Independent non-executive Director
Mr. Chan Ping Keung Independent non-executive Director

(retired on 17 September 2021)

Mr. Chow Ming Po Aaron Independent non-executive Director (appointed on 21 June 2021)

Detailed biographical information of all Directors is contained in the "Biographical Details of Directors and Senior Management" section on pages 11 to 14.

For the financial year ended 31 March 2022, the Company has held four regular meetings at about quarterly intervals and one annual general meeting ("AGM"). The meetings were conducted either on in-person meetings and/or live teleconference basis. The Company Secretary of the Company is responsible for maintaining full minutes of the Board meetings and Committee meetings which are open for inspection at any reasonable time on reasonable notice by any of our directors.

The attendance records of each Director and each member of the Board committees during the financial year ended 31 March 2022 are as follows:

Number of meetings attended/eligible to attend					
		Board	Audit	Remuneration	Nomination
Members	AGM	meetings	Committee	Committee	Committee
Executive Directors					
Ms. Wong Bik Kwan Bikie	1/1	3/4	N/A	2/2	N/A
Non-executive Directors					
Dr. Miu Yin Shun Andrew	1/1	4/4	5/5	N/A	N/A
Mr. Chiu Man Wai	1/1	4/4	N/A	N/A	1/1
Independent non-executive Directors					
Mr. Ng Leung Sing SBS, JP	1/1	4/4	N/A	N/A	1/1
Mr. Wong Lung Wo James	1/1	4/4	5/5	2/2	N/A
Mr. Chan Ping Keung					
(retired on 17 September 2021)	0/1	2/4	3/5	2/2	1/1
Mr. Chow Ming Po Aaron					
(appointed on 21 June 2021)	1/1	3/4	3/5	0/2	0/1

Our Board believes that it has achieved a balanced compositions, including but not limited to the following measurable objectives in terms of age, gender and length of services.

No. of Directors
in the category
4
2
No. of Directors
in the category
1
5
6

Except for that our Directors Dr. Miu Yin Shun Andrew and Ms. Wong Bik Kwan Bikie are in spousal relation, there are no other financial, business, family or other relevant relationships among our board members.

The Board, acting in the interest of the Group and its shareholders, is primarily responsible for overall strategic policy, business development, corporate governance, regulatory compliance and reporting, risk management, internal control systems, dividend policy, shareholders' relationship, accounting policies and financial statements, and other functions assigned to the Board in accordance with the Articles of Association (the "Articles of Association") of the Company.

The Board delegates the daily operations of the Group's business, execution of business development plan, implementation of risk management and internal controls to the management of the Group. The Board remains active in conducting regular reviews of the functions and performance of the management. The management of the Group must obtain the approval of the Board before entering into and arranging any significant transaction/contract.

For the financial year ended 31 March 2022, the Group has complied with the relevant GEM Listing Rules regarding (i) appointment of at least three independent non-executive Directors or to the level of one-third of the Board, among whom at least one independent non-executive Director has appropriate professional qualifications or accounting or related financial management expertise; and (ii) the majority of Audit Committee of the Group are independent non-executive Directors. As at the date of the annual report, each independent non-executive Director has made an annual independence confirmation and the Board is satisfied that all independent non-executive Directors are independent and comply with the independence guidelines of the GEM Listing Rules.

In accordance with the Articles of Association of the Company, at each AGM, one-third of the Directors (if their number is not multiples of three, the nearest but not less than one-third of the number) will retire on a rotation basis, while every Director shall retire at least once every three years at the AGM. A Director who retires on a rotating basis shall include a Director who wishes to retire and does not stand for re-election. Any other retiring Director shall be the Director with the longest term since the last re-election or appointment, if a number of Directors are re-elected on the same day, the Director to be retired shall be determined by drawing lots (unless otherwise agreed). There is no connection among the members of the Board.

#### **Chairman and Chief Executive Officer**

Code provision A.2.1 of the CG Code provides that the role of Chairman and chief executive officer should be separate and should not be performed by the same individual.

For the financial year ended 31 March 2022, the role of Chairman is performed by the CEO, Ms. Wong Bik Kwan Bikie. As the Chairman of the Board, Ms. Wong is responsible for the formulating, planning and directing the Group's overall strategy and always seeks for Board approval for any significant decisions and transactions.

Although Ms. Wong performs both roles, our Board has conducted an assessment and believed that the independence, effectiveness and functionality of the Board and the Group's operations has been and will be highly maintained together with independent check and balance measures in place as the Board has sufficient number of Directors who have diversified background and expertise.

#### Terms of appointment of non-executive directors

Mr. Ng Leung Sing, SBS, JP and Mr. Wong Lung Wo James have respectively entered into an appointment letter for a term commencing from 18 September 2019, until their respective retirement by rotation and re-election at the Company's annual general meeting in accordance with the Articles of Association of the Company in force from time to time and can be terminated by either party by giving at least one month's notice in writing. Mr. Chow Ming Po Aaron has entered into an appointment letter for a term of three years commencing from 21 June 2021, Dr. Miu Yin Shun Andrew and Mr. Chiu Man Wai have respectively entered into an appointment letter for a term of three years commencing from 17 September 2021, subject to their respective retirement by rotation and re-election at the Company's annual general meeting in accordance with the Articles of Association of the Company in force from time to time, and subject to the relevant provisions of Companies Ordinance.

#### **Board Committees**

The Board has established three Board Committees, namely the audit committee (the "Audit Committee"), the remuneration committee (the "Remuneration Committee") and the nomination committee (the "Nomination Committee") of the Group. The terms of reference and assigned specific duties of the above committees are available on the GEM website and the Company's website.

All Directors (including independent non-executive Directors) bring valuable business experience, knowledge and expertise from different areas to the Board facilitating it to operate efficiently and effectively. All Directors have full and timely access to all information of the Group and to the services and advice of the Company Secretary and senior management. The Directors may, where appropriate, seek independent professional advice for performing their duties of the Group, at the expense of the Group. The Directors shall disclose the details of their other duties to the Group and the Board regularly reviews the contributions of the Directors in the discharge of their duties with the Group.

#### **Audit Committee**

The Board has complied with the provisions of the CG Code set out in Appendix 15 to the GEM Listing Rules and established the Audit Committee on 1 March 2018. The written terms of reference of the Audit Committee are posted on the website of the Stock Exchange of Hong Kong Limited (the "Stock Exchange") and on the Company's website.

The Audit Committee consists of two independent non-executive Directors and one non-executive Director, namely:

Mr. Wong Lung Wo James

Mr. Chan Ping Keung

(ceased to act on 17 September 2021)

Mr. Chow Ming Po Aaron

(appointed as member on 21 June 2021)

Dr. Miu Yin Shun Andrew

Chairman of Audit Committee & Independent non-executive Director

Independent non-executive Director

Independent non-executive Director

Non-executive Director

The main responsibilities of the Audit Committee include, but not limited to:

- Making recommendations to the Board on the appointment, reappointment, resignation, dismissal and removal of the external auditors:
- Approving the remuneration and engagement terms of all services provided by the external auditors:
- Reviewing and monitoring the external auditors' independence and objectivity and the effectiveness of the audit process;
- Review of financial information of the Group, including the true and fairness of the guarterly, interim and annual financial statements, accounting policies and practice (or change in, if any), major judgmental areas, going concern consideration, compliance with accounting standards and GEM Listing Rules in relation to financial reporting;
- Reviewing the adequacy of resources, qualifications and experience of accounting staff, and their training programmes and budget of the Company's accounting and financial reporting function;
- Reviewing and monitoring the effectiveness and adequacy of the Group's risk management and internal control measures:

- Ensuring that the internal audit function is adequately resourced and has appropriate standing within the Company, and to review and monitor the effectiveness of the internal audit function;
- Regularly report observations and make recommendations to the board (if any).

The Board as a whole acts as the corporate governance function of the Group, and holds the ultimate responsibilities for the following matters while the Board has delegates these duties to the Audit Committee.

- developing and reviewing the corporate governance policies and practices of the Company make recommendations to the Board;
- reviewing and monitoring the training and continuous professional development of directors and senior management;
- reviewing and monitoring the policies and practices on compliance with legal and regulatory requirements;
- developing, reviewing and monitoring the code of conduct applicable to employees and directors; and
- reviewing the Company's compliance with the CG Code set out in Appendix 15 of the GEM Listing Rules and disclosure in the Corporate Governance Report.

For the financial year ended 31 March 2022, the Audit Committee has held five meetings, by means of live/teleconference, and performed its main duties, including (1) review and advise on the Group's annual reports and results announcements, the relevant accounting principles and practices adopted by the Group; (2) review the risk management and internal control procedures adopted by the Group, the internal control review report, and provide suggestions and comments thereon; and (3) review the effectiveness of the accounting function and internal audit function and provide suggestions and comments thereon.

In addition, the Audit Committee holds private meetings with external auditors in the absence of management to discuss the matters involved in the audit and other matters that the independent auditors wish to raise.

#### **Remuneration Committee**

The Board has complied with the provisions of the CG Code set out in Appendix 15 to the GEM Listing Rules and established the Remuneration Committee; and develop the terms of reference in writing on 1 March 2018.

The Remuneration Committee consists of two independent non-executive Directors and our CEO and executive Director, Ms. Wong, namely:

Mr. Chan Ping Keung (ceased to act as Chairman on 17 September 2021)

Mr. Chow Ming Po Aaron (appointed as member on 21 June 2021 and redesignated as Chairman on 17 September 2021)

Mr. Wong Lung Wo James Ms. Wong Bik Kwan Bikie Chairman of Remuneration Committee and Independent non-executive Director Chairman of Remuneration Committee and Independent non-executive Director

Independent non-executive Director CEO and Executive Director

The Group adopts the remuneration committee model set out in B.1.2 (c) (ii) of Appendix 15 to the GEM Listing Rules.

The main duties of the Remuneration Committee include, but not limited to:

- make recommendations to the Board on the Company's policy and structure for all directors' and senior management remuneration;
- review and approve the management's remuneration proposals with reference to the Board's corporate goals and objectives;
- consider salaries paid by comparable companies, time commitment and responsibilities and employment conditions elsewhere in the group; and
- ensure that no director or any of his associates is involved in deciding his own remuneration.

For the financial year ended 31 March 2022, the Remuneration Committee has held two meetings to review and make recommendations to the Board on the remuneration packages of individual executive Directors, the non-executive Directors, the independent non-executive Directors and senior management; and to review the bonus to senior management.

Details of the senior management's emoluments by band are set out in note 12(c) to the consolidated financial statements.

#### **Nomination Committee**

(appointed on 21 June 2021)

The Board has complied with the provisions of the CG Code set out in Appendix 15 to the GEM Listing Rules and established the Nomination Committee on 1 March 2018. The written terms of reference of the Nomination Committee are posted on the website of the Stock Exchange and on the Company's website.

The Nomination Committee consists of two independent non-executive Directors and one non-executive Director, namely:

Mr. Ng Leung Sing SBS, JP Chairman of Nomination Committee and Independent

non-executive Director

Mr. Chan Ping Keung Independent non-executive Director (ceased to act on 17 September 2021)

Mr. Chow Ming Po Aaron Independent non-executive Director

Mr. Chiu Man Wai

Non-executive Director

The main responsibilities of the Nomination Committee include, but not limited to:

- reviewing the structure, size and composition (including but not limited to gender, age, cultural and educational background, professional experience, skills, knowledge and length of service) of the Board at least annually or when necessary;
- identifying individuals suitably qualified to become members of the Board and selecting or making recommendations to the Board on the selection of, individuals nominated for directorships;
- assessing the independence of the independent non-executive Directors;
- making recommendations to the Board on relevant matters relating to the appointment or re-appointment of Directors and succession planning for Directors;
- reviewing the board diversity policy, as appropriate and making recommendations on any required changes to the board for consideration;
- reviewing the measurable objectives under the board diversity policy and the progress of the attainment of the objectives, so as to ensure effective implementation; and make disclosure of its review results.

For the financial year ended 31 March 2022, the Nomination Committee has held one meeting to review the Board's composition, structure, size and diversity; and is of the view that the Board consisted of members with balanced and diversified attributes, such as gender, age, education background, professional qualifications, experience, skills and knowledge to discuss matter regarding the retirement and re-election of directors and succession planning for directors and to assess the independence of independent non-executive directors and to make recommendation to the Board on the appointment of new Director.

#### Summary of board diversity policy (the "Policy")

The Company has adopted the Policy which is summarized as follows, including measurable objectives that the Company has set for implementing the Policy, and progress on achieving those objectives.

#### **Policy Statement**

The Company believes that board diversity is essential to achieve its strategic development and sustainable development.

In designing the Board's composition, board diversity has been considered from a number of aspects, including but not limited to gender, age, cultural and educational background, ethnicity, professional experience, skills, knowledge and length of service.

All Board appointments are based on meritocracy, and candidates will be considered against objective criteria, having due regard for the benefits of diversity on the board of directors (the "Board").

#### **Measurable Objectives**

Selection of candidates of the Board members is based on a range of diversity perspectives, including but not limited to gender, age, cultural and educational background, ethnicity, professional experience, skills, knowledge and length of service and any other factors that the Board may consider relevant and applicable from time to time.

The ultimate decision is based on merit and contribution that the selected candidates can bring to the Board, having due regard to the benefits of diversity on the Board and also the needs of the Board without focusing on a single diversity aspect.

#### **Monitoring and Reporting**

The Nomination Committee of the Company is responsible for reporting annually on the Board's composition under diversified perspectives, and monitoring the implementation of the Policy.

#### **Review of the Policy**

The Nomination Committee has reviewed the Policy, as appropriate, to ensure the effectiveness of the Policy. The Nomination Committee will also discuss any revisions to the Policy that may be required, and recommend any such revisions to the Board for consideration and approval.

#### **Disclosure of Policy**

The Policy is published on the Company's website for public information.

#### **Nomination Policy and Procedures**

The Board has adopted a nomination policy setting out the selection criteria and procedures for the Nomination Committee to select and recommend suitable candidates for directorship in order to ensure the Board has a balanced and diversified skills, experience and perspectives.

The Nomination Policy requires Nomination Committee to consider a variety of factors, individually and collectively, in assessing the suitability of a proposed candidate, including but not limited to the following criteria:

- The Policy;
- Achievements, Professional qualification and experience appropriate to the business and compliance requirements of the Group;
- Sufficiency of time and interest commitment of the proposed candidates to the Group;
- Level of independence for the appointment of independent non-executive Director; and
- any other relevant and material factors as may be considered by the Nomination Committee.

The Board has also established nomination procedures for Directors' nomination pursuant to the GEM Listing Rules and the Company's Articles of Association as follows:

#### (a) Appointment of New Director

For proposed appointment of new Director, the Nomination Committee must call out a meeting and evaluate the proposed candidate based on the selection criteria mentioned above and make recommendations to the Board regarding whether the proposed candidates are qualified and appropriate for directorship.

For directorship nomination proposed by Shareholders at the general meeting, the Nomination Committee should also evaluate such candidates in accordance to the same selection criteria and the Board should make recommendation to the Shareholders in respect of the proposed election of Director at the general meeting.

#### (b) Re-election of Director at general meeting

Retiring Directors are eligible for nomination by the Board to stand for re-election at the general meeting according to the Articles of Association of the Company.

The Nomination Committee and the Board should review the overall contribution, participation and performance of the retiring Director and the Board should then make recommendation to the Shareholders in respect of the proposed re-election of Director at the General Meeting.

#### **DIRECTORS' TRAINING AND CONTINUOUS DEVELOPMENT**

Each new Director is given formal, comprehensive and customised induction training at the time of first appointment to ensure their proper understanding of the Group's business and operations, and sufficient awareness of the Directors' duties and responsibilities under the GEM Listing Rules and related regulations. The Group also provides continuous briefings and training courses to Directors to keep them up to date on the GEM Listing Rules and other applicable regulatory requirements as well as the Group's business and governance policies.

The Company has received from all directors records of their continuous professional development training for the year ended 31 March 2022, details of which are set out below.

Participation of relevant continuing training courses regarding the latest regulatory requirements

Ms. Wong Bik Kwan Bikie	✓
Dr. Miu Yin Shun Andrew	✓
Mr. Chiu Man Wai	✓
Mr. Ng Leung Sing SBS, JP	✓
Mr. Wong Lung Wo James	✓
Mr. Chan Ping Keung (retired on 17 September 2021)	✓
Mr. Chow Ming Po Aaron (appointed on 21 June 2021)	,

#### **DIRECTORS' RESPONSIBILITY FOR FINANCIAL STATEMENTS**

The Directors acknowledge their responsibility to prepare consolidated financial statements for the financial year ended 31 March 2022, to reflect a true and fair financial position, results and cash flows of the Group for the year then ended, and the proper preparation of financial statements on an on-going basis in accordance with applicable statutory requirements and accounting standards. The Directors are not aware of any material uncertainties that may affect the business of the Group or raise significant questions about the Group's ability to operate on an on-going basis.

#### **AUDITOR'S STATEMENT AND REMUNERATION**

The Directors acknowledged of their responsibility for preparing the financial accounts.

A statement by the Group's auditors on their reporting obligations in respect of the Group's financial statements for the year ended 31 March 2022 is set out in the "Independent Auditor's Report" section of this annual report.

For the financial year ended 31 March 2022, the remuneration of annual audit service provided by the auditor of the Company, BDO Limited, to the Group is HK\$590,000. Save as disclosed above, there was no other non-audit service provided by the auditor during the year ended 31 March 2022.

The Audit Committee has reviewed and approved the remunerations, service terms and independence of the auditors for the financial year ended 31 March 2022.

#### **RISK MANAGEMENT AND INTERNAL CONTROLS**

The Board acknowledges its responsibility for the risk management and internal control systems and its responsibility to continually review their effectiveness and adequacy.

The Group has established a risk management policy setting out the process of identification, evaluation and management of the principal risks affecting the business. Each division is responsible for identifying, assessing and managing risks within its divisions, identifying and assessing the principal risks on a quarterly basis with mitigation plans to manage those risks. The management is responsible for overseeing the risk management and internal control activities of the Group, attending quarterly meetings with each divisions to ensure principal risks are properly managed and new or changing risks are identified and documented. Lastly, the Board is responsible for reviewing and approving the effectiveness and adequacy of the Group's risk management and internal control systems.

For the financial year ended 31 March 2022, the Group has performed a risk assessment of its business and operations and, on that basis, have identified, evaluated and prioritised key risks from financial, operational compliance and risk management aspects. The Group is dedicated in designing and implementing controls and measures to manage the key risks to an acceptable and reasonable level, rather than eliminate them entirely.

The management has also confirmed to the Board and Audit Committee that there are no major deficiencies in the risk management and internal controls system of the Group.

The Group has engaged an independent professional internal control consultant firm (the "Internal Control Consultant") to review the entity level policies, risk assessment and internal control systems of major business processes of the Group for financial year ended 31 March 2022. The Internal Control Consultant performs the review, reports the relevant findings and recommendations to the Board and Audit Committee and follows up on management responses to the recommendations on an on-going basis. Overall, the Board considers the risk management and internal control system of the Group are effective and adequate.

The Group does not have an internal audit department and the Board has reviewed the need for an internal audit function and considered that it more cost-effective to appoint external independent professionals to independently review and continuously evaluate the group's internal monitoring systems and risk management systems, taking into account the size and nature of the Board. The Board will review the need for an internal audit function at least annually.

#### PROCEDURES FOR HANDLING AND DISSEMINATION OF INSIDE INFORMATION

The Company has adopted a policy on disclosure of inside information. If the information is believed as inside information, and must be disclosed, the management must:

- (a) Escalate to the CEO and present the information to the Board;
- (b) Prepare an announcement to the Stock Exchange disclosing the inside information if the announcement is important;
- Send the announcement to the Stock Exchange without delay and send a copy of the announcement to all Directors.

If the information is believed not price sensitive, and need not be disclosed, the management must explain the reason for non-disclosure and record the information in the disclosure file.

#### **COMPANY SECRETARY**

The Company has engaged and appointed Ms. Lee Ka Man, a representative from an external secretarial services provider, as the company secretary of the Company. The primary contact person with the company secretary of the Company is Mr. Cheung Chong Chi, Financial Controller. Ms. Lee is an associate member of both The Hong Kong Chartered Governance Institute (formerly known as The Hong Kong Institute of Chartered Secretaries) and The Chartered Governance Professional (formerly known as The Institute of Chartered Secretaries and Administrators in the United Kingdom). She has over 16 years of experience in the fields of company secretarial and compliance. Ms. Lee has confirmed that she has taken no less than 15 hours of relevant professional training pursuant to Rule 5.15 of the GEM Listing Rules.

#### SHAREHOLDERS' RIGHT

The Board and management are committed to meeting and communicating with shareholders through the AGM of the Group, listening to shareholder opinions and answering questions from shareholders about the group and its business. The Chairman of the Board, the Directors and senior management attend the AGM of the Group to answer questions from shareholders.

In accordance with Article 58 of the Articles of Association of the Company, any one or more Members holding at the date of deposit of the requisition not less than one-tenth of the paid up capital of the Company carrying the right of voting at general meetings of the Company shall at all times have the right, by written requisition to the Board or the Secretary of the Company, to require an extraordinary general meeting to be called by the Board for the transaction of any business specified in such requisition; and such meeting shall be held within two (2) months after the deposit of such requisition. If within twenty-one (21) days of such deposit the Board fails to proceed to convene such meeting the requisitionist(s) himself (themselves) may do so in the same manner, and all reasonable expenses incurred by the requisitionist(s) as a result of the failure of the Board shall be reimbursed to the requisitionist(s) by the Company.

The requisition must be in writing specifying the objects of the meeting, and be signed by the shareholder(s) concerned and deposited at the principal place of business of the Company in Hong Kong.

Shareholders may also make enquiries or recommendations to Directors, company secretary and management at the Shareholders' Meeting. They may do so by sending an e-mail to ir@grandbrilliance.com or by calling the Group (tel: +852 2425 0926).

#### **INVESTORS' RELATIONSHIP**

The Group has established various channels of communication with shareholders and public investors to ensure that they are well-informed with the latest news and developments of the Group. The Group provides shareholders with upto-date information on the Group's development, financial performance and results, and major transactions/decisions through annual, interim and quarterly reports. All published information is uploaded to the Group's website at www.grandbrilliancegroup.com or GEM website www.hkgem.com.

#### CONSTITUTIONAL DOCUMENT

The Articles of Association of the Company remains unchanged from the date of listing to 31 March 2022.

#### **DIVIDEND POLICY**

The Company has adopted a dividend policy on 21 June 2019 pursuant to the relevant GEM Listing Rules, Company's Articles of Association and relevant rules and regulations.

#### **Purpose**

The dividend policy (the "Dividend Policy") aims to set out the principles and guidelines that the Company intends to apply in relation to the declaration, payment or distribution of its profits as dividend to the shareholders of the Company (the "Shareholders").

#### **Principles and Guidelines**

In deciding whether to propose a dividend and in determining the dividend amount, the Board shall take into account, inter alia, the following factors:

- 1. the actual and expected financial performance of the Group;
- 2. the capital and debt level of the Group;
- 3. the general market conditions;
- 4. the expected working capital requirements, capital expenditure requirements and future development plans of the Group;
- 5. retained earnings and distributable reserves of the Company and each of the members of the Group;
- 6. the liquidity position of the Group;
- 7. any restrictions on dividend payouts imposed by any of the Group's lenders;
- 8. the statutory and regulatory restrictions which the Group is subject to from time to time; and
- 9. any other relevant factors that the Board may deem appropriate.

#### Form of Dividend

Subject to the Company's Articles of Association, dividends may be paid in cash or be satisfied wholly or partly in the form of allotment of shares of the Company. The Board may also consider the issuance of bonus shares on a basis permitted by the applicable laws and regulations.

#### **General Restrictions**

The payment of dividend by the Company is subject to any restrictions under the Companies Law of the Cayman Islands and the Articles of Association of the Company.

#### **Approval**

According to the Articles of Association of the Company, any final dividends declared by the Company must be approved by an ordinary resolution of the Shareholders at an AGM and must not exceed the amount recommended by the Board. The Board may from time to time pay the Shareholders such interim and/or special dividends as it considers to be justified by the profits of the Group.

#### Clarification

There is no assurance that dividends will be paid in any particular amount for any specific period. The Company may at its discretion not to declare dividend in consideration of various factors, such as maintaining or adjusting the capital structure and reserving sufficient capital to capture future business opportunities, etc.

#### **Review**

The Board will from time to time review the Dividend Policy and may exercise at its absolute and sole discretion to update, amend and/or modify the Dividend Policy at any time as the Board deems fit and necessary.

#### Disclosure of dividend policy

This Dividend Policy is published on the Company's website for investors' information.

#### INTRODUCTION

Grand Brilliance Group Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "we") is principally engaged in supplying medical devices and providing medical device solutions including market trend analysis, sourcing of medical devices, after-sale services, technical support and training services, medical devices leasing services and quality assurance.

This Environmental, Social and Governance Report (the "ESG Report") summarises the environmental, social and governance ("ESG") initiatives, plans and performances of the Group and demonstrates its commitment to sustainable development.

The Group believes sustainability is the key to achieve continuing success and has integrated this key concept into its business strategy. In order to pursue a successful and sustainable business model, the Group recognises the importance of integrating ESG aspects into its risk management system and has taken corresponding measures in its daily operations and governance perspective.

#### **CHAIRMAN'S STATEMENT**

Dear valued stakeholders.

On behalf of the Board (the "Board") of Directors (the "Directors"), I am pleased to present the ESG Report of the Group, which demonstrates our growing commitment to improving our ESG performance.

The Group believes that sustainable development is vital to the environment and contributes to the long-term prosperity and development of the Group's business. Therefore, the Group also strives to formulate a sound governance structure to effectively manage ESG matters related to the Group. The Board must assess the potential impact of ESG issues on the overall strategy of the Group, set out ESG management approach and strategy, and supervise the Group's ESG issues. Information about the Group's governance structure is stated in the section headed "SUSTAINABILITY GOVERNANCE".

To identify and prioritise major ESG issues that have a significant impact on our operations and stakeholders, we continuously communicate with internal and external stakeholders. The Board has delegated the ESG Working Group (the "Working Group") and hired an independent third party to conduct materiality assessment. Information about the stakeholder engagement channels and the materiality assessment conducted by the Group is stated in the sections headed "STAKEHOLDER ENGAGEMENT" and "MATERIALITY ASSESSMENT" respectively. In order to have a deeper understanding of stakeholders' expectations of the Group's sustainable development, the Group will further strengthen its communication with stakeholders and formulate relevant policies and measures based on their opinions to improve the Group's ESG performance.

As an enterprise that upholds corporate social responsibility, the Group acknowledges the importance of reducing its impact on the environment. To fulfil the Group's commitment to corporate social responsibility and allow the Group's stakeholders to better understand the Group's progress in improving ESG performance, the Group has set targets for ESG issues that are material to the Group. The Board and the Working Group use the ESG-related data collected to compare the Group's performance in different years to track the progress of ESG targets. To achieve these targets, the Group actively implements the principles of sustainable development and adopts relevant measures at operational levels. To achieve the goal, the Group implements different environmental protection measures and raises employees' awareness of ESG. These objectives and environmental protection measures can help raise the environmental awareness of employees and enhance the Group's ESG performance to meet the expectations of the Group's stakeholders.

In closing, on behalf of the Board and the management team of the Group, I would like to express my sincere gratitude to our valued stakeholders for their persistent support, while also expressing my appreciation to our employees for their valuable contribution to the development of the Group. Looking forward, the Group will continue to deepen the integration of ESG concepts into its business strategy and management system, and operate its business in a more responsible and sustainable manner in order to create sustainable value for shareholders and pursue a sustainable future.

Wong Bik Kwan Bikie

Chairman and Executive Director

#### SUSTAINABILITY GOVERNANCE

The Group has established the Working Group to raise employees' awareness of ESG issues. The Working Group is comprised of senior management and general staff with adequate knowledge of ESG. Its members span across different business departments. They are responsible for executing the Group's ESG measures, collecting and analysing ESG data, giving suggestions to the Board on ESG issues and reviewing ESG-related matters across the Group's different departments.

With the assistance of the Working Group, the Board continuously evaluates and monitors the Group's ESG performance, risk, opportunities and targets. The members of the Working Group regularly meet each other to discuss the effectiveness of the Group's policies and procedures and seek opportunities to improve the Group's ESG performance. The Working Group reports its findings to the Board where appropriate so that the Board can find solutions to manage the Group's ESG risks and opportunities.

#### **SCOPE OF REPORTING**

Unless specified otherwise, the ESG Report focuses on the operation as a medical device distributor, which represents the Group's major sources of revenue. The ESG key performance indicators ("KPIs") data is gathered and included companies and subsidiaries under the Group's direct operational control. Compared to the reporting scope of the ESG Report of the year ended 31 March 2021 ("FY2021"), the Group has expanded the scope to include one more operating site due to expansion of the Group's business. The KPIs are shown in the ESG Report as well as supplemented by explanatory notes to establish benchmarks. The Group will extend the scope of disclosures when and where applicable.

#### REPORTING FRAMEWORK

The ESG Report is prepared in accordance with the Environmental, Social and Governance Reporting Guide (the "ESG Reporting Guide") as set out in Appendix 20 to the Rules Governing the Listing of Securities on GEM of the Stock Exchange of Hong Kong Limited. Information relating to the Group's corporate governance practices has been set out in the Corporate Governance Report of this annual report.

During the preparation for this ESG Report, the Group has applied the reporting principles in the ESG Reporting Guide as follow:

Materiality: Materiality assessment was conducted to identify material issues, thereby adopting the confirmed material issues as the focus for the preparation of the ESG Report. The materiality of issues was reviewed and confirmed by the Board and Working Group. For further details, please refer to the sections headed "STAKEHOLDER ENGAGEMENT" and "MATERIALITY ASSESSMENT".

*Quantitative*: The standards, methodologies and applicable assumptions used in the calculation of KPIs data were supplemented by explanatory notes.

Consistency: This ESG Report will use consistent disclosure methodologies to allow for meaningful comparisons of ESG data in the future. The Group has explained the expansion of scope of disclosure in the section headed "SCOPE OF REPORTING". If there are any changes in the calculation methods that may affect comparisons with previous reports, the Group will provide explanations for the corresponding data.

Balance: This ESG Report aims to provide a balanced representation of the Group's ESG performance. It avoids selections, omissions, or presentation formats that may appropriately influence a decision or judgment by the report reader.

#### **REPORTING PERIOD**

The ESG Report specifies the ESG activities, challenges and measures being taken during the financial year ended 31 March 2022 (the "Reporting Period" or "FY2022").

#### STAKEHOLDER ENGAGEMENT

We value our stakeholders and their feedback regarding our businesses and ESG aspects. In order to understand and address their key concerns, the Group has maintained close communication with our key stakeholders, including but not limited to shareholders and investors, customers, suppliers and business partners, government and regulatory authorities, employees, as well as the Board.


In formulating operational strategies and ESG measures, we take into account the stakeholders' expectations and strive to improve the Group's performance through mutual cooperation with the stakeholders, resulting in creating greater value for the community by utilising diversified key communication channels, shown as below:

External Stakeholders	Key Communication Channels	Expectations and Concerns
Shareholders and investors	<ul> <li>General meetings and other shareholder meetings</li> <li>Financial reports</li> <li>Announcements and circulars</li> <li>Website</li> </ul>	<ul><li>Shareholders' rights and interest</li><li>Financial performance</li></ul>
Customers	<ul><li>Regular meetings</li><li>Regular training sessions</li></ul>	<ul><li>Product quality and safety</li><li>Price competitiveness</li></ul>
Suppliers and business partners	<ul><li>Regular meetings</li><li>Suppliers evaluation</li><li>Regular training sessions</li></ul>	<ul><li>Price competitiveness</li><li>Product quality and safety</li></ul>
Government and regulatory authorities	<ul><li>Public news</li><li>Tendering documents</li><li>Enforcement newsletter</li></ul>	<ul><li>Corporate governance</li><li>Regulatory compliance</li></ul>
Internal Stakeholders	Key Communication Channels	Expectations and Concerns
Employees	<ul><li>Daily communication</li><li>Performance evaluation</li><li>Policy development</li><li>Emails and notice board</li></ul>	<ul><li>Remuneration</li><li>Career development</li></ul>
The Board	<ul><li>Daily communication</li><li>Board and committee meetings</li><li>Communication with management</li><li>Product quality and safety</li></ul>	<ul><li>Corporate governance</li><li>Regulatory compliance</li><li>Financial performance</li><li>Sustainable development</li></ul>

#### **MATERIALITY ASSESSMENT**

We identified, assessed and disclosed ESG information that is material and relevant to our businesses and operations based on the above summarised expectation and concerns from our stakeholders, with reference to the ESG Reporting Guide, and industry characteristics. The Group has compiled a questionnaire in accordance with the identified material ESG issues to collect information from relevant stakeholders.

The following is a matrix of the Group's material ESG issues included in the ESG Report:



Number	ESG issues	Number	ESG issues
1	Greenhouse Gas ("GHG") Emissions	9	Supply Chain Management
2	Waste Management	10	Product Safety
3	Use of Resources	11	Protection of Customer Privacy and Intellectual Property
4	Climate Mitigation and Adaptation	12	Advertising and Labelling
5	Employee Welfare	13	Anti-corruption
6	Health and Safety	14	Community Investment
7	Employee Development	15	Regulatory Compliance
8	Prevent Child Labour and Forced Labour	16	Profitability Enhancement

We understand the needs of and are committed to continuous evaluation of our ESG risk management and internal control systems. Accordingly, we have conducted and will continue with an on-going materiality assessment so as to further improve the related ESG concerns and data collection system.

#### **CONTACT US**

#### Stakeholders' Feedback

The Group welcomes stakeholders' feedback on its ESG approach and performance which will help us continuously improve our sustainability performance. For any suggestions or opinions, questions or comments, please send to the Company through the communication channels as stated on the Company's website.

#### **Reporting Mechanism**

We welcome and provide channels for our stakeholders, including suppliers, customers and employees to report instances of suspected unethical act or potential breach of our policy. Suspected non-compliance may be reported to a manager, department head or senior executives.

Stakeholders may also submit enquiries or report suspected cases to our management through e-mailing info@grandbrilliance.com or by calling the Group (tel: +852 2425 0926).

#### A. ENVIRONMENTAL

#### A1. Emissions

The Group strives to protect the environment through the implementation of control and monitoring measures in its business activities and workplace. We are committed to promoting a green environment by introducing environmentally friendly business practices, educating our employees to enhance their awareness of environmental protection and complying with the relevant environmental laws and regulations.

As a corporation providing medical device distribution services, the Group's daily operations have limited impact on the environment while its emissions are limited to exhaust gas emissions, GHG emissions and waste disposal, which are mainly derived from the use of resources in its businesses in Hong Kong. With the aim of lowering the emissions of GHG, the Group focuses on nurturing and strengthening the employees' awareness of environmental protection in their daily work process, and actively implementing the Group's environmental protection measures.

In order to mitigate the environmental impact brought by the Group's operations, the Group has adopted and implemented the Corporate Social Responsibility Policy. These policies apply the waste management principles of "Reduce, Reuse, Recycle and Replace" as well as emission mitigation principle, with objectives of minimising the adverse environmental impacts and ensuring that the waste disposal or emissions being generated are conducted in an environmentally responsible manner.

Within its established Corporate Social Responsibility Policy, the Group is continually looking for different opportunities to pursue environmentally friendly initiatives and enhance our environmental performance by reducing energy and using other resources.

During the Reporting Period, the Group was not aware of any material non-compliance with the relevant environmental laws and regulations in Hong Kong in relation to air and GHG emissions, discharges into water and land, and generation of hazardous and non-hazardous waste. The relevant laws and regulations include, but are not limited to the Waste Disposal Ordinance (Cap. 354).

#### **Air Emissions**

Air emissions from the motor vehicles were the major sources of air pollutants within the Group. The Group has adopted several energy and resources conservation measures in achieving its goal of reducing pollution and use of energy, which include the followings:

- Using fuels that comply with the environmental standards of the places where we operate for our vehicles;
- Refuelling at approved gasoline filling stations so as to ensure oil standard and quality;
- Encouraging our staff to utilise teleconferences and video conferences, to reduce air and GHG emissions related to transportation needed for meetings;
- Disposing of any vehicles reach the useful life limit set by the authority; and
- Requiring drivers to turn off the engine and hand over the car key when waiting for loading and unloading.

Through the above air emissions mitigation measures, the employees' awareness of reducing air emissions has been enhanced.

The summary of air emissions performance was as follow:

Indicators <sup>1</sup>	Unit	FY2022	FY2021
Nitrogen Oxides (NO <sub>x</sub> )	g	3,517	4,580
Sulphur Oxides (SO <sub>x</sub> )	g	115	126
Particulate Matter (PM)	g	259	377

#### Note:

#### **GHG Emissions**

The principal GHG emissions of the Group were direct GHG emissions from the combustion of gasoline for vehicles (Scope 1), energy indirect GHG emissions from purchased electricity (Scope 2) and other indirect GHG emissions from disposal of paper waste at landfill (Scope 3). The Group has set an emissions target of maintaining or reducing the total GHG emissions intensity by the end of the financial year ended 31 March 2030 ("FY2030"), using approximately 0.74 tonnes of carbon dioxide equivalent ("tCO<sub>2</sub>e") per revenue in million in FY2022 as the baseline. The Group actively adopts energy conservation measures as well as other initiatives to reduce GHG emissions, including:

- Actively adopting measures for environmental protection, energy conservation, and water saving. Relevant
  measures are described in the sections headed "Air Emissions" in this Aspect and "Energy Management" in
  Aspect A2; and
- Actively adopting paper saving measures in office. The relevant measures are described in the section headed "Waste Management" in this aspect.

<sup>1.</sup> The calculation method and respective emission factors of air emissions were based on "How to prepare an ESG report — Appendix 2: Reporting Guidance on Environmental KPIs" issued by the Stock Exchange of Hong Kong Limited.

Through the above GHG emissions mitigation measures, the employees' awareness of reducing GHG emissions has been enhanced. However, as the Group has expanded the reporting scope to include one more operating site, the total electricity consumption increased. During the Reporting Period, the Group's total GHG emissions were approximately  $53 \text{ tCO}_2\text{e}$  (FY2021: approximately  $45 \text{ tCO}_2\text{e}$ ), representing an increase of approximately 18%. The summary of GHG emissions performance was as follow:

Indicators <sup>2</sup>	Unit	FY2022	FY2021
Direct GHG emissions (Scope 1) —	tCO <sub>2</sub> e	21	23
Gasoline consumption	tCO₂e	28	18
Energy indirect GHG emissions (Scope 2) — Purchased electricity	lCO₂e	20	10
Other indirect GHG emissions (Scope 3) —	tCO <sub>2</sub> e	4	4
Disposal of paper waste at landfill	12.22		
Total GHG emissions	tCO₂e	53	45
Intensity <sup>3</sup>	tCO₂e/revenue in thousand	0.001	0.001

#### Notes:

- 2. GHG emissions data are presented in terms of carbon dioxide equivalent and are based on, but not limited to, "The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standards" issued by the World Bank Institute and the World Business Council for Sustainable Development, "How to prepare an ESG report Appendix 2: Reporting Guidance on Environmental KPIs" issued by the Stock Exchange of Hong Kong Limited, the "Global Warming Potential Values" from the IPCC Fifth Assessment Report, 2015 (AR5) and the 2021 Sustainability Report published by the CLP Holdings Limited.
- 3. During the Reporting Period, the total amount of revenue was approximately HK\$72.0 million (FY2021: approximately HK\$70.2 million). The amount would also be used for calculating other intensity data.

#### **Waste Management**

Hazardous waste handling method

As the Group did not generate any hazardous wastes during the Reporting Period, the Group has not set any targets for hazardous waste management. However, it has established guidelines governing the management and disposal of hazardous wastes. In case there are any hazardous wastes produced, the Group must engage a qualified chemical waste collector to handle such wastes in order to comply with the relevant environmental laws and regulations.

#### Non-hazardous waste handling method

Although the Group only generated a minimal amount of non-hazardous waste, such as paper, that is mainly from office operation, the Group has placed great emphasis on carbon reduction and waste reduction with the principle of "Reduce, Reuse, Recycle and Replace" to promote better utilisation of environmental resources.

With the aim of minimising the environmental impact of non-hazardous wastes that are generated from its business operations, the Group has developed relevant policies to promote resources conservation. The Group has set a waste generation target of maintaining or reducing the total non-hazardous waste intensity by FY2030, using approximately 11.86 kg per revenue in million in FY2022 as the baseline. We have implemented the following procedures to encourage employees to share responsibilities in waste management and minimise waste generations:

- Using double-sided printing or photocopying wherever possible;
- Recycling one-sided printed paper; and
- Placing "Green Message" reminders on office equipment.

Employee's waste management awareness has been enhanced through the above measures. During the Reporting Period, the Group's total non-hazardous waste generation was approximately 854 kg (FY2021: approximately 740 kg), representing an increase of approximately 15%. Its intensity was maintained at approximately 0.01 kg per revenue in thousand in FY2022 and FY2021.

#### **Discharges into Water**

The Group does not consume significant amounts of water in its business operations, and therefore its business activities did not generate material portion of discharges into water during the Reporting Period. The majority of the water supply and discharge facilities are provided and managed by the property management company.

#### A2. Use of Resources

The Group strives to use its resources effectively, not only because of cost consideration, but it is also beneficial to our environment and can improve the workplace condition for our employees. The Group is committed to the responsible use of resources in its business operations and has developed green office initiatives to promote resource conservation among our staff. Electricity consumption and gasoline consumption account for a substantial part of the carbon emissions by the Group.

#### **Energy Management**

The Corporate Social Responsibility Policy has been developed to set energy conservation as one of the Group's fundamental policies. All employees must implement the adopted measures, including the purchase of energy-efficient products and services, and assume responsibility for the Group's overall energy efficiency. By building up an energy management system, we develop and regularly review our energy objectives and targets to continuously enhance the Group's energy performance. Unexpected high consumption of electricity will be investigated to find out the root cause and preventive measures will be taken. The Group has set an energy use efficiency target of maintaining or reducing the total energy consumption intensity by the end of FY2030, using approximately 2,056.04 kWh per revenue in million in FY2022 as the baseline.

The green office and energy conservation measures are listed as below:

- Turning off the air-conditioning system and idle equipment at night or when staff leave the office to reduce electricity usage;
- Turning off the lights when the office can be dominated by natural light;
- Adopting higher energy-efficiency office equipment in our workplace;
- Posting electricity saving reminder labels in common areas; and
- Encouraging our staff to participate in campaign or activities relating to the promotion of green environment.

Through these energy conservation measures, the employees' awareness on energy management has been enhanced. However, as the Group has expanded the reporting scope to involve one more office, the total electricity consumption increased. During the Reporting Period, the Group's energy consumption was approximately 148,035 kWh (FY2021: approximately 132,563 kWh), representing an increase of approximately 12%. The summary of energy consumption performance was as follow:

Indicators	Unit	FY2022	FY2021
Direct energy consumption — Gasoline consumption <sup>4</sup>	kWh	75,913	83,192
Indirect energy consumption — Purchased electricity	kWh	72,122	49,371
Total energy consumption	kWh	148,035	132,563
Intensity	kWh/revenue in thousand	2.06	1.89

#### Note:

4. During the Reporting Period, gasoline consumption was equivalent to approximately 7,833 litres (FY2021: approximately 8,584 litres). The unit conversion calculation is based on the conversion factors in "How to prepare an ESG report — Appendix 2: Reporting Guidance on Environmental KPIs" issued by the Stock Exchange of Hong Kong Limited and the "Energy Statistics Manual" issued by the International Energy Agency.

#### **Water Consumption**

During the Group's operation, water consumption is minimal, and is mainly for cleaning and sanitation. However, the Group endeavours to encourage all employees and customers to develop the habit of conserving water consciously. The Group has set a water efficiency target of maintaining or reducing the total water consumption by the end of FY2030, using approximately 2 cubic meters in FY2022 as the baseline. The Group has been strengthening its water-saving promotion, posting water-saving slogans, and guiding employees to use water reasonably. Through these water conservation measures, the employees' awareness of water conservation has been enhanced. As the expenditure related to water consumption was not incurred by the Group during the Reporting Period, the Group was unable to obtain the complete water consumption data during the Reporting Period. During the Reporting Period, the total water consumption of the Group was approximately 2 cubic meters (FY2021: approximately 3 cubic meters), representing a decrease of approximately 33%. During the Reporting Period, the Group's total water consumption intensity was approximately 0.03 cubic meters per revenue in million (FY2021: approximately 0.04 cubic meters per revenue in million), representing a decrease of approximately 25%.

Due to the Group's business nature and its operation location, there was no significant issue regarding sourcing water that is fit for purpose.

#### **Packaging Materials**

The Group only consumed a limited amount of plastic films in its business and operation, and therefore it is considered immaterial.

#### A3. The Environment and Natural Resources

Although the core business of the Group has limited impact on the environment and natural resources, as an ongoing commitment to good corporate social responsibility, we recognise the responsibility of minimising the negative environmental impacts of our operations in achieving sustainable development to generate long-term values to our stakeholders and the community.

The Group has set up the Corporate Social Responsibility Policy to work tirelessly to mitigate the environmental impacts of its activities through adopting industry best practices, targeted at reduction of natural resources consumption and effective emission management. We regularly assess our businesses' environmental risks, and adopt preventive measures to reduce those risks and ensure compliance with relevant laws and regulations.

#### **Indoor Air Quality**

Good indoor air quality is important as employees spend most of their time working at office. Indoor air quality in our workplace is regularly monitored and measured. Air pollutants, contaminants and dust particles are filtered out by air purifying equipment in the workplace, and regular cleaning of air conditioning system is conducted to ensure office's indoor air quality.

#### A4. Climate Change

The Group recognises that climate change has been affecting our stakeholders, business operations and communities in different aspects. The Group has formulated the Climate Change Policy to enhance its ability to respond to climate impacts and mitigate the risks and impacts of climate change on the Group, thereby helping the Group to adapt to and resist climate change. In FY2022, the Group paid close attention to the impact of climate change as described below.

#### **Physical Risks**

The increasing frequency and severity of extreme weather events such as extreme cold or extreme heat, storms, rainstorms and typhoons, could lead to an increased risk of power shortages, interrupt the supply chain and damage the Group's assets, disrupting the Group's operation. Climate change may lead to delay in shipment from our suppliers or to our customers, increase in the cost of production, leading to higher price of medical devices and resulting in reduced revenue, as well as increasing the cost of handling supply chain disruption and/or damaged sites. These events could also disrupt the work of employees and even cause casualties. As a countermeasure, the Group has formulated contingency arrangement to reduce or avoid losses when extreme weather events affect the Group's supply chain and/or operating sites. The Group will identify these risks and prioritise those that may have a significant impact to take precautionary measures in the first place. At the same time, the Group will examine the possibility of a change of business model to reduce or avoid these serious effects on business operations.

#### **Transition Risks**

To achieve sustainable development, governments are enacting climate-related legislation or tightening regulations to support the global vision of decarbonisation. The Stock Exchange of Hong Kong Limited has also required listed companies to enhance climate-related disclosures in their ESG reports, which may result in increased compliance costs. Failure to meet the climate change compliance requirements may expose the Group to risks of claims and lawsuits. Corporate reputation may also decline. The Group will regularly monitor existing and emerging climate-related trends, policies and regulations to avoid reputational risks due to delayed response. In addition, in order to reduce the Group's environmental impact and to comply with the requirements of the Stock Exchange of Hong Kong Limited, the Group has set targets to reduce energy consumption and GHG emissions. The Group will continue to assess the effectiveness of the Group's actions to address climate change and enhance its resilience against climate-related issues.


#### **B. SOCIAL**


#### **B1. Employment**

Human resources are the foundation in supporting the development of the Group. Hence, the Group has adopted Human Resource Management Policy and procedures to fulfil its vision of people-oriented management and realising the full potential of employees. These policies cover recruitment, compensation, promotion, working hours and rest periods, diversity and equal opportunity, etc.

During the Reporting Period, the Group was not aware of any material non-compliance with relevant laws and regulations that have a significant impact on the Group relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare. The relevant laws and regulations include, but are not limited to, the Employment Ordinance (Cap. 57), the Mandatory Provident Fund Schemes Ordinance (Cap. 485) and the Minimum Wage Ordinance (Cap. 608).

As at 31 March 2022, the Group had a total of 41 (As at 31 March 2021: 34). During the Reporting Period, all employees were located in Hong Kong. Further illustrations of our staff composition are as below:





The Group's overall turnover rate<sup>5</sup> during the Reporting Period was approximately 5.3% (FY2021: 35.8%). The Group's turnover rate<sup>6</sup> by gender, age group and geographical region was as follow:

Indicators	Unit	FY2022	FY2021
Overall turnover rate	%	5.3%	35.8%
By gender			
Male	%	4.4%	42.1%
Female	%	6.7%	27.6%
By age group			
18–35	%	7.7%	56.0%
36–55	%	4.4%	25.0%
56 or above	%	_	_
By geographical region			
Hong Kong	%	5.3%	35.8%

#### Notes:

- 5. Calculation method of the overall turnover rate: (total number of departures in the year ÷ ((total number of employees at the beginning of the year + total number of employees at the end of the year) ÷ 2))× 100%.
- 6. Calculation method of the employee turnover rate by category: (number of departures in the category in the year ÷ ((number of employees in the category at the beginning of the year + total number of employees in the category at the end of the year) ÷ 2))× 100%.

#### **Recruitment, Promotion and Dismissal**

We apply robust and transparent recruitment processes based on merit selection against the job criteria, and recruit individuals based on their experience, qualifications and expertise required for the position and potential to fulfil the Group's current and future needs.

Our basis for compensation and promotion are job-related skills, qualifications and performances, ensuring that we treat and evaluate employees and applicants in a fair way and compensate employees relative to the industry and local labour markets in which we operate, which consists of competitive level of fixed and variable compensation.

Unreasonable dismissal under any circumstances is forbidden in the Group. Dismissal process will only be preceded with a reasonable basis and a warning letter must be sent prior to the dismissal. Official dismissal will only be considered when the employee fails to correct the problems after receiving warning letter.

#### **Employee Welfare**

The Group determines the employee's remuneration based on factors such as qualification, contribution and years of experience. Remuneration packages include holidays, annual leave, medical scheme, dental scheme, group insurance, mandatory provident fund and discretionary bonus. The key principle of the Group's remuneration policy is to remunerate employees in a manner that is market competitive. The Group regularly carries its staff evaluation to assess their performance.

In addition, the Group has formulated policies for determining the working hours and rest periods for employees following local employment laws.

#### Diversity, Equal opportunity and Anti-discrimination

The Group is committed to creating and maintaining an inclusive and collaborative workplace culture in which all can thrive. With the aim of ensuring fair and equal protection for all employees, the Group has zero-tolerance for sexual harassment or abuse in the workplace in any form. The Group is dedicated to providing equal opportunity in all aspects of employment and maintaining workplace that is free from discrimination against any individual on the basis of race, religion, colour, gender, physical or mental disability, age, place of origin, marital status and sexual orientation.

#### **B2. Health and Safety**

We are committed to providing and maintaining a safe and healthy environment for all our employees. The Group has established relevant policies on the prevention and remediation of safety accidents, and detection of potential safety hazards in workplace, so as to maintain a safe working environment. During the Reporting Period, the number of working days lost by the Group due to work-related injuries was zero. No work-related fatalities occurred between 1 April 2019 and 31 March 2022.

During the Reporting Period, the Group was not aware of any material non-compliance with the relevant laws and regulations relating to providing a safe working environment and protecting employees from occupational hazards. The relevant laws and regulations include, but are not limited to, the Occupational Safety and Health Ordinance (Cap. 509) and the Employees' Compensation Ordinance (Cap. 282).

#### **Occupational Health and Safety**

The Group follows the occupational health and safety guidelines recommended by the Labour Department and the Occupational Safety and Health Council.

Human Resource Department takes responsibilities for offices' occupational health and safety and relevant promotions and monitoring. It is responsible for monitoring and reviewing the safety and security management system periodically, and performing regular checking in the office to ensure the safety of employees. On top of current practice, the Group has designed and implemented on-site and mechanical safety training to minimise the possibilities of significant occupational safety and health impacts.

The Group is formulating occupational safety education and training for employees to enhance their safety awareness by introducing training course based on health and safety rules and regulations as stipulated in the Occupational Safety and Health Ordinance. The Group was not subject to any claim or penalty or request of such in relation to health, work safety and had not been involved in any accident or fatality.

#### Other Health and Safety Measures

In the face of the coronavirus disease 2019 ("COVID-19") pandemic, the Group is highly conscious of the potential health and safety impacts brought to its employees. The Group has strengthened the sanitation of its operations to ensure a healthy and safe working environment. In addition, the Group has provided its employees with disinfection supplies like surgical masks, protective gowns and protective glasses subjected to their needs. The Group has set up a series of measures to reduce the risk of infection in the office, including but not limited to: staff in the office must wear face mask, service staff are equipped with face mask and shield, gloves and alcohol, staff are required to have a Rapid Antigen Test ("RAT") every week, staff taking any kind of sick leave are required to provide RAT test before being allowed to returning to work. The Group also sent out guidelines to employees advising on reporting measures in case of outbreak of the COVID-19 among employees and related family members.

#### **B3. Development and Training**

#### **Employee Development**

The Group regards our staff as the most important asset and resource. The Group recognises the valuable contribution of our talents to the continued success of the Group. The Group is committed to inspiring our human capital towards delivering excellence. This is achieved through the development of training strategy that focuses on creating value and serving the needs of its customers, talents and society. In light of this, the Group provides regular training, development programmes and training sponsorship for its employees.

To ensure the effectiveness of the training programmes, the Group has developed relevant policies for controlling the related training procedures. A training plan is developed by the management based on the requirements of various departments and employees. Training content is regularly updated to ensure contents are relevant to stakeholders' changing needs such as laws and regulations, market trend, product trend and customer behaviour change. The Group encourages and supports employees to participate in personal and professional training to fulfil the needs of the Group's development. The Group also encourages the culture of sharing knowledge and experience. On the other hand, the Group provides on-the-job training to enhance its staff's professional knowledge and expertise, as well as some external training courses and seminars.

During the Reporting Period, the percentage of total employees trained<sup>7</sup> was approximately 100% (FY2021: 85%). During the Reporting Period, the Group's average training hours completed per employee<sup>8</sup> were approximately 9.9 hours (FY2021: 7.9 hours). Training activities included but were not limited to safety regulations, performance management, business ethics and equipment and consumable trainings provided by suppliers.

Further illustrations of our training composition9 are as below:



The average training hours completed per employee<sup>10</sup> were as below:

Indicators	Unit	FY2022	FY2021
Average training hours completed nor employee	hours	9.9	7.9
Average training hours completed per employee  By employee category	Hours	9.9	7.9
Senior management	hours	2.0	4.0
Middle management	hours	11.1	11.3
General staff	hours	10.0	7.0
By gender			
Male	hours	11.4	8.3
Female	hours	7.6	7.4

#### Notes:

- 7. Calculation method of percentage of total employees trained: (number of employees trained ÷ total number of employees at the end of the year) × 100%.
- 8. Calculation method of average training hours completed per employee: total training hours ÷ total number of employees.
- Calculation method of percentage of employees trained by category: (number of employees trained in the category ÷ number of employees trained) x 100%.
- 10. Calculation method of average hours of training completed per employee by category: training hours of employees in the category ÷ number of employees in the category.

We believe that a harmonious working environment could enhance the Group's performance. During the Reporting Period, the Group did not organise annual dinner and other team building gatherings due to COVID-19 pandemic. However, the Group has promoted team spirit, strengthened the interdepartmental communication and enhance the work efficiency at workplace.

#### **B4. Labour Standards**

#### **Prevention of Child and Forced Labour**

Child and forced labour are strictly prohibited during the recruitment process as defined by laws and regulations. The Group strictly complies with local laws and conducts recruitment based on the Employment Ordinance (Cap. 57). During the Reporting Period, the Group was not aware of any material non-compliance with laws and regulations related to preventing child and forced labour that would have a significant impact on the Group. The relevant laws and regulations include, but are not limited to, Employment Ordinance (Cap. 57).

The Group has established a recruitment process to check the background of candidates and the formal reporting procedures to deal with any exceptions, and conducts regular reviews and inspections to prevent child and forced labour in operation. Personal data are collected during the process to assist in the selection of suitable candidates and to verify candidates' personal data. The Human Resources Department also ensures identity documents are carefully checked. If violation is involved, it will be dealt with in the light of the circumstances as clearly stated in the Group's Staff Handbook.

Furthermore, employees of the Group work overtime on a voluntary basis to prevent any breach of labour standards. We also prohibit any punishments, management methods and behaviours involving verbal abuse, physical punishment, physical abuse, oppression, sexual harassment, etc. against its employees for any reason.

If child labour or forced labour is found to be employed as a result of a breach of the recruitment process, the Group will immediately stop the work of the child labour or forced labour and conduct an investigation.

#### **B5. Supply Chain Management**

Suppliers of the Group's operation are primarily focused on supplying medical devices and providing medical device solutions, whereas suppliers of its medical devices services mainly comprised medical devices manufacturers, technicians and quality inspectors, etc. The Group has maintained long-term and stable relationships with major suppliers and business partners. All suppliers and business partners are evaluated carefully and are subjected to regular monitoring and assessment. As at 31 March 2022, the Group had a total of 46 suppliers around the world, including 19 in China, 15 in the United States, 5 in Germany, 4 in France and 3 in Malaysia. During the Reporting Period, all the 46 suppliers of the Group met the standard in the Group's regular supplier performance evaluation or compiled with the Group's Purchasing Policy.

#### **Environmental and Social Risks of Supply Chain**

In view of the increasing environmental concerns in society, the Group is aware of the importance in managing environmental and social risks of its supply chain. The Group has embedded environmental and social considerations in the procurement process and supplier communication. The Group will continue to monitor its supply chain regarding the environmental and social standards. Besides the above management procedures, we have formulated the related policies to clearly classify the suppliers, sub-contractors and sub-suppliers who deal with the Group, in order to manage the potential environmental and social risks along the supply chain.

We have also formulated the Purchasing Policy to ensure that the suppliers could be selected in a transparent and fair way. The Group should not differentiate or discriminate treatment of certain suppliers. The procedures include measures to prevent all kinds of business bribery and conflict of interest such as, the avoidance of employees' personal interests directly or indirectly in or given by the suppliers.

#### **Suppliers Selection**

Unless the customers specify, the Group selects its suppliers from our internal list of approved suppliers which is reviewed and updated periodically based on various factors such as track record, pricing, product quality, market reputation, timeliness of delivery, financial conditions and after-sales services.

The Group serves as a bridge between our overseas suppliers of medical devices and the manufacturers to manage the pre-market and post-market matters of the relevant medical devices, such that any updated medical device information can be disseminated to the relevant parties while feedbacks can be collected and delivered to the manufacturers for actions:



Our quality management rest on:

- 1. Efficient communication channels;
- 2. Application for listing medical devices;
- 3. Keeping detail distribution records;
- 4. Prompt feedback handling;
- 5. Maintenance and repair service arrangements; and
- 6. Product alerts modifications and recalls.

The Group is continuously performing assessment on our suppliers' performance, pricing competitiveness and compliance status through close communications and monitoring over daily operations.

#### **Green Procurement**

The Group is committed to supporting local economies by prioritising procurement from local suppliers to reduce the carbon footprint from transportation. The Group continuously monitors the policies implemented by the local government in the locations where it operates. If the information on environmentally friendly products or services are found published by official organisations, the Group will seriously consider adopting the recommendations of official organisations, to purchase goods and services that have less impact on the environment. If any of our suppliers commit any material violations of laws and regulations, we will consider terminating our contract with them.

#### **B6. Product Responsibility**

The Group attaches great importance to product quality and corporate reputation, actively ensuring its product and service quality through internal controls, and is committed to supplying quality products that meet the international standards. We also maintain close communication with customers to ensure we understand and meet their needs and expectation. We hope to understand customer's satisfaction, in order to continuously improve our products and services, so as to achieve customer satisfaction.

During the Reporting Period, the Group was not aware of any material non-compliance with the relevant laws and regulations relating to the prevention of child and forced labour. The relevant laws and regulations include, but are not limited to, the Group was not aware of any material non-compliance with child and forced labour-related laws and regulations including, but not limited to, Trade Descriptions Ordinance (Cap. 362), the Trade Marks Ordinance (Cap. 559), the Copyright Ordinance (Cap. 528) and the Personal Data (Privacy) Ordinance (Cap. 486).

Also, the Group did not have any recalled products due to safety and health reasons and did not receive any complaints in relation to product and services during the Reporting Period.

#### **Product Quality and Safety**

The Group pays high attention to the quality and safety of its services and products. The Group has a stringent quality assurance process across all operation-related departments and it strives to provide a pleasant user experience for its customers. The Group has designed and implemented certain measures to ensure our services and products meet a high standard of quality and safety and, that the risk of our product liability is contained. Our key measures include, but are not limited to:

- 1. Procurement from approved vendors only;
- 2. Appointed designated staff and engineers to inspect our medical devices and equipment on a regular basis;
- 3. Regularly review our inventory levels for slow-moving inventory, obsolescence or declines in market values;
- 4. Accepted reasonable returns or exchanges for minor defective products after careful examination;
- 5. Offered warranty (generally in one year term) on products to our customers; and
- 6. Established mechanism to report obsolete or expired products to senior executives.

As a risk transfer measure, we have procured insurance over our product liability. The Board continuously assesses the reasonable sufficiency and cost-effectiveness of such insurance policy and coverage. In addition, the suppliers may be required to indemnify us against any liabilities, losses and damages on account of any infringement by the products of any patent or trademark or any property damage or personal injury arising solely out of any defect in suppliers' manufacture, materials or workmanship of any products.

The Group carefully manages and monitors the quality of products. All products the Group sells are properly labelled to help the Group to keep track of its products. If there are quality issues with the products sold by the Group, the Group promptly identifies the source of defects and the defective batch of products through its tracking system. When necessary, the products will be recalled to rectify the issues and prevent recurrence in the future.

#### **IP Rights**

The Group believes that its branding and IP rights are critical to its success. The Group believes that many of its customers and target audience are attracted to it because of its strong brand names and reputation. The continuing success and growth of both of the Group's supplying medical devices and providing medical devices solutions services therefore depend on its ability to protect and promote its brands, trademarks, copyrights and other IP rights. During the Reporting Period, there were no disputes or infringements in connection with our IP rights pending or threatened against the Group which could have a material adverse effect on its operations or financial performance.

#### **Customer Privacy Protection**

The Group is committed to strengthening the protection of customers' privacy. The Group's employees are trained to maintain the confidentiality of its customers' information. The Group also has a data backup system through which our back-up data is stored in different locations to reduce the risk of data loss. We have also implemented firewall, anti-virus and anti-spam solutions for our IT systems to prevent leakage of confidential information, which are upgraded constantly. The Group regularly reviews the effectiveness of its information security controls to meet its privacy and data protection obligations.

#### **Advertising and Labelling**

The Group strictly complies with laws and regulations including the Trade Descriptions Ordinance (Cap. 362), continues to adopt fair marketing practices and ensures all products that it sells are properly labelled. The Group has regulated the conduct of marketing personnel in the process of product sales and contract signing, strictly prohibiting the dissemination of misleading and ambiguous product information and excessive commitment, and protecting customers' information rights.

#### **B7.** Anti-corruption

The Group does not tolerate any corruptions, frauds and all other behaviours violating work ethics. The Group values and upholds integrity, honesty and fairness in our business.

During the Reporting Period, the Group was not aware of any material non-compliance with the relevant laws and regulations relating to bribery, extortion, fraud and money laundering. The relevant laws and regulations include, but are not limited to, the Prevention of Bribery Ordinance (Cap. 201) and the Competition Ordinance (Cap. 619). There were no concluded legal cases regarding corrupt practices brought against the Group or its employees during the Reporting Period.

The Group regularly provides anti-corruption training, which covers legal knowledge about anti-corruption and integrity behaviours in the workplace. The anti-corruption training helps to encourage a clean and honest style of work, so that employees can be strict with themselves and fulfil their duties. During the Reporting Period, the Directors and employees of the Group received a total of approximately 4 hours and 38 hours of anti-corruption training respectively.

All Directors and staff of the Group are expected to carry out their work in an honest and ethical manner as outlined by the Code of Conduct.

#### **Anti-bribery**

The Group has established the Anti-bribery Guidelines to forbid the employees to solicit or accept an advantage in connection with his or her employment without permission of Directors, or make any payment or offer of payment or advantage that he or she knows with reasonable certainty will be given to any related parties to comply with the relevant laws and regulations. According to the Anti-bribery Policy, the Group has designed and implemented certain key anti-bribery measures including:

- 1. At least three suppliers must be invited to bid for deals that involve a large amount;
- 2. According to our approval matrix, material transactions must be approved by different work personnel and the senior management; and
- 3. Prohibit the use of business opportunities or authority to gain personal benefits or advantages.

#### **Anti-fraud**

The Group has also established the Anti-fraud Policy to detect and prevent fraud within the Group. By implementing the fraud risk assessment mechanism, the Group is able to dictate the frequency of risk assessment and apply relative investigation procedures so as to minimise the fraud risk to an acceptable level.

#### Whistle-blowing Policy

The Group has also implemented the Whistle-blowing Policy which allows all employees as well as independent third parties (e.g. customers, suppliers, contractors, etc.) who deal with the Group to report any possible improprieties, misconducts, malpractices or irregularities in matters of financial reporting, internal control or other matters to the Board or the audit committee anonymously. The Group will handle the reports and complaints with care and will treat the whistle-blowers' concerns fairly and properly. Any person who is found to have victimized or retaliated against those who have raised concerns under this policy will be subjected to disciplinary sanctions. The Board and the audit committee will supervise and review the implementation and effectiveness of the Whistle-blowing Policy on a regular basis.

#### **B8. Community Investment**

#### **Community Participation**

The Group is committed to supporting the public by means of social participation and contribution as part of its strategic development. As mentioned in our Corporate Social Responsibility Policy, the Group's community investment focuses on areas including education, and elderly care. To nurture corporate culture and strengthen practices of corporate citizenship, we embrace human capital into the social management strategies so as to sustain our corporate social responsibility and support the Group's strategic development. Our employees are encouraged to donate to recognised charitable institutions in order to help the grass-root community or those in need, so that they can receive proper education and medical care.

During the Reporting Period, we have donated HK\$12,500 to Rice Packing Service Volunteer organised by St. James' Settlement.

Furthermore, the Group received several awards from different organisations during the Reporting Period, assuring our effort in achieving sustainable development while contributing to the community:

- Caring Company 2021/2022 from The Hong Kong Council of Social Service;
- Honorary Fellow from The Professional Validation Centre of Hong Kong Business Sector Ltd. (Bikie Wong, Chairman of the Board and Chief Executive Officer); and
- HKMA/Viu TV & Now TV Awards for Marketing from the Hong Kong Management Association (Bikie Wong, Chairman of the Board and Chief Executive Officer).

#### THE ESG REPORTING GUIDE CONTENT INDEX OF THE STOCK EXCHANGE OF **HONG KONG LIMITED (1)**

Mandatory Disclosure Requirements	Sections
2	
Governance Structure	CHAIRMAN'S STATEMENT; SUSTAINABILITY GOVERNANCE;
	STAKEHOLDER ENGAGEMENT; MATERIALITY ASSESSMENT
Reporting Principles	REPORTING FRAMEWORK
Reporting Boundary	SCOPE OF REPORTING

#### THE ESG REPORTING GUIDE CONTENT INDEX OF THE STOCK EXCHANGE OF **HONG KONG LIMITED (2)**

Aspects, General		
Disclosures and KPIs	Descriptions	Sections/Declarations
Aspect A1: Emissions		
General Disclosure	Information on:  (a) the policies; and  (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air and greenhouse gas emissions, discharges into water and land, and generation of	A1. Emissions
	hazardous and non-hazardous waste.	
KPI A1.1	The types of emissions and respective emissions data.	A1. Emissions — Air Emissions
KPI A1.2	Direct (Scope 1) and energy indirect (Scope 2) greenhouse gas emissions (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	A1. Emissions — GHG Emissions
KPI A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	A1. Emissions — Waste Management (Not applicable — explained)
KPI A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	A1. Emissions — Waste Management
KPI A1.5	Description of emissions target(s) set and steps taken to achieve them.	A1. Emissions — GHG Emissions
KPI A1.6	Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.	A1. Emissions — Waste Management

Aspects, General		
Disclosures and KPIs	Descriptions	Sections/Declarations
Aspect A2: Use of Reso	urces	
General Disclosure	Policies on the efficient use of resources, including energy, water and other raw materials.	A2. Use of Resources
KPI A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	A2. Use of Resources — Energy Management
KPI A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	A2. Use of Resources — Water Consumption
KPI A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them	A2. Use of Resources — Energy Management
KPI A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	A2. Use of Resources — Water Consumption
KPI A2.5	Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	A2. Use of Resources — Packaging Materials (Not applicable — explained)
Aspect A3: The Environ	ment and Natural Resources	
General Disclosure	Policies on minimising the issuer's significant impacts on the environment and natural resources.	A3. The Environment and Natural Resources
KPI A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	A3. The Environment and Natural Resources
Aspect A4: Climate Cha	nge	
General Disclosure	Policies on identification and mitigation of significant climate-related issues which have impacted, and those which may impact, the issuer.	A4. Climate Change
KPI A4.1	Description of the significant climate-related issues which have impacted, and those which may impact, the issuer, and the actions taken to manage them.	A4. Climate Change — Physical Risks; A4. Climate Change — Transition Risks

Aspects, General		
Disclosures and KPIs	Descriptions	Sections/Declarations
Aspect B1: Employment		
General Disclosure	Information on:	B1. Employment
	(a) the policies; and	
	(b) compliance with relevant laws and regulations that have a significant impact on the issuer	
	relating to compensation and dismissal, recruitment	
	and promotion, working hours, rest periods, equal	
	opportunity, diversity, anti-discrimination, and other	
	benefits and welfare.	
KPI B1.1	Total workforce by gender, employment type (for	B1. Employment
	example, full- or part-time), age group and	
KPI B1.2	geographical region.	D4 Francisco una cust
NPIDI.2	Employee turnover rate by gender, age group and geographical region.	B1. Employment
	goograpmoarrogion.	
Aspect B2: Health and S	afety	
General Disclosure	Information on:	B2. Health and Safety
	(a) the policies; and	
	(b) compliance with relevant laws and regulations	
	that have a significant impact on the issuer	
	relating to providing a safe working environment and protecting employees from occupational hazards.	
KPI B2.1	Number and rate of work-related fatalities occurred in	B2. Health and Safety
	each of the past three years including the reporting	,
	year.	
KPI B2.2	Lost days due to work injury.	B2. Health and Safety
KPI B2.3	Description of occupational health and safety	B2. Health and Safety —
	measures adopted, and how they are implemented	Occupational Health and Safety;
	and monitored.	B2. Health and Safety — Other Health and Safety Measures
		ricaliti and dalety weasures
Aspect B3: Development	t and Training	
General Disclosure	Policies on improving employees' knowledge and	B3. Development and Training
	skills for discharging duties at work. Description of	<ul> <li>Employee Development</li> </ul>
I/DI DO 1	training activities.	P2 Dayslanment and Training
KPI B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle	B3. Development and Training  — Employee Development
	management).	Employee Development
KPI B3.2	The average training hours completed per employee	B3. Development and Training
	by gender and employee category.	— Employee Development

Aspects, General Disclosures and KPIs	Descriptions	Sections/Declarations
Aspect B4: Labour Stan	ndards	
General Disclosure	Information on:	B4. Labour Standards —
	(a) the policies; and	Prevention of Child and Forced
	(b) compliance with relevant laws and regulations that have a significant impact on the issuer	Labour
	relating to preventing child and forced labour.	
KPI B4.1	Description of measures to review employment	B4. Labour Standards — Prevention of Child and Forced
	practices to avoid child and forced labour.	Labour
KPI B4.2	Description of steps taken to eliminate such practices	B4. Labour Standards —
	when discovered.	Prevention of Child and Forced Labour
Aspect B5: Supply Chai	in Management	
General Disclosure	Policies on managing environmental and social risks of the supply chain.	B5. Supply Chain Management
KPI B5.1	Number of suppliers by geographical region.	B5. Supply Chain Management
KPI B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored	B5. Supply Chain Management — Suppliers Selection
KPI B5.3	Description of practices used to identify	B5. Supply Chain Management
	environmental and social risks along the supply chain, and how they are implemented and monitored.	<ul> <li>Environmental and Social Risks of Supply Chain</li> </ul>
KPI B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	B5. Supply Chain Management  — Green Procurement

to recalls for safety and health reasons.  KPI B6.2 Number of products and service related complaints received and how they are dealt with.  KPI B6.3 Description of practices relating to observing and protecting intellectual property rights.  KPI B6.4 Description of quality assurance process and recall product Responsibility — IP Rescription of quality assurance process and recall product Quality and Safety Product Quality and Safety B6. Product Responsibility — Product Quality and Safety Product Quality and Safety Product Quality and Safety Product Quality and Safety B6. Product Responsibility — Product Quality and Safety Product Quality and Safety Product Quality and Safety B6. Product Responsibility — Customer Privacy Protection monitored.  Aspect B7: Anti-corruption  General Disclosure Information on:  (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.	Aspects, General Disclosures and KPIs	Descriptions	Sections/Declarations
General Disclosure  Information on:  (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.  KPI B6.1 Percentage of total products sold or shipped subject to recalls for safety and health reasons.  KPI B6.2 Number of products and service related complaints received and how they are dealt with.  KPI B6.3 Description of practices relating to observing and protecting intellectual property rights.  KPI B6.4 Description of quality assurance process and recall procedures.  KPI B6.5 Description of consumer data protection and privacy policies, and how they are implemented and monitored.  Aspect B7: Anti-corruption  General Disclosure Information on:  (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;	Aspect PS: Product Pos	noncibility.	
(a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.  KPI B6.1 Percentage of total products sold or shipped subject to recalls for safety and health reasons.  KPI B6.2 Number of products and service related complaints received and how they are dealt with.  KPI B6.3 Description of practices relating to observing and protecting intellectual property rights.  KPI B6.4 Description of quality assurance process and recall procedures.  KPI B6.5 Description of consumer data protection and privacy policies, and how they are implemented and monitored.  Aspect B7: Anti-corruption  General Disclosure Information on:  (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;	=		R6 Product Rosponsibility
(b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.  KPI B6.1 Percentage of total products sold or shipped subject to recalls for safety and health reasons.  KPI B6.2 Number of products and service related complaints received and how they are dealt with.  KPI B6.3 Description of practices relating to observing and protecting intellectual property rights.  KPI B6.4 Description of quality assurance process and recall procedures.  KPI B6.5 Description of consumer data protection and privacy policies, and how they are implemented and monitored.  Aspect B7: Anti-corruption  General Disclosure Information on:  (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;	General Disclosure		Bo. Froduct Nesponsibility
that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.  KPI B6.1 Percentage of total products sold or shipped subject to recalls for safety and health reasons.  KPI B6.2 Number of products and service related complaints received and how they are dealt with.  KPI B6.3 Description of practices relating to observing and protecting intellectual property rights.  KPI B6.4 Description of quality assurance process and recall procedures.  KPI B6.5 Description of consumer data protection and privacy policies, and how they are implemented and monitored.  Aspect B7: Anti-corruption  General Disclosure Information on:  (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;			
relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.  KPI B6.1 Percentage of total products sold or shipped subject to recalls for safety and health reasons.  KPI B6.2 Number of products and service related complaints received and how they are dealt with.  KPI B6.3 Description of practices relating to observing and protecting intellectual property rights.  KPI B6.4 Description of quality assurance process and recall procedures.  KPI B6.5 Description of consumer data protection and privacy policies, and how they are implemented and monitored.  Aspect B7: Anti-corruption  General Disclosure Information on:  (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;			
and privacy matters relating to products and services provided and methods of redress.  KPI B6.1 Percentage of total products sold or shipped subject to recalls for safety and health reasons.  KPI B6.2 Number of products and service related complaints received and how they are dealt with.  KPI B6.3 Description of practices relating to observing and protecting intellectual property rights.  KPI B6.4 Description of quality assurance process and recall procedures.  KPI B6.5 Description of consumer data protection and privacy policies, and how they are implemented and monitored.  Aspect B7: Anti-corruption  General Disclosure Information on:  (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;			
RPI B6.1 Percentage of total products sold or shipped subject to recalls for safety and health reasons.  KPI B6.2 Number of products and service related complaints received and how they are dealt with.  KPI B6.3 Description of practices relating to observing and protecting intellectual property rights.  KPI B6.4 Description of quality assurance process and recall procedures.  KPI B6.5 Description of consumer data protection and privacy policies, and how they are implemented and monitored.  Aspect B7: Anti-corruption  General Disclosure Information on:  (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented to B7. Anti-corruption — Whistlebry implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;			
to recalls for safety and health reasons.  KPI B6.2 Number of products and service related complaints received and how they are dealt with.  KPI B6.3 Description of practices relating to observing and protecting intellectual property rights.  KPI B6.4 Description of quality assurance process and recall procedures.  KPI B6.5 Description of consumer data protection and privacy policies, and how they are implemented and monitored.  Aspect B7: Anti-corruption  General Disclosure Information on:  (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery; implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;			
KPI B6.2 Number of products and service related complaints received and how they are dealt with.  KPI B6.3 Description of practices relating to observing and protecting intellectual property rights.  KPI B6.4 Description of quality assurance process and recall procedures.  KPI B6.5 Description of consumer data protection and privacy policies, and how they are implemented and monitored.  Aspect B7: Anti-corruption  General Disclosure Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;	KPI B6.1	Percentage of total products sold or shipped subject	B6. Product Responsibility
received and how they are dealt with.  KPI B6.3  Description of practices relating to observing and protecting intellectual property rights.  KPI B6.4  Description of quality assurance process and recall product Responsibility — Product Quality and Safety B6. Product Responsibility — Customer Privacy Protection monitored.  Aspect B7: Anti-corruption  General Disclosure  Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1  Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2  Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3  Description of anti-corruption training provided to  B7. Anti-corruption — Anti-bribery;		to recalls for safety and health reasons.	
KPI B6.3  Description of practices relating to observing and protecting intellectual property rights.  KPI B6.4  Description of quality assurance process and recall procedures.  KPI B6.5  Description of consumer data protection and privacy policies, and how they are implemented and monitored.  Aspect B7: Anti-corruption  General Disclosure  Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1  Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2  Description of anti-corruption training provided to  B6. Product Responsibility — Product Quality and Safety B6. Product Responsibility — Product Qua	KPI B6.2	Number of products and service related complaints	B6. Product Responsibility
protecting intellectual property rights.  KPI B6.4  Description of quality assurance process and recall product Responsibility — procedures.  KPI B6.5  Description of consumer data protection and privacy policies, and how they are implemented and monitored.  Aspect B7: Anti-corruption  General Disclosure  Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1  Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2  Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3  Description of anti-corruption training provided to  B7. Anti-corruption — Anti-bribery;		received and how they are dealt with.	
KPI B6.4 Description of quality assurance process and recall procedures.  KPI B6.5 Description of consumer data protection and privacy policies, and how they are implemented and monitored.  Aspect B7: Anti-corruption  General Disclosure Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;	KPI B6.3	Description of practices relating to observing and	B6. Product Responsibility — IP
procedures.  Description of consumer data protection and privacy policies, and how they are implemented and monitored.  Aspect B7: Anti-corruption  General Disclosure  Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1  Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2  Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3  Description of anti-corruption training provided to  B7. Anti-corruption — Whistle-blowing Policy  B7. Anti-corruption — Anti-bribery;		protecting intellectual property rights.	Rights
KPI B6.5  Description of consumer data protection and privacy policies, and how they are implemented and monitored.  Customer Privacy Protection  Customer Privacy Protection  Customer Privacy Protection  B7. Anti-corruption  B7. Anti-corruption — Whistle-whistleblowing procedures, how they are implemented and monitored.  B7. Anti-corruption — Whistle-blowing Policy  B7. Anti-corruption — Anti-bribery;  B7. Anti-corruption — Anti-bribery;	KPI B6.4	Description of quality assurance process and recall	
policies, and how they are implemented and monitored.  Aspect B7: Anti-corruption  General Disclosure  Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1  Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2  Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3  Description of anti-corruption training provided to  B7. Anti-corruption — Anti-bribery;		·	
Aspect B7: Anti-corruption  General Disclosure Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;	KPI B6.5		
Aspect B7: Anti-corruption  General Disclosure Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;			Customer Privacy Protection
General Disclosure  Information on:  (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1  Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2  Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3  Description of anti-corruption training provided to  B7. Anti-corruption — Whistle- blowing Policy implemented and monitored.  B7. Anti-corruption — Anti-bribery;		monitored.	
(a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to  B7. Anti-corruption — Whistle- blowing Policy implemented and monitored.  B7. Anti-corruption — Anti-bribery;	Aspect B7: Anti-corrupt	ion	
(b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to  B7. Anti-corruption — Whistle- blowing Policy implemented and monitored.  B7. Anti-corruption — Anti-bribery;	General Disclosure		B7. Anti-corruption
that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are blowing Policy implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;			
relating to bribery, extortion, fraud and money laundering.  KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;		, ,	
KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;		_ · · · · · · · · · · · · · · · · · · ·	
KPI B7.1 Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;			
practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and blowing Policy implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;	I/DI D7 4	<u> </u>	DZ Anti mu mti
during the reporting period and the outcomes of the cases.  KPI B7.2 Description of preventive measures and blowing Policy implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;	KPI B7.1		B7. Anti-corruption
cases.  KPI B7.2 Description of preventive measures and B7. Anti-corruption — Whistle-whistleblowing procedures, how they are blowing Policy implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;			
KPI B7.2 Description of preventive measures and whistleblowing procedures, how they are blowing Policy implemented and monitored.  KPI B7.3 Description of preventive measures and blowing Policy blowing Policy B7. Anti-corruption — Anti-bribery;			
whistleblowing procedures, how they are blowing Policy implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;	KPI R7 2		B7 Anti-corruntion — Whietle
implemented and monitored.  KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;	M 1 D1.2		·
KPI B7.3 Description of anti-corruption training provided to B7. Anti-corruption — Anti-bribery;			Stating Folloy
	KPI B7.3	·	B7. Anti-corruption — Anti-bribery:
	-		

Aspects, General Disclosures and KPIs	Descriptions	Sections/Declarations
Aspect B8: Community	Investment	
General Disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	B8. Community Investment — Community Participation
KPI B8.1	Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).	B8. Community Investment — Community Participation
KPI B8.2	Resources contributed (e.g. money or time) to the focus area.	B8. Community Investment — Community Participation

The Directors present their report and the audited consolidated financial statements of the Group for the year ended 31 March 2022.

#### PRINCIPAL ACTIVITIES

The principal activity of the Company is investment holding. The activities of the subsidiaries are set out in note 32 to the consolidated financial statements.

#### **BUSINESS REVIEW**

A fair review of the Group's business and the analysis of the Group's performance for the year ended 31 March 2022 as well as outlook/prospects of the Group's business are provided in the sections "Chairman's Statement" on page 4, and "Management Discussion and Analysis" on pages 5 to 10 of this annual report.

Description of key risk factors and uncertainties that the Group is facing is provided in Management Discussion and Analysis on pages 5 to 10 of this annual report and in note 5 to the consolidated financial statements while the financial risk management objectives and policies of the Group can be found in note 35 to the consolidated financial statements. An analysis of the Group's performance during the year using financial key performance indicators is provided in the Financial Summary on page 120 of the annual report. In addition, discussions on the Group's compliance with relevant laws and regulations which have a significant impact on the Group, relationships with its key stakeholders and environmental policy are contained in the Directors' Report on pages 55 to 64 of the annual report and in the Environmental, Social and Governance Report on pages 27 to 54 respectively.

#### **SEGMENTAL INFORMATION**

An analysis of the Group's revenue from operations by geographical locations of customers for the year ended 31 March 2022 is set out in note 6 to the consolidated financial statements.

#### **RESULTS AND DIVIDENDS**

The results of the Group for the year ended 31 March 2022 and its consolidated financial position as at that date are set out in the consolidated financial statements on pages 69 and 70 of this annual report respectively.

The Board declared payment of an interim dividend of HK0.3 cent (2021: HK0.45 cent) per ordinary share, in lieu of final dividend, for the year ended 31 March 2022.

#### **CLOSURE OF THE REGISTER OF MEMBERS**

#### (A) Entitlement to Interim Dividend

For the purpose of determining Shareholders' entitlement to the interim dividend, the register of members of the Company will be closed from Wednesday, 6 July 2022 to Friday, 8 July 2022, both days inclusive, during which period no transfer of Shares will be registered. The record date will be Friday, 8 July 2022. In order to qualify for the entitlement of the interim dividend, all transfer documents accompanied by the relevant share certificates must be lodged with the Company's Hong Kong branch share registrar and transfer office, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong, for registration no later than 4:30 p.m. on Tuesday, 5 July 2022.

#### (B) Entitlement to Attend and Vote at the AGM

For the purpose of determining Shareholders' entitlement to attend and vote at the forthcoming AGM to be held on Friday, 16 September 2022, the register of members of the Company will be closed from Tuesday, 13 September 2022 to Friday, 16 September 2022, both days inclusive, during which period no transfer of Shares will be registered. In order to qualify for attending and voting at the AGM, all transfer documents accompanied by the relevant share certificates must be lodged with the Company's Hong Kong branch share registrar and transfer office, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong for registration no later than 4:30 p.m. on Friday, 9 September 2022.

#### **DONATIONS**

Donations made by the Group during the year amounted to approximately HK\$13,000.

#### SUMMARY OF FINANCIAL INFORMATION

A summary of the published results and assets and liabilities of the Group for the last five financial years, as extracted from the audited financial statements and the Prospectus, is set out on page 120 in this annual report.

#### PROPERTY, PLANT AND EQUIPMENT

Details of movements in the property, plant and equipment of the Group during the financial year are set out in note 15 to the consolidated financial statements.

#### SHARE CAPITAL

Details of the Company's share capital are set out in note 26 to the consolidated financial statements.

#### **RESERVES**

Details of the movements in the reserves of the Company and the Group are set out in note 27 to the consolidated financial statements and the consolidated statement of changes in equity, respectively.

#### **PRE-EMPTIVE RIGHTS**

There is no provision for pre-emptive rights under the Articles of Association of the Company or the laws of the Cayman Islands, being the jurisdiction in which the Company was incorporated, which would oblige the Company to offer new shares on a pro rata basis to existing shareholders.

#### **DISTRIBUTABLE RESERVES**

As at 31 March 2022, the distributable reserves of the Company amounted to approximately HK\$80.5 million.

Under the Companies Law of the Cayman Islands, subject to the provisions of Articles of Association of the Company, the Company's share premium account may be applied to pay distributions or dividends to shareholders provided that immediately following the date of distribution or dividend is proposed to be paid, the Company is able to pay its debts as they fall due in the ordinary course of business.

#### **MAJOR CUSTOMERS AND SUPPLIERS**

During the year ended 31 March 2022, so far as the Company is aware, the aggregate revenue attributable to our five largest customers and the largest customer accounted for approximately 38.0% and 10.6%, respectively, of the Group's total revenue for the financial year. Purchases from the Group's five largest suppliers accounted for approximately 76.6% of the Group's total purchases for the financial year and the purchase from the largest supplier included therein amounted to approximately 34.9%.

None of the Directors, or any of his or her close associates (as defined under the GEM Listing Rules) or shareholders (which, to the best knowledge of the Directors, own more than 5% of the Company's issued share capital), had any beneficial interest in the Group's five largest customers or suppliers during the financial year.

#### **DIRECTORS**

The Directors during the year and up to the date of this report were as follows:

#### **Executive Directors**

Ms. Wong Bik Kwan Bikie (Chairman and Chief Executive Officer)

#### **Non-executive Directors**

Dr. Miu Yin Shun Andrew

Mr. Chiu Man Wai

#### **Independent non-executive Directors**

Mr. Ng Leung Sing SBS, JP

Mr. Wong Lung Wo James

Mr. Chow Ming Po Aaron (appointed on 21 June 2021)

Mr. Chan Ping Keung (retired on 17 September 2021)

Pursuant to Article 84(1) of the Articles, one-third of the Directors for the time being (or, if their number is not a multiple of three (3), the number nearest to but not less than one-third) shall retire from office by rotation at each annual general meeting, provided that every Director shall be subject to retirement at an annual general meeting at least once every three years. Mr. Ng Leung Sing, SBS, JP and Mr. Wong Lung Wo James will retire by rotation at the 2022 AGM, and being eligible, will offer themselves for re-election.

#### PERMITTED INDEMNITY PROVISION

Every Director shall be entitled under the Articles of Association of the Company to be indemnified out of the assets of the Company against all actions, costs, charges, losses, damages and expenses incurred or sustained by him or her as a Director in the execution or discharge of his or her duty.

The Company has taken out insurance against the liability and costs associated with defending any proceedings which may be brought against the Directors.

#### **COMPLIANCE WITH THE RELEVANT LAWS AND REGULATIONS**

During the year, there was no material breach of or non-compliance with the applicable laws and regulations by the Group.

#### **DIRECTORS' SERVICE CONTRACTS**

The executive Director entered into a service contract with the Company on 1 March 2021 for an initial term of three years commencing 1 March 2021. The service contract is subject to termination in accordance with her terms. The service contract may be renewed in accordance with the Articles of Association of the Company and the applicable GEM Listing Rules. Mr. Chiu Man Wai and Dr. Miu Yin Shun Andrew have respectively entered into an appointment letter for a term of three years commencing from 17 September 2021, Mr. Chow Ming Po Aaron has entered into an appointment letter for a term of three years commencing on 21 June 2021. Mr. Ng Leung Sing, SBS, JP and Mr. Wong Lung Wo James have respectively entered into an appointment letter for a term commencing from 18 September 2019, until their respective retirement by rotation and re-election at the Company's annual general meeting in accordance with the Articles of Association of the Company in force from time to time and can be terminated by either party by giving at least one month's notice in writing.

None of the Directors has or is proposed to have a service contract with the Company or any of its subsidiaries other than contracts expiring or determinable by the employer within one year without the payment of compensation (other than statutory compensation).

#### **DIRECTORS' AND SENIOR MANAGEMENT'S BIOGRAPHIES**

Biographical details of the Directors and the senior management of the Company are set out on pages 11 to 14 of this annual report.

#### **EMOLUMENTS OF DIRECTORS AND FIVE HIGHEST PAID INDIVIDUALS**

Details of the emoluments of the Directors and the five highest paid individuals of the Group are set out in note 12 to the consolidated financial statements.

#### REMUNERATION POLICY

The Company's remuneration policy comprises primarily a fixed component (in the form of a base salary) and a variable component (which includes commissions, discretionary bonus and other merit payments), taking into account factors such as their experience, level of responsibility, individual performance, the profit performance of our Group and general market conditions.

The remuneration of the Directors is determined on the basis of the relevant Director's experience, responsibility, performance and the time devoted to the business.

The Remuneration Committee will meet at least once for each year to discuss remuneration related matters (including the remuneration of the Directors and the senior management of the Company) and review the remuneration policy of the Group.

#### RELATIONSHIPS WITH EMPLOYEES, SUPPLIERS AND CUSTOMERS

The Group's management policies, working environment, career prospects and employees' benefits have contributed to building a good employee relations and employee retention of the Group. The Group offers competitive remuneration packages commensurate with industry practice and provides various fringe benefits to employees including medical benefits, social insurance, mandatory provident funds, bonuses and a share option scheme. The management regularly reviews its employee's remuneration packages to ensure they are up to prevailing market standard.

The Group has established long term business relationships with its major suppliers and customers for over years. The Group will endeavor to maintain its established relationship with these existing suppliers and customers.

#### **ENVIRONMENTAL, SOCIAL AND GOVERNANCE POLICY**

The Group believes sustainability is the key to achieve continuing success and has integrated this key concept into its business strategy. In order to pursue a successful and sustainable business model, the Group recognises the importance of integrating ESG aspects into its risk management system and has taken corresponding measures in its daily operations and governance perspective.

#### RETIREMENT BENEFITS PLAN

Particulars of retirement benefits plan of the Group for the year ended 31 March 2022 are set out in note 4m(ii) to the consolidated financial statements.

#### MANAGEMENT CONTRACTS

During the financial year, the Company did not enter into or have any management and administration contracts in respect of the whole or any principal business of the Company.

#### DIRECTORS' RIGHT TO ACQUIRE SHARES OR DEBENTURES

Save as the share option scheme as set out in section headed "Share Option Scheme", at no time during the financial year were rights to acquire benefits by means of the acquisition of shares or debentures of the Company granted to any Director or their respective associates, or were any such rights exercised by them; or was the Company, or any of the Company's subsidiaries a party to any arrangement to enable the Directors or their respective associates to acquire such rights in any other body corporate.

# DIRECTORS' AND CHIEF EXECUTIVE'S INTEREST AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES OR DEBENTURES OF THE COMPANY OR ANY ASSOCIATED CORPORATION

As at 31 March 2022, the interests and short positions of the Directors and chief executive of the Company in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) which shall have to be notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they are taken or deemed to have under such provisions of the SFO) or which shall be required, pursuant to section 352 of the SFO, to be recorded in the register referred to therein or which shall be required to notify the Company and the Hong Kong Stock Exchange pursuant to Rule 5.46 to Rule 5.67 of the GEM Listing Rules, were as follows:

#### Long position in the shares of the Company and associated corporations

Name of Director/ chief executive	Name of Group member/associated corporation	Nature of Interest	Number of shares	Number of underlying shares	Aggregate Interest	Approximate percentage of shareholding
Ms. Wong (Note 1)	The Company	Interest in a controlled corporation	557,424,000	-		
		Beneficial owner		7,980,000		
			557,424,000	7,980,000	565,404,000	70.68%
	B&A Success	Beneficial owner	100 shares of US\$1.00 each	-	-	100%
Dr. Miu (Note 2)	The Company	Interest of spouse	557,424,000	7,980,000	565,404,000	70.68%
Mr. Chiu (Note 3)	The Company	Interest in a controlled corporation	20,224,001	-	20,224,001	2.53%
	Infinite Crystal Limited	Beneficial owner	900 shares of US\$1.00 each	-	-	100%
Mr. Chow	The Company	Beneficial owner	7,810,000	-	7,810,000	0.98%

#### Notes:

- The shares are registered in the name of B&A Success Limited ("B&A Success"), the entire issued share capital of which is legally and beneficially owned by Ms. Wong. Under the SFO, Ms. Wong is deemed to be interested in the same number of shares held by B&A Success.
- 2. Dr. Miu is the spouse of Ms. Wong. Under the SFO, Dr. Miu is deemed to be interested in the same number of shares deemed to be held by Ms. Wong.
- 3. The shares are registered in the name of Infinite Crystal Limited, the entire issued share capital of which is legally and beneficially owned by Mr. Chiu. Under the SFO, Mr. Chiu is deemed to be interested in the same number of shares held by Infinite Crystal Limited.

Save as disclosed above, as at 31 March 2022, none of the Directors and chief executive of the Company had any interests or short positions in any shares, underlying shares and debenture of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which would have to be notified to the Company and the Hong Kong Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO), or which were recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO, or which were required to be notified to the Company and the Hong Kong Stock Exchange, pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules.

#### SUBSTANTIAL SHAREHOLDERS' AND OTHER PERSONS' INTERESTS AND SHORT POSITIONS IN SHARES OR UNDERLYING SHARES OF THE COMPANY

As at 31 March 2022, so far as the Directors are aware, other than the Directors or chief executive of the Company whose interests are disclosed under the paragraph headed "Directors' and chief executive's interest and short positions in shares, underlying shares or debentures of the Company or any associated corporation" above, the following persons had an interest or short position in the shares or underlying shares of the Company which shall be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or, directly or indirectly, were interested in 5.0% or more of the issued voting shares of any member of the Group:

#### Long position in the shares of the Company

Name of shareholders	Nature of Interest	Total number of shares	Approximate percentage of shareholding
B&A Success	Beneficial owner	557,424,000	69.68%

Saved as disclosed above and so far as is known to the Directors, the Directors were not aware of any other persons other than the Directors or chief executive of the Company who held an interest or short positions in the shares and underlying shares of the Company as at 31 March 2022 which required to be recorded pursuant to section 336 of the SFO.

#### SHARE OPTION SCHEME

The Company has adopted the share option scheme (the "Share Option Scheme") on 1 March 2018. The total number of shares which may be issued upon exercise of all options to be granted under the Share Option Scheme shall not in aggregate exceed 80,000,000 shares, being 10% of the total number of shares in issue at the time dealings in the shares first commenced on the Hong Kong Stock Exchange. The total number of shares issued and which may fall to be issued upon exercise of the options granted under the Share Option Scheme and any other share option scheme of the Group (including both exercised and outstanding options) to each participant in any 12-month period shall not exceed 1.0% of the shares in issue as at the date of grant.

The purpose of the Share Option Scheme is to enable the Group to grant options to selected participants as incentives or rewards for their contribution to the Group. The Directors consider the Share Option Scheme will enable the Group to reward the employees, Directors and other selected participants for their contributions to the Group. The Board may, at its discretion, grant an option to the eligible participants to subscribe for shares at an exercise price and subject to the other terms of the Share Option Scheme.

The subscription price for shares under the Share Option Scheme will be a price determined by the Board and shall be the highest of (i) the closing price of the shares as stated in the Hong Kong Stock Exchange's daily quotations sheet on the date of the offer of grant; (ii) the average closing price of the shares as stated in the Hong Kong Stock Exchange's daily quotations sheet for the five trading days immediately preceding the date of the offer of grant; and (iii) the nominal value of a share.

The Share Option Scheme will remain in force for a period of ten years commencing on the date on which the Share Option Scheme is adopted. Subject to certain restrictions contained in the Share Option Scheme, an option may be exercised in accordance with the terms of the Share Option Scheme and the terms of grant thereof at any time during the applicable option period, which is not more than ten years from the date of grant of option. There is no general requirement on the minimum period under the Share Option Scheme for the holding of an option before it can be exercised. However, at the time of granting any option, the Board may, on a case by case basis, make such grant subject to such conditions, restrictions or limitations including (without limitation) those in relation to the minimum period of the options to be held and/or the performance targets to be achieved as the Board may determine in its absolute discretion.

A nominal consideration of HK\$1.0 is payable on acceptance of the grant of an option.

A total of 71,940,000 Shares are available for issue under the Share Option Scheme, representing 8.99% of the total issued capital of the Company as at the date of this Annual Report.

Details of Share Options granted and their movements during the year ended 31 March 2022 are as follows:

			Number of Shares issuable under the options						
	Date of Grant	Exercise price per Share HK\$	as at 01/04/ 2021	granted during the period	exercised during the period	lapsed during the period	as at 31/3/ 2022	Exercise period	
<b>Directors</b> Ms. Wong	18/04/2019	0.12	7,980,000	-	-	-	7,980,000	Note 1	
Employees of the Group									
In aggregate	18/04/2019	0.12	13,480,000	_	_	_	13,480,000	Note 1	
			21,460,000	-	-	-	21,460,000		

#### Notes:

- 1. (i) up to 40% of the Share Options are exercisable on or after 18 April 2019;
  - (ii) up to 70% of the Share Options are exercisable on or after 18 April 2020;
  - (iii) all the remaining Share Options are exercisable on or after 18 April 2021;

and in each case, not later than 17 April 2024.

Save as disclosed above, no options were granted, exercised, forfeited, cancelled or lapsed during the year ended 31 March 2022.

#### PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities during the year.

#### **DIRECTORS' INTEREST IN COMPETING BUSINESS**

None of the Directors and Directors of the Company's subsidiaries, or any of their respective associates, as defined in the GEM Listing Rules, had interest in any business that competes or may compete, either directly or indirectly, with the businesses of the Group or has any other conflict of interests with the Group (other than being a director of the Company and/or its subsidiaries and their respective associates) during year ended 31 March 2022.

#### **DEED OF NON-COMPETITION**

Ms. Wong Bik Kwan Bikie and B&A Success (collectively the "Controlling Shareholders") have confirmed to the Company of their compliance with the non-competition undertakings provided to the Company under a deed of non-competition dated 1 March 2018. The independent non-executive Directors have reviewed the status of compliance and confirmed that all the undertakings under the deed of non-competition have been complied with by the Controlling Shareholders during the year.

#### RELATED PARTY TRANSACTIONS

Save as disclosed in note 31 to the consolidated financial statements, no other related party transactions were conducted by the Group during the year.

#### CONNECTED TRANSACTIONS

The rental expenses paid to Solaire International Limited as disclosed in note 31 "related party transactions" to the consolidated financial statements for the year ended 31 March 2022 constituted a connected transaction as defined in Chapter 20 of the GEM Listing Rules.

The transaction is a de minimis transaction in accordance with GEM Listing Rules 20.74(1) fully exempt from the reporting, annual review, announcement, circular (including independent financial advice) and shareholders' approval requirements.

There are no other non-exempt connected transactions during the year.

## DIRECTORS'/CONTROLLING SHAREHOLDERS' INTERESTS IN CONTRACTS OF SIGNIFICANCE

Save as the related party transactions disclosed in note 31 to the consolidated financial statements, no Director or Controlling Shareholder had a material interest, either directly or indirectly, in any contract of significance to the business of the Group to which the Company or any of its subsidiaries was a party and subsisted as at 31 March 2022 or during the financial year.

#### **USE OF PROCEEDS FROM THE LISTING**

Details of the use of proceeds from the Listing are set out in the section headed "Management Discussion and Analysis" of this annual report.

#### **CORPORATE GOVERNANCE**

Details of the Company's corporate governance practices are set out in the Corporate Governance Report on pages 15 to 26 of this annual report.

#### SUFFICIENCY OF PUBLIC FLOAT

Based on the information that is publicly available to the Company and to the best knowledge of the Directors, the Company has maintained the public float as required under the GEM Listing Rules during the year.

#### INDEPENDENCE OF INDEPENDENT NON-EXECUTIVE DIRECTORS

The Company has received from each of the independent non-executive Directors in writing an annual confirmation of his independence pursuant to Rule 5.09 of the GEM Listing Rules and the Company considers all the independent non-executive Directors to be independent.

#### **EQUITY-LINKED AGREEMENTS**

Save for the Share Option Scheme, no equity-linked agreements were entered into during the year or subsisted at the end of the year.

#### INDEPENDENT AUDITOR

The financial statements of the Company for the year ended 31 March 2022 were audited by BDO Limited. A resolution will be proposed at the forthcoming AGM of the Company to re-appoint BDO Limited as auditor of the Company.

No change in auditors of the Company since the date of listing.

#### **EVENTS AFTER THE REPORTING PERIOD**

Save as disclosed in note 37 to the consolidated financial statements, the Group did not have any other significant subsequent event after the report period and up to the date of this annual report.

ON BEHALF OF THE BOARD

**Grand Brilliance Group Holdings Limited** 

#### Wong Bik Kwan Bikie

Chairman and Chief Executive Officer

Hong Kong, 17 June 2022



Tel: +852 2218 8288 Fax: +852 2815 2239 www.bdo.com.hk

電話:+852 2218 8288 傳真:+852 2815 2239 www.bdo.com.hk 25<sup>th</sup> Floor Wing On Centre 111 Connaught Road Central

Hong Kong

香港干諾道中111號 永安中心25樓

#### TO THE SHAREHOLDERS OF GRAND BRILLIANCE GROUP HOLDINGS LIMITED

(君百延集團控股有限公司)

(Incorporated in the Cayman Islands with limited liability)

#### **OPINION**

We have audited the consolidated financial statements of Grand Brilliance Group Holdings Limited (the "Company") and its subsidiaries (together the "Group") set out on pages 65 to 119, which comprise the consolidated statement of financial position as at 31 March 2022, and the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 March 2022, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

#### **BASIS FOR OPINION**

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSAs") issued by the HKICPA. Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Statements" section of our report. We are independent of the Group in accordance with the HKICPA's "Code of Ethics for Professional Accountants" (the "Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **KEY AUDIT MATTERS**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

#### **Inventories provision**

(Refer to Notes 5(ii) and 21 to the consolidated financial statements)

As at 31 March 2022, the Group had inventories amounting to approximately HK\$22,442,000. The associated provision for inventories for the year ended 31 March 2022 was approximately HK\$713,000. Management estimated the net realisable value of inventories at the end of the reporting period, and make provision for write-down in value, if any.

BDO Limited 香港立信德豪會計師事務所有限公司

BDO Limited, a Hong Kong limited company, is a member of BDO International Limited, a UK company limited by guarantee, and forms part of the international BDO network of independent member firms.

#### **KEY AUDIT MATTERS** (Continued)

#### **Inventories provision** (Continued)

The considerations of an appropriate level of provision for inventories included inventory ageing, condition of inventories, historical and current sales information, as well as different market factors impacting the net realisable value of these inventories. In addition, the determination of provision on inventories as a result of the changed prevailing market conditions, requires an exercise of significant judgement of the management, based on historical experience.

Accordingly, the provisions carried against inventory are considered to be a key audit matter. Our procedures in relation to management's assessment of inventory provision included:

- Understanding and evaluating the Group's provision policy on inventories and basis of the assessment;
- Reviewing and assessing management's process of the identification of slow moving inventories and estimation of the net realisable value of these inventories;
- Evaluating historical accuracy of inventory provisioning by comparing historical provision made to the loss incurred for actual sales;
- Reviewing inventory ageing analysis and analysing the level of aged inventory and their associated provisions;
- Performing substantive procedures related to the purchase cost and selling price with reference to the purchase invoices and subsequent sales records; and
- Recalculating the provision.

#### OTHER INFORMATION IN THE ANNUAL REPORT

The directors are responsible for the other information. The other information comprises the information included in the Company's annual report, but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

## DIRECTORS' RESPONSIBILITIES FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with Hong Kong Financial Reporting Standards issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

The directors are also responsible for overseeing the Group's financial reporting process. The Audit Committee assists the directors in discharging their responsibility in this regard.

## AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. This report is made solely to you, as a body, in accordance with the terms of our engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with HKSAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- identify and assess the risks of material misstatement of the consolidated financial statements, whether due to
  fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is
  sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement
  resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional
  omissions, misrepresentations, or the override of internal control.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are
  appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the
  Group's internal control.
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

## AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS (Continued)

- conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- evaluate the overall presentation, structure and content of the consolidated financial statements, including the
  disclosures, and whether the consolidated financial statements represent the underlying transactions and events
  in a manner that achieves fair presentation.
- obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with the Audit Committee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Audit Committee with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### **BDO** Limited

Certified Public Accountants

Leung Tze Wai Practising Certificate Number P06158 Hong Kong, 17 June 2022

## CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the year ended 31 March 2022

	Notes	2022 HK\$'000	2021 HK\$'000
Revenue	7	71,978	70,241
Cost of revenue	,	(35,631)	(36,626)
Gross profit		36,347	33,615
Other income	8	26	2,006
Other gains or losses		(326)	114
Distribution and selling expenses  Administrative and other operating expenses		(1,197) (29,232)	(899) (25,370)
Finance costs	9	(140)	(109)
Profit before income tax	10	5,478	9,357
Income tax expense	11	(1,430)	(1,498)
Profit for the year and total comprehensive income attributable			
to owners of the Company		4,048	7,859
		HK cent(s)	HK cent(s)
Earnings per share attributable to owners of the company			_
Basic and diluted earnings per share	14	0.51	0.98

## CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 March 2022

	Notes	2022 HK\$'000	2021 HK\$'000
ACCETC AND LIABILITIES			
ASSETS AND LIABILITIES Non-current assets			
Property, plant and equipment	15	1,057	888
Interest in an associate	16	780	_
Other asset	17	2,690	2,690
Financial assets measured at fair value through profit or loss Deposits	18	2,880 597	810 700
Right-of-use assets	19	4,830	5,095
Deferred tax assets	20	68	77
		12,902	10,260
Current assets Inventories	21	22,442	21,104
Financial assets measured at fair value through profit or loss	18	409	46
Trade and other receivables, deposits and prepayments	22	19,132	9,530
Tax recoverable		103	858
Cash and cash equivalents	23	55,336	70,212
		97,422	101,750
Current liabilities			
Trade and other payables Contract liabilities	24 25	11,380 954	12,520 1,566
Lease liabilities	19	2,400	3,456
25000 102	, 0		3,.00
		14,734	17,542
Net current assets		82,688	84,208
Total assets less current liabilities		95,590	94,468
		·	
Non-current liabilities			
Lease liabilities	19	2,081	1,416
Net assets		93,509	93,052
CAPITAL AND RESERVES	22	0.003	2.222
Share capital Reserves	26 27	8,000 85,509	8,000 85,052
110301703	21	65,509	00,002
Total equity		93,509	93,052
	-		

On behalf of the directors

Wong Bik Kwan Bikie

Chairman and Executive Director

**Wong Lung Wo James** 

Director

## **CONSOLIDATED STATEMENT OF CHANGES IN EQUITY**

For the year ended 31 March 2022

	Share capital (note 26) HK\$'000	Share premium* (note 27) HK\$'000	Merger reserve* (note 27) HK\$'000	Share option reserve* (note 28) HK\$'000	Retained earnings* (note 27) HK\$'000	<b>Total</b> HK\$'000
At 1 April 2020	8,000	52,499	1,500	813	25,670	88,482
Profit and total comprehensive income for the year	-	-	-	-	7,859	7,859
Recognition of equity-settled share-based payment	_	-	_	211	_	211
Lapse of share options Dividend declared (note 13)		- -	- -	(18)	18 (3,500)	(3,500)
At 31 March 2021 and 1 April 2021	8,000	52,499	1,500	1,006	30,047	93,052
Profit and total comprehensive income for the year	-	-	_	-	4,048	4,048
Recognition of equity-settled share-based payment	-	-	-	9	-	9
Dividend declared (note 13)	-	-	_	-	(3,600)	(3,600)
At 31 March 2022	8,000	52,499	1,500	1,015	30,495	93,509

The total of these equity accounts as at the end of the reporting periods represent "Reserves" in the consolidated statement of financial position

# **CONSOLIDATED STATEMENT OF CASH FLOWS**

For the year ended 31 March 2022

Not	2022 te HK\$'000	2021 HK\$'000
Cash flows from operating activities		
Profit before income tax	5,478	9,357
Adjustments for:		
Bank interest income Dividend income	(11)	(357)
Changes in fair value of financial assets measured	(10)	_
at fair value through profit or loss	(16)	15
Loss on early termination of lease	79	21
Depreciation of property, plant and equipment	615	835
Depreciation of right-of-use assets	3,637	2,605
Interest expenses	140	109
Equity-settled share-based payment expenses  Provision/(Reversal) of loss allowance for trade receivables	9 87	211 (28)
Provision for inventories	713	1,326
		.,020
Operating profit before working capital changes	10,721	14,094
Decrease in contract costs	-	2,195
Decrease/(Increase) in deposits Increase in inventories	103	(568)
(Increase)/Decrease in trade and other receivables,	(2,051)	(6,976)
deposits and prepayments	(9,689)	1,201
(Decrease)/Increase in trade and other payables	(1,140)	4,208
Decrease in amount due to a related company		(98)
Decrease in contract liabilities	(612)	(4,374)
Cash (used in)/generated from operations	(2,668)	9,682
Income tax paid	(666)	(3,670)
Net cash (used in)/generated from operating activities	(3,334)	6,012
Cash flows from investing activities		
Bank interest received	11	357
Dividend income received	10	_
Purchase of property, plant and equipment	(784)	(388)
Acquisition of financial assets measured at fair value through profit or loss	(2,417)	(51)
Acquisition of equity interest in an associate	(780)	_
Net cash used in investing activities	(3,960)	(82)
Cash flows from financing activities		
Repayment of principal portion of lease liabilities 30	(3,842)	(2,746)
Interest paid on lease liabilities 30	(140)	(109)
Dividend paid	(3,600)	(3,500)
Net cash used in financing activities	(7,582)	(6,355)
Net decrease in cash and cash equivalents	(14,876)	(425)
Cash and cash equivalents at beginning of the year	70,212	70,637
Cash and cash equivalents at end of the year	55,336	70,212
Analysis of the balances of cash and cash equivalents		

For the year ended 31 March 2022

#### 1. GENERAL INFORMATION

Grand Brilliance Group Holdings Limited (the "Company") was incorporated in the Cayman Islands with limited liability under the Companies Law, Cap. 22 of the Cayman Islands on 5 July 2017. Its shares have been listed on GEM of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") since 29 March 2018. The address of the Company's registered office is situated at Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands. The principal place of business of the Company is situated at Units 2901–2903 and 2905, 29/F, The Octagon, 6 Sha Tsui Road, Tsuen Wan, New Territories, Hong Kong.

The Company is an investment holding company. The Company and its subsidiaries (collectively referred hereafter as the "Group") are principally engaged in supplying medical devices and providing medical device solutions including market trend analysis, sourcing of medical devices, after-sale services, technical support and training services, medical devices leasing services and quality assurance.

The Company's parent is B&A Success Limited ("B&A Success"), a company incorporated in the British Virgin Islands ("BVI"). In the opinion of the directors, B&A Success is also the ultimate parent of the Company.

The financial statements for the year ended 31 March 2022 were approved and authorised for issue by the directors on 17 June 2022.

### 2. ADOPTION OF HONG KONG FINANCIAL REPORTING STANDARDS ("HKFRSs")

### (a) Adoption of new/revised HKFRSs — effective on 1 April 2021

The following new/revised HKFRSs, which are effective from current year, have been adopted by the Group.

Amendment to HKFRS 16 2021 Amendment to HKFRS 16 Amendments to HKFRS 9, HKAS 39, HKFRS 7, HKFRS 4 and HKFRS 16 COVID-19-Related Rent Concessions
COVID-19-Related Rent Concessions Beyond 30 June 2021
Interest Rate Benchmark Reform — Phase 2

None of the new or revised standards and interpretation that are effective from 1 April 2021 have had a material effect on the Group's accounting policies. The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

For the year ended 31 March 2022

### 2. ADOPTION OF HONG KONG FINANCIAL REPORTING STANDARDS ("HKFRSs")

(Continued)

### (b) New/revised HKFRSs that have been issued but are not yet effective

The following new/revised HKFRSs, potentially relevant to the Group's financial statements, have been issued, but are not yet effective and have not been early adopted by the Group. The Group's current intention is to apply these changes on the date they become effective.

Amendments to HKAS 37
Amendments to HKAS 16
Annual Improvements to
HKFRSs 2018–2020
Amendments to HKFRS 3
Amendments to HKAS 1
HK Interpretation 5 (2020)

Amendments to HKAS 1 and HKFRS Practice Statement 2 Amendments to HKAS 8 Amendments to HKAS 12 Onerous Contracts — Cost of Fulfilling a Contract¹
Property, Plant and Equipment — Proceeds before Intended Use¹

Amendments to HKFRS 9 Financial Instruments and Illustrative Examples accompanying HKFRS 16 Leases<sup>1</sup>

Reference to the Conceptual Framework<sup>2</sup>

Classification of Liabilities as Current or Non-current<sup>3</sup>
Presentation of Financial Statements — Classification by the Borrower of a Term Loan that Contains a Repayment on Demand Clause<sup>3</sup>

Disclosure of Accounting Policy<sup>3</sup>

Definition of Accounting Estimates<sup>3</sup>

Deferred Tax Related to Assets and Liabilities arising from a Single Transaction<sup>3</sup>

- <sup>1</sup> Effective for annual periods beginning on or after 1 January 2022
- Effective for business combinations for which the date of acquisition is on or after the beginning of the first annual period beginning on or after 1 January 2022
- Effective for annual periods beginning on or after 1 January 2023

The directors of the Company anticipate that all of the pronouncements will be adopted in the Group's accounting policy for the first period beginning after the effective date of the pronouncement. The directors of the Company are currently assessing the possible impact of these new or revised standards on the Group's results and financial position in the first year of application. They consider that these new or revised HKFRSs are not expected to have a material impact on the Group's financial statements.

For the year ended 31 March 2022

#### 3. BASIS OF PREPARATION

### (a) Statement of compliance

The Group's consolidated financial statements have been prepared in accordance with all HKFRSs, Hong Kong Accounting Standards ("HKAS") and Interpretations (hereinafter collectively referred to as the Hong Kong Financial Reporting Standards) and the disclosure requirements of the Hong Kong Companies Ordinance. In addition, the financial statements include applicable disclosures required by the Rules Governing the Listing of Securities on GEM of the Stock Exchange.

#### (b) Basis of measurement

The consolidated financial statements have been prepared under the historical cost convention except for certain financial instruments, which are measured at fair values as explained in the accounting policies set out below.

#### (c) Functional and presentation currency

The consolidated financial statements are presented in Hong Kong dollars ("HK\$"), which is the same as the functional currency of the Company and its major subsidiaries.

#### 4. SIGNIFICANT ACCOUNTING POLICIES

#### (a) Basis of consolidation

The consolidated financial statements comprise the financial statements of the Company and its subsidiaries. Intra-group balances, transactions and cash flows and any unrealised profits arising from intra-group transactions are eliminated in full in preparing the consolidated financial statements. Unrealised losses resulting from intra-group transactions are eliminated in the same way as unrealised gains but only to the extent that there is no evidence of impairment.

### (b) Subsidiaries

A subsidiary is an investee over which the Company is able to exercise control. The Company controls an investee if all three of the following elements are present: power over the investee, exposure, or rights, to variable returns from the investee, and the ability to use its power to affect those variable returns. Control is reassessed whenever facts and circumstances indicate that there may be a change in any of these elements of control.

In the Company's statement of financial position, interests in subsidiaries are stated at cost less impairment loss, if any. The results of subsidiaries are accounted for by the Company on the basis of dividend received and receivable.

For the year ended 31 March 2022

### **SIGNIFICANT ACCOUNTING POLICIES** (Continued)

### (c) Associates

An associate is an entity over which the Group has significant influence and that is neither a subsidiary nor a joint arrangement. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control over those policies.

Associates are accounted for using the equity method whereby they are initially recognised at cost and thereafter, their carrying amount are adjusted for the Group's share of the post-acquisition change in the associates' net assets except that losses in excess of the Group's interest in the associate are not recognised unless there is an obligation to make good those losses.

Profits and losses arising on transactions between the Group and its associates are recognised only to the extent of unrelated investors' interests in the associate. The investor's share in the associate's profits and losses resulting from these transactions are eliminated against the carrying value of the associate. Where unrealised losses provide evidence of impairment of the asset transferred, they are recognised immediately in profit or loss.

Any premium paid for an associate above the fair value of the Group's share of the identifiable assets, liabilities and contingent liabilities acquired is capitalised and included in the carrying amount of the associate. Any excess of the Group's share of the net fair value of the identifiable assets and liabilities over the cost of investment, after reassessment, is recognised immediately in profit or loss. Where there is objective evidence that the investment in an associate has been impaired, the carrying amount of the investment is tested for impairment in the same way as other non-financial assets.

The Group discontinues the use of the equity method from the date when the investment ceases to be an associate. When the Group retains an interest in the former associate and the retained interest is a financial asset, the Group measures the retained interest at fair value at that date and the fair value is regarded as its fair value on initial recognition in accordance with HKFRS 9. The difference between the carrying amount of the associate at the date the equity method was discontinued, and the fair value of any retained interest and any proceeds from disposing a part interest in the associate is included in the determination of the gain or loss on disposal of the associate. In addition, all amounts previously recognised in other comprehensive income in relation to that associate are recognised on the same basis as would be required if that associate had directly disposed of the related assets or liabilities.

When the Group reduces its ownership interest in an associate but the Group continues to use the equity method, the Group reclassifies to profit or loss the proportion of the gain or loss that had previously been recognised in other comprehensive income relating to that reduction in ownership interest if that gain or loss would be reclassified to profit or loss on the disposal of the related assets or liabilities.

In the Company's statement of financial position, investments in associates are carried at cost less impairment losses, if any. The results of associates are accounted for by the Company on the basis of dividends received and receivable during the year.

For the year ended 31 March 2022

### 4. SIGNIFICANT ACCOUNTING POLICIES (Continued)

### (d) Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any.

The cost of property, plant and equipment includes its purchase price and the costs directly attributable to the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognised. All other costs, such as repairs and maintenance, are recognised as an expense in profit or loss during the financial period in which they are incurred.

Property, plant and equipment are depreciated so as to write off their cost net of expected residual value over their estimated useful lives on a straight-line basis as follows:

Furniture, fixtures, moulds and equipment 20%

Leasehold improvements Over the shorter of the remaining lease terms or 20%

Motor vehicles 30%

The useful lives, residual value and depreciation method are reviewed, and adjusted if appropriate, at the end of each reporting period.

An asset is written down immediately to its recoverable amount if its carrying amount is higher than the asset's estimated recoverable amount (note 4(n)).

The gain or loss on disposal of an item of property, plant and equipment is the difference between the net sale proceeds and its carrying amount, and is recognised in profit or loss on disposal.

### (e) Other asset

Other asset represents club membership held for long-term purposes and are with an indefinite useful life. Other asset acquired separately is initially recognised at cost and subsequently carried at cost less accumulated impairment losses.

Other asset with indefinite useful life is tested for impairment at least annually, irrespective of whether there is any indication that they are impaired, by comparing its carrying amount with its recoverable amount (see note 4(n)). If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount.

An impairment loss is recognised as an expense immediately, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as revaluation decrease to the extent of its revaluation surplus.

For the year ended 31 March 2022

### 4. SIGNIFICANT ACCOUNTING POLICIES (Continued)

#### (f) Leasing

#### (i) The Group as lessee

All leases (irrespective of they are operating leases or finance leases) are required to be capitalised in the statement of financial position as right-of-use assets and lease liabilities, but accounting policy choices exist for an entity to choose not to capitalise (i) leases which are short-term leases and/or (ii) leases for which the underlying asset is of low-value. The Group has elected not to recognise right-of-use assets and lease liabilities for low-value assets and leases for which at the commencement date have a lease term of 12 months or less and do not contain purchase option.. The lease payments associated with those leases have been expensed on straight-line basis over the lease term.

#### Right-of-use asset

The right-of-use asset should be recognised at cost and would comprise: (i) the amount of the initial measurement of the lease liability (see below for the accounting policy to account for lease liability); (ii) any lease payments made at or before the commencement date, less any lease incentives received; (iii) any initial direct costs incurred by the lessee; and (iv) an estimate of costs to be incurred by the lessee in dismantling and removing the underlying asset to the condition required by the terms and conditions of the lease. The Group measures the right-of-use assets applying a cost model. Under cost model, the right-of-use assets are measured at cost, less any accumulated depreciation and any impairment losses, and adjusted for any remeasurement of lease liability.

#### Lease liability

The lease liability is recognised at the present value of the lease payments that are not paid at the date of commencement of the lease. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Group uses the lessee's incremental borrowing rate.

The following payments for the right-of-use asset during the lease term that are not paid at the commencement date of the lease are considered to be lease payments: (i) fixed payments less any lease incentives receivable; (ii) variable lease payments that depend on an index or a rate, initially measured using the index or rate as at commencement date; (iii) amounts expected to be payable by the lessee under residual value guarantees; (iv) the exercise price of a purchase option if the lessee is reasonably certain to exercise that option; and (v) payments of penalties for terminating the lease, if the lease term reflects the lessee exercising an option to terminate the lease.

Subsequent to the commencement date, the Group measures the lease liability by: (i) increasing the carrying amount to reflect interest on the lease liability; (ii) reducing the carrying amount to reflect the lease payments made; and (iii) remeasuring the carrying amount to reflect any reassessment or lease modifications, e.g., a change in future lease payments arising from change in an index or rate, a change in the lease term, a change in the in-substance fixed lease payments or a change in assessment to purchase the underlying asset.

For the year ended 31 March 2022

### 4. SIGNIFICANT ACCOUNTING POLICIES (Continued)

### (f) Leasing (Continued)

### (ii) The Group as lessor

Leases in which the Group does not transfer substantially all the risks and rewards incidental to ownership of the medical devices to the lessee are classified as operating leases. The Group has determined, based on an evaluation of the terms and conditions of the arrangements, such as the lease term not constituting a major part of the economic life of the medical devices and the present value of the minimum lease payments not amounting to substantially all the fair value of the medical devices, that it retains substantially all the significant risks and rewards incidental to ownership of these medical devices which are leased out and accounts for the contracts as operating leases. Rental income from operating leases is recognised in profit or loss on a straight-line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised as an expense on a straight-line basis over the lease terms.

### (g) Financial instruments

#### (i) Financial assets

A financial asset (unless it is a trade receivable without a significant financing component) is initially measured at fair value plus, for an item not at fair value through profit or loss, transaction costs that are directly attributable to its acquisition or issue. A trade receivable without a significant financing component is initially measured at the transaction price.

All regular way purchases and sales of financial assets are recognised on the trade date, that is, the date that the Group commits to purchase or sell the asset. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the period generally established by regulation or convention in the market place.

Financial assets with embedded derivatives are considered in their entirely when determining whether their cash flows are solely payment of principal and interest on the principal outstanding.

The Group classifies its financial assets in the following measurement categories:

- Financial assets at amortised cost;
- Financial assets at fair value through other comprehensive income; and
- Financial assets at fair value through profit or loss.

The classification is generally based on two criteria:

- the business model under which the financial asset is managed; and
- the contractual cash flow characteristics of the financial asset.

For the year ended 31 March 2022

### 4. SIGNIFICANT ACCOUNTING POLICIES (Continued)

### (g) Financial instruments (Continued)

#### (i) Financial assets (Continued)

The subsequent measurement of financial assets depends on their classification as follows:

#### Debt instruments

There are three measurement categories into which the Group classifies its debt instruments:

Amortised cost: Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. Financial assets at amortised cost are subsequently measured using the effective interest method. Interest income, foreign exchange gains and losses and impairment are recognised in profit or loss. Any gain or loss on derecognition is recognised in profit or loss.

Fair value through other comprehensive income: Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets' cash flows represent solely payments of principal and interest, are measured at fair value through other comprehensive income. Debt investments at fair value through other comprehensive income are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognised in profit or loss. Other net gains and losses are recognised in other comprehensive income. On derecognition, gains and losses accumulated in other comprehensive income are reclassified to profit or loss.

Fair value through profit or loss: Financial assets at fair value through profit or loss include financial assets held for trading, financial assets designated upon initial recognition at fair value through profit or loss, or financial assets mandatorily required to be measured at fair value. Financial assets are classified as held for trading if they are acquired for the purpose of selling or repurchasing in the near term. Derivatives, including separated embedded derivatives, are also classified as held for trading unless they are designated as effective hedging instruments. Financial assets with cash flows that are not solely payments of principal and interest are classified and measured at fair value through profit or loss, irrespective of the business model. Notwithstanding the criteria for debt instruments to be classified at amortised cost or at fair value through other comprehensive income, as described above, debt instruments may be designated at fair value through profit or loss on initial recognition if doing so eliminates, or significantly reduces, an accounting mismatch. Changes in fair value and interest income are recognised in profit or loss.

### Equity instruments

On initial recognition of an equity investment that is not held for trading, the Group could irrevocably elect to present subsequent changes in the investment's fair value in other comprehensive income. This election is made on an investment-by-investment basis. Equity investments at fair value through other comprehensive income are measured at fair value. Dividend income are recognised in profit or loss unless the dividend income clearly represents a recovery of part of the cost of the investments. Other net gains and losses are recognised in other comprehensive income and are not reclassified to profit or loss. All other equity instruments are classified as fair value through profit or loss, whereby changes in fair value, dividends and interest income are recognised in profit or loss.

For the year ended 31 March 2022

### 4. SIGNIFICANT ACCOUNTING POLICIES (Continued)

### (g) Financial instruments (Continued)

#### (ii) Impairment loss on financial assets

The Group recognises loss allowances for expected credit losses ("ECLs") on trade receivables and other financial assets measured at amortised cost. The ECLs are measured on either of the following bases: (1) 12 months ECLs: these are the ECLs that result from possible default events within the 12 months after the end of the reporting period, and (2) lifetime ECLs: these are ECLs that result from all possible default events over the expected life of a financial instrument. The maximum period considered when estimating ECLs is the maximum contractual period over which the Group is exposed to credit risk.

ECLs are probability-weighted estimate of credit losses. Credit losses are measured as the difference between all contractual cash flows that are due to the Group in accordance with the contract and all the cash flows that the Group expects to receive. The shortfall is then discounted at an approximation to the assets' original effective interest rate.

The Group measures loss allowances for trade receivables using HKFRS 9 *Financial Instruments* simplified approach and has calculated ECLs based on lifetime ECLs. For trade receivables which are not assessed for ECLs individually, the Group has established a provision matrix that is based on the Group's historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

For other debt financial assets, the ECLs are based on the 12-months ECLs. However, when there has been a significant increase in credit risk since origination, the allowance will be based on the lifetime ECLs.

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECLs, the Group considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information analysis, based on the Group's historical experience and informed credit assessment and including forward-looking information.

The Group assumes that the credit risk on a financial asset has increased significantly if it is more than 30 days past due.

The Group considers a financial asset to be credit-impaired when: (1) the borrower is unlikely to pay its credit obligations to the Group in full, without recourse by the Group to actions such as realising security (if any is held); or (2) the financial asset is more than 90 days past due.

Interest income on credit-impaired financial assets is calculated based on the amortised cost (i.e. the gross carrying amount less loss allowance) of the financial asset. For non-credit-impaired financial assets, interest income is calculated based on the gross carrying amount.

For the year ended 31 March 2022

### 4. SIGNIFICANT ACCOUNTING POLICIES (Continued)

### (g) Financial instruments (Continued)

### (iii) Financial liabilities

The Group classifies its financial liabilities, depending on the purpose for which the liabilities were incurred. Financial liabilities at amortised cost are initially measured at fair value, net of directly attributable costs incurred.

Financial liabilities at amortised cost

Financial liabilities at amortised cost are subsequently measured at amortised cost, using the effective interest method. The related interest expense is recognised in profit or loss.

Gains or losses are recognised in profit or loss when the liabilities are derecognised as well as through the amortisation process.

### (iv) Effective interest method

The effective interest method is a method of calculating the amortised cost of a financial asset or financial liability and of allocating interest income or interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts or payments through the expected life of the financial asset or liability, or where appropriate, a shorter period.

#### (v) Equity instruments

Equity instruments issued by the Company are recorded at the proceeds received, net of direct issue costs.

### (vi) Derecognition

The Group derecognises a financial asset when the contractual rights to the future cash flows in relation to the financial asset expire or when the financial asset has been transferred and the transfer meets the criteria for derecognition in accordance with HKFRS 9.

Financial liabilities are derecognised when the obligation specified in the relevant contract is discharged, cancelled or expires.

### (h) Inventories

Inventories are initially recognised at cost, and subsequently at the lower of cost and net realisable value. Cost comprises all costs of purchase and other costs incurred in bringing the inventories to their present location and condition. Cost is calculated using the weighted average method. Net realisable value represents the estimated selling price in the ordinary course of business less the estimated costs necessary to make the sale.

For the year ended 31 March 2022

### 4. SIGNIFICANT ACCOUNTING POLICIES (Continued)

### (i) Recognition of revenue and other income

Revenue from contracts with customers is recognised when control of goods or services is transferred to the customers at an amount that reflects the consideration to which the Group expects to be entitled in exchange for those goods or services, excluding those amounts collected on behalf of third parties. Revenue excludes value added tax or other sales taxes and is after deduction of any trade discounts.

Depending on the terms of the contract and the laws that apply to the contract, control of the goods or service may be transferred over time or at a point in time. Control of the goods or service is transferred over time if the Group's performance:

- provides all of the benefits received and consumed simultaneously by the customer;
- creates or enhances an asset that the customer controls as the Group performs; or
- does not create an asset with an alternative use to the Group and the Group has an enforceable right to payment for performance completed to date.

If control of the goods or services transfers over time, revenue is recognised over the period of the contract by reference to the progress towards complete satisfaction of that performance obligation. Otherwise, revenue is recognised at a point in time when the customer obtains control of the goods or service.

When the contract contains a financing component which provides the customer a significant benefit of financing the transfer of goods or services to the customer for more than one year, revenue is measured at the present value of the amounts receivable, discounted using the discount rate that would be reflected in a separate financing transaction between the Group and the customer at contract inception. Where the contract contains a financing component which provides a significant financing benefit to the Group, revenue recognised under that contract includes the interest expense accreted on the contract liability under the effective interest method. For contracts where the period between the payment and the transfer of the promised goods or services is one year or less, the transaction price is not adjusted for the effects of a significant financing component, using the practical expedient in HKFRS 15 *Revenue from Contracts with Customers*.

- (i) Revenue from sales of medical consumables, medical instruments and certain medical equipment are recognised at point in time when the goods are delivered and have been accepted by the customers. There is generally only one performance obligation.
- (ii) Revenue from sales medical equipment subject to installation generally includes only one performance obligation and is recognised at point in time when the customer has accepted the goods after the installation services have been rendered.
- (iii) Revenue from rendering of maintenance services is recognised over time with the contractual period of the maintenance services.
- (iv) Revenue from leasing of medical devices is recognised over time based on the terms of the relevant rental agreement.
- (v) Interest income is recognised on time-proportion basis using effective interest method.

For the year ended 31 March 2022

### 4. SIGNIFICANT ACCOUNTING POLICIES (Continued)

#### (i) Recognition of revenue and other income (Continued)

#### Contract assets and liabilities

A contract asset represents the Group's right to consideration in exchange for services that the Group has transferred to a customer that is not yet unconditional. In contrast, a receivable represents the Group's unconditional right to consideration, i.e. only the passage of time is required before payment of that consideration is due.

A contract liability represents the Group's obligation to transfer services to a customer for which the Group has received consideration (or an amount of consideration is due) from the customer.

#### (j) Cash and cash equivalents

Cash and cash equivalents comprise cash on hand, demand deposits and short-term, highly liquid investments with original maturities of three months or less that are readily convertible into known amount of cash and which are subject to an insignificant risk of changes in value.

#### (k) Income taxes

Income taxes comprise current tax and deferred tax.

Current tax is based on the profit or loss from ordinary activities adjusted for items that are non-assessable or disallowable for income tax purposes and is calculated using tax rates that have been enacted or substantively enacted at the end of the reporting period.

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the corresponding amounts used for tax purposes. Except for goodwill and recognised assets and liabilities that affect neither accounting nor taxable profits, deferred tax liabilities are recognised for all taxable temporary differences. Deferred tax assets are recognised to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilised. Deferred tax is measured at the tax rates appropriate to the expected manner in which the carrying amount of the asset or liability is realised or settled and that have been enacted or substantively enacted at the end of the reporting period.

Deferred tax liabilities are recognised for taxable temporary differences arising from investments in subsidiaries and associate, except where the Group is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future.

Income taxes are recognised in profit or loss except when they relate to items recognised in other comprehensive income in which case the taxes are also recognised in other comprehensive income or when they relate to items recognised directly in equity in which case the taxes are also recognised directly in equity.

For the year ended 31 March 2022

### 4. SIGNIFICANT ACCOUNTING POLICIES (Continued)

#### (I) Foreign currency

Transactions entered into by group entities in currencies other than the currency of the primary economic environment in which they operate (the "functional currency") are recorded at the rates ruling when the transactions occur. Foreign currency monetary assets and liabilities are translated at the rates ruling at the end of the reporting period. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing on the date when the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

Exchange differences arising on the settlement of monetary items, and on the translation of monetary items, are recognised in profit or loss in the period in which they arise. Exchange differences arising on the retranslation of non-monetary items carried at fair value are included in profit or loss for the period except for differences arising on re-translation of non-monetary items in respect of which gains and losses are recognised in other comprehensive income, in which case, the exchange differences are also recognised in other comprehensive income.

#### (m) Employee benefits

### (i) Short-term employee benefits

Short-term employee benefits are employee benefits (other than termination benefits) that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render the related service. Short-term employee benefits are recognised in the period when the employees render the related service.

Employee entitlements to annual leave are recognised when they accrue to employees. A provision is made for the estimated liability for annual leave as a result of services rendered by employees up to the end of the reporting period.

Non-accumulating compensated absence such as sick leave and maternity leave are not recognised until the time of leave.

#### (ii) Defined contribution retirement plan

Retirement benefits to employees are provided through defined contribution plans. The Group operates a defined contribution retirement benefit scheme (the "MPF Scheme") under the Mandatory Provident Fund Schemes Ordinance, for all its employees who are eligible to participate in the MPF Scheme. The MPF Scheme is administered by independent trustees. Under the MPF scheme, the employer and its employees are each required to make contributions to the plan at 5% of the employees' relevant income, subject to a cap of monthly relevant income of HK\$30,000. The Group has no further payment obligations once the contributions have been paid. Contributions to the MPF Scheme are recognised as an expense in profit of loss when the services are rendered by the employees.

#### (iii) Termination benefits

Termination benefits are recognised on the earlier of when the Group can no longer withdraw the offer of those benefits and when the Group recognises restructuring costs involving the payment of termination benefits.

For the year ended 31 March 2022

### 4. SIGNIFICANT ACCOUNTING POLICIES (Continued)

### (n) Impairment of non-financial assets

Property, plant and equipment, right-of-use assets, interests in associate and other asset are subject to impairment testing. Intangible assets with indefinite useful life or those not yet available for use are tested for impairment at least annually, irrespective of whether there is any indication that they are impaired. All other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

For the purposes of assessing impairment, where an asset does not generate cash inflows largely independent of those from other assets, the recoverable amount is determined for the smallest group of assets that generate cash inflows independently (i.e. a cash-generating unit ("CGU")). As a result, some assets are tested individually for impairment and some are tested at CGU level.

An impairment loss is recognised as an expense immediately for the amount by which the asset's or cashgenerating unit's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of fair value, reflecting market conditions less costs of disposal, and value-in-use. In assessing value-in-use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessment of time value of money and the risk specific to the asset.

An impairment loss is reversed if there has been a favourable change in the estimates used to determine the asset's or cash-generating unit's recoverable amount and only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised. A reversal of such impairment is credited to profit or loss in the period in which it arises.

#### (o) Borrowing costs

Borrowing costs attributable directly to the acquisition, construction or production of qualifying assets which require a substantial period of time to be ready for their intended use or sale, are capitalised as part of the cost of those assets. Income earned on temporary investments of specific borrowings pending their expenditure on those assets is deducted from borrowing costs capitalised. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

For the year ended 31 March 2022

### 4. SIGNIFICANT ACCOUNTING POLICIES (Continued)

### (p) Government grants

Government grants are recognised where there is reasonable assurance that the grant will be received and all attaching conditions will be complied with. When the grant relates to an expense item, it is recognised as income on a systematic basis over the periods that the costs, which it is intended to compensate, are expensed.

### (q) Research and development expenditure

Expenditure on research activities is recognised as an expense in the period in which it is incurred.

An internally-generated intangible asset arising from development (or from the development phase of an internal project) is recognised if, and only if, all of the following have been demonstrated:

- the technical feasibility of completing the intangible asset so that it will be available for use or sale;
- the intention to complete the intangible asset and use or sell it;
- the ability to use or sell the intangible asset;
- how the intangible asset will generate probable future economic benefits;
- the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
- the ability to measure reliably the expenditure attributable to the intangible asset during its development.

The amount initially recognised for an internally-generated intangible asset is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognised, development expenditure is charged to profit or loss in the period in which it is incurred.

Subsequent to initial recognition, internally-generated intangible asset is measured at cost less accumulated amortisation and accumulated impairment losses (if any), on the same basis as intangible assets acquired separately.

For the year ended 31 March 2022

### 4. SIGNIFICANT ACCOUNTING POLICIES (Continued)

### (r) Provisions and contingent liabilities

Provisions are recognised for liabilities of uncertain timing or amount when the Group has a legal or constructive obligation arising as a result of a past event, which will probably result in an outflow of economic benefits that can be reasonably estimated.

Where it is not probable that an outflow of economic benefits will be required, or the amount cannot be estimated reliably, the obligation is disclosed as a contingent liability, unless the probability of outflow of economic benefits is remote. Possible obligations, the existence of which will only be confirmed by the occurrence or non-occurrence of one or more future events, are also disclosed as contingent liabilities unless the probability of outflow of economic benefits is remote.

### (s) Share-based employee compensation

The Group operates equity-settled share-based compensation plans to remunerate its employee and directors.

All employee services received in exchange for the grant of any share-based compensation are measured at their fair values. These are indirectly determined by reference to the share options awarded. Their value is appraised at the grant date and excludes the impact of any non-market vesting conditions.

Share-based compensation is recognised as an expense in full at the grant date when the share options granted vest immediately, with the corresponding increase in share option reserve. If vesting periods or other vesting conditions apply, the expense is recognised over the vesting period, based on the best available estimate of the number of share options expected to vest. Non-market vesting conditions are taken into account by adjusting the number of equity instruments expected to vest at the end of each reporting period so that, ultimately, the cumulative amount recognised over the vesting period is based on the number of options that eventually vest. Market vesting conditions are factored into the fair value of the options granted. As long as all other vesting conditions are satisfied, a charge is made irrespective of whether the market vesting conditions are satisfied. The cumulative expense is not adjusted for failure to achieve a market vesting condition.

At the time when the share options are exercised, the amount previously recognised in share option reserve will be transferred to share premium. When the share options are later forfeited or are still not exercised at the expiry date, the amount previously recognised in share option reserve will be transferred to retained earnings.

#### (t) Segment reporting

The Group identifies operating segments and prepares segment information based on the regular internal financial information reported to the executive directors for their decisions about resources allocation to the Group's business components and for their review of the performance of those components.

For the year ended 31 March 2022

### 4. SIGNIFICANT ACCOUNTING POLICIES (Continued)

### (u) Related parties

- (a) A person or a close member of that person's family is related to the Group if that person:
  - (i) has control or joint control over the Group;
  - (ii) has significant influence over the Group; or
  - (iii) is a member of key management personnel of the Group or the Company's parent.
- (b) An entity is related to the Group if any of the following conditions apply:
  - (i) The entity and the Group are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others).
  - (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member).
  - (iii) Both entities are joint ventures of the same third party.
  - (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity.
  - (v) The entity is a post-employment benefit plan for the benefit of the employees of the Group or an entity related to the Group.
  - (vi) The entity is controlled or jointly controlled by a person identified in (a).
  - (vii) A person identified in (a)(i) has significant influence over the entity or is a member of key management personnel of the entity (or of a parent of the entity).
  - (viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the Group or to the Company's parent.

Close members of the family of a person are those family members who may be expected to influence, or be influenced by, that person in their dealings with the entity and include:

- (i) that person's children and spouse or domestic partner;
- (ii) children of that person's spouse or domestic partner; and
- (iii) dependents of that person or that person's spouse or domestic partner.

For the year ended 31 March 2022

# 5. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the Group's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

#### **Key sources of estimation uncertainty**

The estimates and assumptions that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are as follows:

#### (i) Impairment of non-financial assets

Management assesses impairment by evaluating conditions specific to the Group that may lead to impairment of non-financial assets. When an impairment trigger exists and in the case of intangible asset with indefinite use life that is required to be tested for impairment annually, the recoverable amount of the asset is determined. Value-in-use calculations performed in assessing recoverable amounts incorporate a number of key estimates and assumptions about future events, which are subject to uncertainty and might materially differ from the actual results. In making these key estimates and judgments, the directors take into consideration assumptions that are mainly based on market conditions existing at the end of the reporting period and appropriate market and discount rates. These estimates are regularly compared to actual market data and actual transactions entered into by the Group. Future changes in the events and conditions underlying the estimates and judgments would affect the estimation of recoverable amounts and result in adjustments to their carrying amounts.

#### (ii) Allowance for inventories

Management carries out inventory review on a product-by-product basis at the end of each reporting period and makes allowance for obsolete items. A considerable amount of judgment and estimates is required in determining such allowance. If conditions which have an impact on the net realisable value of inventories deteriorate, additional allowances may be required. Management reviews the inventory aging analysis at the end of the reporting period to identify slow-moving inventories that are no longer suitable for consumption and saleable. Management estimates the net realisable value for such inventories based primarily on the latest invoice prices and current market conditions.

### (iii) Impairment loss on receivables (including trade and other receivables)

The measurement of impairment losses under HKFRS 9 requires judgment, in particular, the estimation of the amount and timing of future cash flows when determining impairment losses and the assessment of a significant increase in credit risk. These estimates are driven by a number of factors, changes in which can result in different levels of allowances.

At the end of the reporting period, the Group assesses whether there has been a significant increase in credit risk for exposures since initial recognition by comparing the risk of default occurring over the expected life between the end of the reporting period and the date of initial recognition. The Group considers reasonable and supportable information that is relevant and available without undue cost or effort for this purpose. This includes quantitative and qualitative information, based on the Group's historical experience and informed credit assessment and also, forward-looking analysis.

For the year ended 31 March 2022

# 5. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY (Continued)

### **Key sources of estimation uncertainty** (Continued)

#### (iv) Incremental borrowing rate

The Group cannot readily determine the interest rate implicit in a lease, and therefore, it uses an incremental borrowing rate ("IBR") to measure lease liabilities. The IBR is the rate of interest that the Group would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. The IBR therefore reflects what the Group "would have to pay", which requires estimation when no observable rates are available or when it needs to be adjusted to reflect the terms and conditions of the lease. The Group estimates the IBR using observable inputs (such as market interest rates) when available and is required to make certain entity-specific estimates (such as the subsidiaries' stand-alone credit rating).

### 6. SEGMENT INFORMATION

### (a) Operating segment information

The Group determines its operating segments based on the reports reviewed by the chief operating decision-maker, i.e. directors of the Company who are used to make strategic decisions.

During the reporting period, the directors assess the operating performance and allocate the resources of the Group as a whole as the Group is primarily engaged in supplying medical devices and providing medical device solutions including market trend analysis, sourcing of medical devices, after-sale services, technical support and training services, medical devices leasing services and quality assurance. Therefore, the Group has only one operating segment that qualifies as reportable segment under HKFRS 8 *Operating Segment*.

### (b) Geographical segment information

The Company is an investment holding company and the principal place of the Group's operations is in Hong Kong. Accordingly, management determines that the Group is domiciled in Hong Kong. All of the Group's revenue are derived from and most of the Group's non-current assets are located in Hong Kong. As a result, no separate segmental analysis is presented.

#### (c) Disaggregation of revenue from contracts with customers

	2022 HK\$'000	2021 HK\$'000
Timing of revenue recognition Over time At a point in time	1,394 70,395	2,009 67,996
	71,789	70,005

### (d) Information about major customers

For the year ended 31 March 2022, revenue from a customer (2021: one customer) amounted to HK\$7,648,000 (2021: HK\$9,986,000) which represented approximately 11% (2021: 14%) of the Group's revenue.

For the year ended 31 March 2022

#### **REVENUE** 7.

The Group is principally engaged in supplying medical devices and providing medical device solutions including market trend analysis, sourcing of medical devices, after-sale services, technical support and training services, medical devices leasing services and quality assurance. Revenue derived from the principal activities comprises the following:

	2022 HK\$'000	2021 HK\$'000
Revenue from contracts with customers:		
Sales of medical devices and products		
Medical consumables	53,699	48,320
Medical equipment	14,251	17,410
Medical instruments	2,445	2,266
	70,395	67,996
Rendering of maintenance services	1,394	2,009
	71,789	70,005
Revenue from other source:		
Rental income from leasing medical devices	189	236
	71,978	70,241

The following table provides information about the trade receivables and contract liabilities from contracts with customers:

	2022 HK\$'000	2021 HK\$'000
Trade receivables (note 22) Contract liabilities (note 25)	17,310 954	7,731 1,566

### OTHER INCOME

	2022 HK\$'000	2021 HK\$'000
Bank interest income	11	357
Government grants (note)	-	1,649
Dividend income	10	_
Sundry income	5	_
	26	2,006

Note: The Group was granted subsidies of HK\$1,590,000 under the Employment Support Scheme ("ESS") under the Anti-epidemic Fund launched by the Government of the Hong Kong Special Administrative Region for supporting the payroll of the Group's employees during the year ended 31 March 2021. The Group has complied with the requirements set out the in the ESS for the year.

For the year ended 31 March 2022

### 9. FINANCE COSTS

	2022 HK\$'000	2021 HK\$'000
Interest on lease liabilities	140	109

### 10. PROFIT BEFORE INCOME TAX

Profit before income tax is arrived at after charging/(crediting):

	2022 HK\$'000	2021 HK\$'000
Auditor's remuneration  Cost of inventories recognised as expense#	590	590
<ul><li>Carrying amount of inventories consumed</li><li>Allowance for inventories</li></ul>	34,918 713	35,300 1,326
	35,631	36,626
Changes in fair value of financial assets measured at fair value through profit or loss  Depreciation of property, plant and equipment* (note 15)  Depreciation of right-of-use assets* (note 19)  Employee costs (including directors' emoluments (note 12(a)))  — Salaries, allowances and other benefits  — Contributions to defined contribution retirement plans  — Equity-settled share-based payment expenses (note 28)	(16) 615 3,637 17,661 505 9	15 835 2,605 14,927 470 211
	18,175	15,608
Loss on early termination of lease Exchange difference, net Research and development expenditure^ Provision/(Reversal) of loss allowance for trade receivables	79 176 2,066 87	21 (122) 583 (28)

Included in cost of revenue

Included in administrative and other operating expenses

Included in research and development expenditure are staff costs amounted to approximately HK\$2,003,000 for the year (2021: HK\$531,000) which have been included in the employee costs above

For the year ended 31 March 2022, no forfeited contribution in respect of the defined contribution retirement plans were utilised by the Group to reduce the contribution payable to the plans (2021: nil). As at 31 March 2022, no forfeited contribution under these plans is available to reduce future contribution (2021: nil)

For the year ended 31 March 2022

### 11. INCOME TAX EXPENSE

The amount of income tax expense in the consolidated statement of comprehensive income represents:

	2022 HK\$'000	2021 HK\$'000
Current tax for the year		
— Hong Kong Profits Tax	1,431	1,588
Over-provision in respect of prior years	(10)	(20)
	1,421	1,568
Deferred tax (note 20)	9	(70)
	1,430	1,498

The Group has no income subject to taxation in the Cayman Islands, the British Virgin Islands and United Kingdom. The Company and its Hong Kong incorporated subsidiaries are subject to Hong Kong Profits Tax, which is calculated at tax rate of 16.5% on the estimated assessable profits arising in Hong Kong during the year, except for one subsidiary of the Company which is a qualifying entity under the two-tiered profits tax rates regime. The first HK\$2,000,000 of assessable profits of this subsidiary are taxed at 8.25% and the remaining assessable profits are taxed at 16.5%.

The income tax expense for the year can be reconciled to the profit before income tax in the consolidated statement of comprehensive income as follows:

	2022 HK\$'000	2021 HK\$'000
Profit before income tax	5,478	9,357
Tay adaylated at applicable Llang Kong profits toy rate	004	1 5 4 4
Tax calculated at applicable Hong Kong profits tax rate Income tax on concessionary rate	904 (165)	1,544 (165)
Tax effect of revenue not taxable for tax purposes  Tax effect of expenses not deductible for tax purposes	(24) 737	(351) 392
Tax effect of tax losses not recognised  Over-provision in respect of prior years	– (10)	113 (20)
Others	(12)	(15)
Income tax expense	1,430	1,498

For the year ended 31 March 2022

### 12. DIRECTORS' EMOLUMENTS, FIVE HIGHEST PAID INDIVIDUALS AND SENIOR **MANAGEMENT'S EMOLUMENTS**

### (a) Directors' emoluments

The emoluments of each of the directors are set out as follows:

	Fees HK\$'000	Salaries, allowances and other benefits HK\$'000	Discretionary bonuses HK\$'000	Pension scheme contribution HK\$'000	Equity settled share-based payment expenses (Note 28) HK\$'000	<b>Total</b> HK\$'000
Year ended 31 March 2022						
Executive director						
Ms. Wong Bik Kwan Bikie ("Ms. Wong")	-	2,958	1,208	20	4	4,190
Non-executive directors						
Dr. Miu Yin Shun Andrew	120	-	-	-	-	120
Mr. Chiu Man Wai	120	-	-	-	-	120
Independent non-executive directors	120					120
Mr. Ng Leung Sing SBS, JP Mr. Wong Lung Wo James	120	_	_	_	_	120
Mr. Chow Ming Po Aaron (note (i))	93	_	_	_	_	93
Mr. Chan Ping Keung (note (ii))	56	_	_	-		56
	629	2,958	1,208	20	4	4,819
Year ended 31 March 2021						
Executive director Ms. Wong	_	2,823	1,184	18	96	4,121
Non-executive directors						
Dr. Miu Yin Shun Andrew	120	_	_	_	_	120
Mr. Chiu Man Wai	120	-	-	-	-	120
Independent non-executive directors						
Mr. Ng Leung Sing SBS, JP	120	-	-	-	-	120
Mr. Wong Lung Wo James	120	-	-	-	-	120
Mr. Chan Ping Keung (note (ii))	120	_	_	_	_	120
	600	2,823	1,184	18	96	4,721

#### Note:

<sup>(</sup>i) Mr. Chow Ming Po Aaron has been appointed as an independent non-executive director on 21 June 2021.

Mr. Chan Ping Keung retired as an independent non-executive director on 17 September 2021.

For the year ended 31 March 2022

# 12. DIRECTORS' EMOLUMENTS, FIVE HIGHEST PAID INDIVIDUALS AND SENIOR MANAGEMENT'S EMOLUMENTS (Continued)

### (b) Five highest paid individuals

The five individuals whose emoluments were the highest in the Group for the year ended 31 March 2022 included 1 director (2021: 1 director) of the Company whose emoluments are reflected in the analysis presented in note (a) above. The emoluments payable to the remaining 4 (2021: 4) highest paid individuals for the year ended 31 March 2022 are as follows:

	2022 HK\$'000	2021 HK\$'000
Salaries, allowances and other benefits Discretionary bonuses Contributions to defined contribution retirement plan Equity-settled share-based payment expenses	2,516 734 70 3	2,531 317 72 101
	3,323	3,021

The emoluments of the above non-director highest paid individuals were within the following band:

	2022	2021
	Number of	Number of
	individuals	individuals
Nil to HK\$1,000,000	4	4

During the year, no emoluments were paid by the Group to the directors or the highest paid individuals as an inducement to join or upon joining the Group or as compensation for loss of office (2021: nil). In addition, none of the directors waived or agreed to waive any emoluments during the year (2021: nil).

The discretionary bonus is determined with reference to the performance of director and individuals of the Group.

#### (c) Senior management's emoluments

Emoluments paid or payable to members of senior management who are not directors were within the following band:

	2022	2021
	Number of	Number of
	individuals	individuals
Nil to HK\$1,000,000	4	3

For the year ended 31 March 2022

#### 13. DIVIDENDS

	2022 HK\$'000	2021 HK\$'000
Interim dividend	3,600	3,500

The dividend for the years ended 31 March 2022 and 2021 amounting HK\$3,600,000 and HK\$3,500,000 respectively represented interim dividend declared by the Company to its shareholders.

Subsequent to the end of the reporting period, an interim dividend of HK0.3 cent (2021: HK0.45 cent) per ordinary share, totally amounting to HK\$2,400,000 (2021: HK\$3,600,000) in respect of the year ended 31 March 2022 has been declared by the directors. The interim dividend declared after the year ended 31 March 2022 was not recognised as a liability as at 31 March 2022 as it had not been approved by the board of directors of the Company as at 31 March 2022.

### 14. EARNINGS PER SHARE ATTRIBUTABLE TO OWNERS OF THE COMPANY

The calculation of basic and diluted earnings per share is based on the following data:

	2022 HK\$'000	2021 HK\$'000
Earnings		
Profit for the year attributable to owners of the Company	4,048	7,859
	'000	,000
Weighted average number of ordinary shares in issue Weighted average number of ordinary shares for the purpose of		
calculating the basic and diluted earnings per share	800,000	800,000

For the purpose of calculating diluted earnings per share for the years ended 31 March 2022 and 2021, no adjustment has been made as the exercise of the outstanding share options has an anti-dilutive effect of the basic earnings per share.

For the year ended 31 March 2022

### 15. PROPERTY, PLANT AND EQUIPMENT

	Furniture,			
	fixtures, moulds and	Leasehold	Motor	
	equipment	improvements	vehicles	Total
	HK\$'000	HK\$'000	HK\$'000	HK\$'000
Cost				
At 1 April 2020	1,623	1,044	2,020	4,687
Additions	321	67		388
As at 31 March 2021 and 1 April 2021	1,944	1,111	2,020	5,075
Additions	557	227	_	784
At 31 March 2022	2,501	1,338	2,020	5,859
Accumulated depreciation				
At 1 April 2020	1,051	886	1,415	3,352
Charge for the year	249	182	404	835
At 31 March 2021 and 1 April 2021	1,300	1,068	1,819	4,187
Charge for the year	333	81	201	615
At 31 March 2022	1,633	1,149	2,020	4,802
Net carrying amount				
At 31 March 2022	868	189	_	1,057
At 31 March 2021	644	43	201	888

For the year ended 31 March 2022

### 16. INTEREST IN AN ASSOCIATE

	2022 HK\$'000
Share of net assets	780

Details of the Group's associate are as follows:

Name of Company	Date of incorporation/ place of incorporation and operation	Paid up registered capital	Percentage of equity interests	Principal activities
Sonne Techmetics Limited	19 August 2021/ Hong Kong	US\$500,000 (equivalent to approximately HK\$3,900,000)	20%	Provision of autonomous mobile robots solutions for healthcare industries; sourcing of original equipment manufacturer; and research and development

Note: Upon completion of the subscription of shares of the associate, the associate is owned as to 40% by Ms. Wong, an executive director and the controlling shareholder of the Company.

Summarised financial information of an associate are disclosed below:

	2022 HK\$'000
As at 31 March	
Current assets	3,900
Net assets	3,900
Include in the above assets	
Cash and cash equivalents	3,900
Year ended 31 March	
Result for the year*	_
Total comprehensive income*	_

Note: The above associate is accounted for using equity method in the consolidated financial statements.

<sup>\*</sup> Result and total comprehensive income for the year amounted to HK\$272.

For the year ended 31 March 2022

#### 17. OTHER ASSET

Other asset represents club membership held by the Company for long-term investment purposes. Club membership is tested for impairment annually by comparing its carrying amount with its recoverable amount. For the purpose of impairment testing, the carrying amount of other asset is allocated to the CGU which engaged in supplying medical devices and providing medical device solutions, the only one operating segment of the Group.

Recoverable amount for the CGU is determined based on value-in-use calculation. The calculation uses the cash flow projections based on the financial budgets approved by management covering a two-year period with 1% (2021: 1%) growth rate. The growth rate is determined based on management's expectations for the market development and is not expected to exceed the average long-term growth rate for the relevant industry. Discount rate used of 22% (2021: 16%) is pre-tax and reflect specific risks relating to the relevant business. Apart from the considerations described in determining value-in-use of the CGU above, the Group's management is not currently aware of any other probable changes that would necessitate changes in its key estimates. In the opinion of the directors, club membership worth at least its carrying value at the end of the reporting period.

### 18. FINANCIAL ASSET MEASURED AT FAIR VALUE THROUGH PROFIT OR LOSS

	2022 HK\$'000	2021 HK\$'000
Financial asset measured at fair value through profit or loss Unlisted investment:		
— Unlisted equity securities (note (i))  — Club debenture (note (ii))	1,950 930	- 810
	2,880	810
Listed equity securities held for trading	409	46

#### Notes:

- The fair value of the unlisted equity securities as at 31 March 2022 was determined by Asset Appraisal Limited, an independent (i) professional valuer.
- (ii) The fair values of the club debenture as at 31 March 2022 and 2021 were determined by Asset Appraisal Limited, an independent professional valuer.

Details of the fair value measurement for the financial assets measured at fair value through profit or loss are set out in note 34(b). The Group does not intend to dispose of the unlisted equity securities and club debenture in the near future.

For the year ended 31 March 2022

### 19. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

The Group leases a number of office premise and warehouses in Hong Kong. The leases of buildings comprise only fixed payments over the lease terms.

### **Right-of-use assets**

	Buildings HK\$'000
Cost	
At 1 April 2020	2,797
Additions	7,019
Written off arising from early termination of lease	(571)
At 31 March 2021 and 1 April 2021	9,245
Additions	4,627
Written off arising from early termination of lease	(2,317)
At 31 March 2022	11,555
Accumulated depreciation	
At 1 April 2020	1,883
Charge for the year	2,605
Written off arising from early termination of lease	(338)
At 31 March 2021 and 1 April 2021	4,150
Charge for the year	3,637
Written off arising from early termination of lease	(1,062)
At 31 March 2022	6,725
Net carrying amount	
At 31 March 2022	4,830
At 31 March 2021	5,095

For the year ended 31 March 2022

### 19. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Continued)

**Lease liabilities** 

	31 March 2022		31 March 2021	
	Present		Present	
	value of	Total	value of	Total
	minimum	minimum	minimum	minimum
	lease	lease	lease	lease
	payment	payment	payment	payment
	HK\$'000	HK\$'000	HK\$'000	HK\$'000
Maturity analysis:				
Within 1 year	2,400	2,483	3,456	3,548
After 1 year but within 2 years	1,660	1,694	1,416	1,428
After 2 years but within 5 years	421	423	_	
	4,481	4,600	4,872	4,976
Less: total future interest expenses	_	(119)	_	(104)
	_	4,481	_	4,872
Analysed as:				
Non-current		2,081		1,416
Current	_	2,400	_	3,456
		4,481	_	4,872

The maturity analysis of lease liabilities is disclosed in note 35(d) to the financial statements.

The analysis of expense items in relation to leases recognised in profit or loss is as follow:

	2022 HK\$'000	2021 HK\$'000
Depreciation expense of right-of-use assets	3,637	2,605
Interest on lease liabilities (note 9)	140	109
Expenses relating to short-term leases	1,228	1,951

For the year ended 31 March 2022

### 20. DEFERRED TAX ASSETS

Details of the deferred tax assets recognised and movements during the year are as follows:

	Depreciation in excess of related depreciation allowance HK\$'000
At 1 April 2020	7
Credited to profit or loss for the year (note 11)	
At 31 March 2021 and 1 April 2021	77
Charged to profit or loss for the year (note 11)	(9)
At 31 March 2022	68

As at 31 March 2022, the Group had unused tax losses of HK\$2,921,000 (2021: HK\$2,921,000) available for offset against future profits. The tax losses are subject to the final assessment of Hong Kong Inland Revenue Department. No deferred tax assets have been recognised in respect of these tax losses due to the unpredictability of future profit streams. These tax losses have no expiry date.

### 21. INVENTORIES

	2022	2021
	HK\$'000	HK\$'000
Finished goods	22,442	21,104

For the year ended 31 March 2022

### 22. TRADE AND OTHER RECEIVABLES, DEPOSITS AND PREPAYMENTS

	2022 HK\$'000	2021 HK\$'000
Trade receivables	18,842	9,176
Less: Allowance for impairment	(1,532)	(1,445)
Trade receivables, net	17,310	7,731
Other receivables	191	116
Deposits and prepayments	1,631	1,683
	19,132	9,530

The credit period granted to customers ranged from 0 to 30 days.

As at 31 March 2022 and 2021, the allowance for impairment on trade receivables has been recognised in accordance with the simplified approach, i.e. lifetime ECLs set out in HKFRS 9. Details of the movement in loss allowance on trade receivables are set out in note 35(a).

The ageing analysis of the trade receivables (net), based on invoice date, as of the end of the reporting period is as follows:

	2022 HK\$'000	2021 HK\$'000
0–30 days	8,135	5,958
31–60 days	1,881	873
61–90 days	2,046	408
Over 90 days	5,248	492
	17,310	7,731

For the year ended 31 March 2022

### 23. CASH AND CASH EQUIVALENTS

	2022 HK\$'000	2021 HK\$'000
Cash at banks and on hand	55,336	70,212

Cash at banks earns interest at floating rate based on daily bank deposits rates.

### 24. TRADE AND OTHER PAYABLES

	2022 HK\$'000	2021 HK\$'000
Trade payables Accruals and other payables	7,107 4,273	8,532 3,988
	11,380	12,520

The credit period granted by suppliers ranged from 0 to 90 days.

The ageing analysis of the trade payables, based on invoice date, as of the end of the reporting period is as follows:

	2022	2021
	HK\$'000	HK\$'000
0–30 days	4,454	7,093
31–60 days	963	474
61–90 days	960	227
Over 90 days	730	738
	7,107	8,532

For the year ended 31 March 2022

### 25. CONTRACT LIABILITIES

The movement in contract liabilities during the year is as follows:

	2022 HK\$'000	2021 HK\$'000
Balance as at 1 April	1,566	5,940
Decrease in contract liabilities as a result of recognising revenue during the year that was included in the contract liabilities at the beginning of the year	(1,566)	(5,940)
Increase in contract liabilities as a result of receipt in advance from sales of medical devices and products and rendering of maintenance services	954	1,566
Balance as at 31 March	954	1,566

The contract liabilities mainly relate to the advance consideration received from customers for (i) sales of medical devices and products and (ii) rendering of maintenance services. The Group will recognise the expected revenue in future when such performance obligation is satisfied, which is expected to occur in the next 12 months.

The Group has applied the practical expedient to its sales contracts for medical devices and products and rendering of maintenance services and therefore the above information does not include information about revenue that the Group will be entitled to when it satisfies the remaining performance obligations under the contracts for sales of medical devices and products; and for rendering of maintenance services that had an original expected duration of one year or less.

### **26. SHARE CAPITAL**

Ordinary shares	Number of shares	<b>Amount</b> HK\$'000
Authorised: Ordinary shares of HK\$0.01 each		
At 31 March 2021, 1 April 2021 and 31 March 2022	8,000,000,000	80,000
Issued and fully paid: Ordinary shares of HK\$0.01 each		
At 31 March 2021, 1 April 2021 and 31 March 2022	800,000,000	8,000

For the year ended 31 March 2022

### 27. RESERVES

### **The Group**

Details of the movements of the Group's reserves for the years ended 31 March 2022 and 2021 are presented in the consolidated statement of changes in equity. The nature of the reserves within equity is as follows:

### Share premium

Share premium is the excess of the proceeds received over the nominal value of the shares issued at a premium, less expenses incurred in connection with the issue of the shares.

### Merger reserve

Merger reserve arose from combining the financial statements of the companies now comprising the Group under the reorganisation for the listing purpose.

### **Retained earnings**

Retained earnings is the cumulated net profits and losses recognised in profit or loss.

### **The Company**

The movement of the Company's reserves during the years ended 31 March 2022 and 2021 are as follows:

01----

Share				
Share	option	Retained		
premium	reserve	earnings	Total	
HK\$'000	HK\$'000	HK\$'000	HK\$'000	
70,308	813	5,046	76,167	
_	_	7,212	7,212	
_	211	_	211	
_	(18)	18	_	
_	_	(3,500)	(3,500)	
70.308	1.006	8.776	80.090	
_	_	4,035	4,035	
_	9	_	9	
_	_	(3,600)	(3,600)	
70,308	1,015	9,211	80,534	
	premium HK\$'000  70,308 70,308	Share premium Premium         option reserve HK\$'000           70,308         813           -         -           -         211           -         (18)           -         -           70,308         1,006           -         -           -         9           -         -	Share premium Premium HK\$'000         Option reserve HK\$'000         Retained earnings HK\$'000           70,308         813         5,046           -         -         7,212           -         211         -           -         (18)         18           -         -         (3,500)           70,308         1,006         8,776           -         -         4,035           -         9         -           -         -         (3,600)	

For the year ended 31 March 2022

#### 28. SHARE-BASED PAYMENTS

The Company has adopted a share option scheme (the "Share Option Scheme") on 1 March 2018. The total number of shares which may be issued upon exercise of all options to be granted under the Share Option Scheme shall not in aggregate exceed 80,000,000 shares, being 10% of the total number of the Company's shares in issue at the time dealings in the shares first commenced on the Stock Exchange. The total number of shares issued and which may fall to be issued upon exercise of the options granted under the Share Option Scheme and any other share option scheme of the Group (including both exercised and outstanding options) to each participant in any 12-month period shall not exceed 1.0% of the Company's shares in issue as at the date of grant.

The purpose of the Share Option Scheme is to enable the Group to grant options to selected participants as incentives or rewards for their contribution to the Group. The directors consider that the Share Option Scheme will enable the Group to reward the employees, directors and other selected participants for their contributions to the Group. The board of directors may, at its discretion, grant an option to the eligible participants to subscribe for shares at an exercise price and subject to the other terms of the Share Option Scheme.

A nominal consideration of HK\$1.0 is payable on acceptance of the grant of an option.

On 18 April 2019, the Group offered to grant 39,500,000 share options to certain eligible participants under the Share Option Scheme to subscribe at an exercise price of HK\$0.12 per share for a total of 39,500,000 ordinary shares of HK\$0.01 each in the share capital of the Company. The grant of the said share options is subject to acceptance of the respective grantees.

The share options shall have a validity period of 5 years from 18 April 2019 to 17 April 2024, both dates inclusive, subject to the vesting conditions as stated in the offer letters to the grantees. No share options can be exercised until the relevant share options have been unconditionally vested.

During the year ended 31 March 2022, the Group recognised expense of approximately HK\$9,000 (2021: HK\$211,000) in the consolidated statement of comprehensive income in relation to share options granted by the Company.

Movement in share options to subscribe for ordinary shares in the Company under the Share Option Scheme are as follows:

	Weighted average Number of share option exercise price			•
	2022	<b>2022</b> 2021		2021
Outstanding at 1 April Lapsed	21,460,000	22,460,000 (1,000,000)	0.12 0.12	0.12 0.12
Outstanding at 31 March	21,460,000	21,460,000	0.12	0.12
Exercisable at 31 March	21,460,000	13,210,000	0.12	0.12

Note: The weighted average remaining contractual life of share options outstanding as at 31 March 2022 is 2.05 years (2021: 3.05 years).

For the year ended 31 March 2022

# 29. STATEMENT OF FINANCIAL POSITION OF THE COMPANY

Notes	2022 HK\$'000	2021 HK\$'000
1,666	THE GOOD	1114 000
ASSETS AND LIABILITIES		
Non-current asset		
Investment in a subsidiary	17,809	17,809
Current assets		
Prepayments	203	245
Amounts due from subsidiaries	71,064	70,336
Cash and bank balances	204	427
	71,471	71,008
Current liabilities		
Other payables	746	727
Net current assets	70,725	70,281
Net assets	88,534	88,090
CAPITAL AND RESERVES		
Share capital 26	8,000	8,000
Reserves 27	80,534	80,090
Total equity	88,534	88,090

On behalf of the directors

Wong Bik Kwan Bikie

Chairman and Executive Director

**Wong Lung Wo James** 

Director

For the year ended 31 March 2022

## 30. NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS

## Reconciliation of liabilities arising from financing activities:

The table below details changes in the Group's liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are liabilities for which cash flows were, or future cash flows will be, classified in the consolidated statement of cash flows as cash flows from financing activities.

# Lease liabilities

(note 19)

	,	/
	2022	2021
	HK\$'000	HK\$'000
At 1 April	4,872	811
Changes from financing cash flows:		
Capital element of lease payment	(3,842)	(2,746)
Interest element of lease payment	(140)	(109)
	890	(2,044)
Other change:		
Recognition of lease liabilities during the year	4,627	7,019
Written off arising from early termination of leases	(1,176)	(212)
Interest incurred for the year	140	109
As at 31 March	4,481	4,872

## 31. RELATED PARTY TRANSACTIONS

Save as disclosed elsewhere in these consolidated financial statements, the Group had the following transactions with its related parties during the year:

	2022 HK\$'000	2021 HK\$'000
Rental expense paid to a related company (note (i))	1,066	1,066
Compensation of key management personnel (note (ii))		
Fees Salaries, allowances and other benefits Contributions to defined contribution retirement plan Equity-settled share-based payment expenses	629 8,008 108 9	600 6,132 72 196
	8,754	7,000

#### Notes:

- (i) The Group entered into a lease agreement of warehouse with Solaire International Limited ("Solaire"). Solaire is held by Ms. Wong, Chairman, Chief Executive Officer and Executive Director of the Company. The transaction was conducted in accordance with terms mutually agreed between the Group and Solaire.
- (ii) The compensation represents the remuneration paid and was payable to the directors and other members of key management during the reporting periods.

For the year ended 31 March 2022

#### 32. SUBSIDIARIES

Details of the Company's subsidiaries are disclosed as follows:

Name of Company	Place and date of incorporation and type of legal entity	Place of operations	Issued and paid up capital	Equity intere		Principal activities
				Directly	Indirectly	
A&A Brilliance Limited	The BVI/ 4 July 2017/ Limited liability company	Hong Kong	100 shares of United States dollars ("US\$")1 each	100%	-	Investment holding
Solar-Med Limited	Hong Kong/ 15 October 1997/ Limited liability company	Hong Kong	1,500,000 ordinary shares of HK\$1,500,000	-	100%	Sourcing of medical devices and provision of after-sale services
Sonne International Company Limited	Hong Kong/ 11 March 2009/ Limited liability company	Hong Kong	1 ordinary share of HK\$1	-	100%	Sourcing of medical devices and development of healthcare products
Sonne Technology International Limited	Hong Kong/ 4 July 2016/ Limited liability company	Hong Kong	1 ordinary share of HK\$1	-	100%	Trademark holding
Sonne (UK) Limited	United Kingdom/ 26 August 2016/ Limited liability company	Hong Kong	1 ordinary share of 1 Great British Pound	-	100%	Trademark holding
Solar Service Engineering Holdings Limited	The BVI/ 12 March 2019/ Limited liability company	Hong Kong	100 shares of US\$1 each	-	100%	Investment holding
Solar Service Engineering Limited	Hong Kong/ 10 May 2019/ Limited liability company	Hong Kong	1 ordinary share of HK\$1	-	100%	Provision of maintenance services

#### 33. CAPITAL MANAGEMENT

The Group's capital management objectives are to safeguard the Group's ability to continue as a going concern so that it can provide returns for shareholders and benefits for other stakeholders, to maintain an optimal capital structure to reduce the cost of capital and to support the Group's stability and growth.

Management regards total equity in the consolidated statement of financial position as capital for capital management purpose. The directors of the Company actively and regularly review and manage the Group's capital structure, taking into consideration the future capital requirements of the Group, to ensure optimal shareholders' returns. The Group manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares, raise new debts or sells assets to reduce debt.

For the year ended 31 March 2022

# 33. CAPITAL MANAGEMENT (Continued)

The total equity to total assets ratio at the end of the reporting period is as follows:

	2022 HK\$'000	2021 HK\$'000
Total equity	93,509	93,052
Total assets	110,324	112,010
Total equity to total assets ratio	0.85:1	0.83:1

### 34. SUMMARY OF FINANCIAL INSTRUMENTS BY CATEGORY

The following table shows the carrying amounts of each of the categories of financial instruments:

	2022 HK\$'000	2021 HK\$'000
Financial assets		
Financial assets measured at fair value through profit or loss	3,289	856
Financial assets at amortised cost		
— Deposits	597	700
<ul> <li>Trade and other receivables and deposits</li> </ul>	18,187	8,246
— Cash and cash equivalents	55,336	70,212
	77,409	80,014
Financial liabilities		
At amortised cost		
— Trade and other payables	11,380	12,520
Other financial instruments		
— Lease liabilities	4,481	4,872

#### (a) Financial instruments not measured at fair value

Financial instruments not measured at fair value include trade and other receivables and deposits, cash and bank balances, trade and other payables and lease liabilities.

Due to their short term nature, the carrying values of the above financial instruments approximate their fair values.

For the year ended 31 March 2022

## 34. SUMMARY OF FINANCIAL INSTRUMENTS BY CATEGORY (Continued)

## (b) Financial instruments measured at fair value

The Group's listed equity securities, unlisted equity securities and club debenture disclosed in note 18 is measured at fair value at the end of the reporting period.

The following table provides an analysis of financial instruments carried at fair value by level of the fair value hierarchy:

- Level 1: Quoted prices (unadjusted) in active market for identical assets or liabilities;
- Level 2: Inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3: Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	Total
	HK\$'000	HK\$'000	HK\$'000	HK\$'000
At 31 March 2022 Financial assets measured at fair value through profit or loss: — Listed equity securities — Unlisted equity securities (note (ii)) — Club debenture (note (iii))	409	-	_	409
	-	-	1,950	1,950
	-	930	_	930
	409	930	1,950	3,289
At 31 March 2021 Financial assets measured at fair value through profit or loss: — Listed equity securities — Club debenture (note (ii))	46	-	-	46
	-	810	-	810
	46	810	-	856

There were no transfers between levels of the fair value hierarchy during the reporting periods.

#### Notes:

- (i) The fair value of the unlisted equity securities embedded with a conversion option as at 31 March 2022 have been estimated with reference to the valuation carried out by Asset Appraisal Limited, an independent professional valuer using the option pricing model under equity allocation approach and backsolve from most recent transaction price. The option pricing model under equity allocation approach is based on main inputs, such as 100% equity value through a backsolve analysis, risk-free rate of 2.5%, expected volatility of 41.5% and expected time to expiration.
- (ii) The fair values of the club debenture as at 31 March 2022 and 2021 have been estimated with reference to the valuations carried out by Asset Appraisal Limited, an independent professional valuer using sales comparison approach. In the sales comparison approach, value is estimated for the assets appraised through analysis of market price information of comparable club debenture with reference to the prices quoted in the second hand market. There were no changes in valuation technique during the reporting periods.

For the year ended 31 March 2022

#### 35. FINANCIAL RISK MANAGEMENT

The Group's activities expose it to a variety of financial risks which comprise credit risk, market risk (including interest rate risk and foreign currency risk), and liquidity risk. The Group's overall risk management focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Group's financial performance. Risk management is carried out by key management under the policies approved by the board of directors. The Group does not have written risk management policies. However, the directors of the Company identify and evaluate risks regularly and formulate strategies to manage financial risks.

Generally, the Group employs a conservative strategy regarding its financial risk management. As the directors consider that the Group's exposure to financial risk is kept at a minimum level, the Group has not used any derivatives or other instruments for hedging purposes. The most significant risks to which the Group is exposed to are described below:

## (a) Credit risk

Credit risk of the Group mainly arises from bank balances and trade and other receivables and deposits. The carrying amounts of these balances on the consolidated statement of financial position represent the Group's maximum exposure to credit risk in relation to its financial assets. Management has a credit policy in place and the exposures to credit risk are monitored on an ongoing basis.

In respect of trade and other receivables and deposits, it is the Group's policy to deal only with creditworthy counterparties. In order to minimise credit risk, management has formulated a credit policy and delegated a team responsible for determination of credit limits, credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debts. Normally, the Group does not obtain collateral from the counterparties. Also, management reviews regularly the recoverable amount of trade and other receivables and deposits to ensure that adequate impairment provision is made for irrecoverable amount.

The Group measures loss allowances for trade receivables at an amount equal to lifetime ECLs, which is calculated individually or collectively using a provision matrix by reference to previous default experience of the debtor and current market condition in relation to each debtor's exposure and time value of money where appropriate. The ECLs also incorporate forward looking information with reference to general macroeconomic conditions that may affect the ability of the debtors to settle the trade receivables. The following table provides information about the Group's exposure to credit risk and ECLs for trade receivables as at 31 March 2022 and 2021:

	Expected loss rate (%)	Gross carrying amount HK\$'000	Loss allowance HK\$'000
Trade receivables subject to collective assessment			
Not yet past due	0.23%	8,146	19
Past due for less than 30 days	0.42%	1,896	8
Past due for 30 days or more but less than 60 days	0.46%	1,954	9
Past due for 60 days or more but less than 90 days	0.64%	2,830	18
Past due for 90 days or more but less than 365 days	2.31%	2,598	60
Trade receivables subject to individual assessment	100%	1,418	1,418
At 31 March 2022	_	18,842	1,532

For the year ended 31 March 2022

# 35. FINANCIAL RISK MANAGEMENT (Continued)

## (a) Credit risk (Continued)

		Gross	
	Expected	carrying	Loss
	loss rate	amount	allowance
	(%)	HK\$'000	HK\$'000
Trade receivables subject to collective assessment			
Not yet past due	0.15%	5,964	9
Past due for less than 30 days	0.34%	872	3
Past due for 30 days or more but less than 60 days	0.49%	410	2
Past due for 60 days or more but less than 90 days	0.87%	231	2
Past due for 90 days or more but less than 365 days	3.91%	281	11
Trade receivables subject to individual assessment	100%	1,418	1,418
At 31 March 2021	_	9,176	1,445

Receivables that were not yet past due related to a range of customers for whom there was no recent history of default. Receivables that were past due related to customers with long business relationship and have good settlement record with the Group. Based on past experience, management believes that there has not been a significant change in their credit quality since inception.

The movements in loss allowance of trade receivables during the years ended 31 March 2022 and 2021 are as follows:

	2022 HK\$'000	2021 HK\$'000
As at 1 April Provision/(Reversal) of allowance for impairment	1,445 87	1,473 (28)
As at 31 March	1,532	1,445

In respect of other receivables and deposits, the balances are considered to have low credit risk as the counterparties have a low risk of default and does not have any past due amounts. Loss allowance for these balances is measured at an amount equal to 12-month ECLs. No loss allowance was recognised as the amount of ECLs for these balances is insignificant.

In respect of bank balances, the credit risk is limited because deposits are placed with reputable banks with high quality external credit ratings. There was no recent history of default of cash and cash equivalents from such financial institutions.

For the year ended 31 March 2022

### 35. FINANCIAL RISK MANAGEMENT (Continued)

#### (a) Credit risk (Continued)

The credit policies have been consistently applied and are considered to be effective in limiting the Group's exposure to credit risk to a desirable level.

The Group had concentration of credit risk as approximately 39% (2021: 26%) of the Group's total year end trade receivables was due from the Group's two largest debtors (2021: one) as at 31 March 2022. The directors of the Company considered that the receivable balance from these customers do not represent a significant credit risk based on past collection experience and no actual loss has incurred against trade receivables due from these customers. Other than that, the Group has no other significant concentration of credit risk.

### (b) Interest rate risk

Interest rate risk relates to the risk that the fair value or cash flows of a financial instrument will fluctuate because of changes in market interest rate. The Group's interest rate risk mainly arises from bank deposits.

The Group's bank balances expose it to cash flow interest rate risk due to the fluctuation of the prevailing market interest rate on bank balances. The directors consider that the Group's exposure to interest rate risk in respect of bank balances is not significant due to low level of deposit interest rate.

### (c) Foreign currency risk

Foreign currency risk refers to the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

The functional currencies of the Company and its subsidiaries are mainly HK\$. The Group operates in Hong Kong with certain of its business transactions being settled in HK\$, US\$ and EURO ("EUR"). The Group is thus exposed to currency risk arising from fluctuation in exchange rates of foreign currencies, primarily US\$ and EUR against the functional currencies of the relevant group entities.

Management monitors foreign currency exposure of the Group and will consider undertaking foreign exchange hedging activities to reduce the impact of foreign exchange rate movements on the Group's operating result.

The net carrying amounts of the Group's major financial assets and financial liabilities denominated in a currency other than the functional currencies of the group entities in net position as at 31 March 2022 and 2021 are as follows:

	2022	2021
	HK\$'000	HK\$'000
Net monetary assets		
EUR	3,166	3,170
US\$	13,077	18,192

For the year ended 31 March 2022

## 35. FINANCIAL RISK MANAGEMENT (Continued)

## (c) Foreign currency risk (Continued)

#### Sensitivity analysis

As HK\$ is pegged to US\$, exposure in respect of US\$ is considered insignificant. The following table illustrates the approximate change in the Group's profit for the year and retained earnings in response to reasonably possible changes in the foreign exchange rates to which the Group has significant exposure, i.e. EUR at the end of the reporting period.

	-	Increase in profit for the year and retained earnings		
	Year ended 31 March			
	2022 HK\$'000	2021 HK\$'000		
EUR appreciated by 5%	132	132		

The changes in exchange rates do not affect the Group's other component of equity. The same percentage depreciation in the foreign currencies against the functional currency of the respective group entities would have the same magnitude on profit for the year and retained earnings but of opposite effect.

The sensitivity analysis has been determined assuming that the change in foreign exchange rates had occurred at the end of the reporting periods and had been applied to each of the group entities; exposure to currency risk for financial instruments in existence at that date, and that all other variables, in particular interest rates, remain constant. The stated changes represent management's assessment of reasonably possible changes in foreign exchange rates over the period until the next annual reporting date.

In management's opinion, the sensitivity analysis is unrepresentative of the inherent foreign exchange risk because exposure at the end of the reporting period does not reflect the exposure during the respective periods.

## (d) Liquidity risk

Liquidity risk relates to the risk that the Group will not be able to meet its obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Group is exposed to liquidity risk in respect of settlement of trade and other payables, lease liabilities and its financing obligations, and also in respect of its cash flow management. The Group's policy is to regularly monitor its liquidity requirements to ensure that it maintains sufficient reserves of cash and adequate committed lines of funding from major financial institutions to meet its liquidity requirements in the short and longer term. The liquidity policy has been followed by the Group since prior years and is considered to have been effective in managing liquidity risks.

For the year ended 31 March 2022

# 35. FINANCIAL RISK MANAGEMENT (Continued)

## (d) Liquidity risk (Continued)

The following tables summarise the remaining contractual maturities of the Group's financial liabilities, based on undiscounted cash flows (including interest payments computed using contractual rates or if floating, based on rates ruling at the end of the reporting period) and the earliest date the Group can be required to pay.

	Carrying amount	Total contractual undiscounted cash flow	Within 1 year or on demand	After 1 year but within 2 years	After 2 years but within 5 years
	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
At 31 March 2022 Trade and other payables	11,380	11,380	11,380	<del>-</del>	<u>-</u>
Lease liabilities	4,481	4,600	2,483	1,694	423
	15,861	15,980	13,863	1,694	423
At 31 March 2021					
Trade and other payables	12,520	12,520	12,520	_	_
Lease liabilities	4,872	4,976	3,548	1,428	
	17,392	17,496	16,068	1,428	

### **36. GUARANTEES**

The Group provided guarantees in respect of the surety bonds issued by a bank in favour of the customers of certain tender contracts. Details of these guarantees as of the end of each of the reporting period are as follows:

	2022 HK\$'000	2021 HK\$'000
Aggregate value of the surety bonds issued in favour of customers	1,084	1,165

The surety bonds are required for the entire period of the relevant tender contracts. As at 31 March 2022, the respective tender contracts are expected to be completed in year 2024 (2021: year 2024).

As assessed by the directors, it is highly not probable that the bank would claim the Group for losses in respect of the guarantee contracts as it is highly unlikely that the Group is unable to fulfill the performance requirements of the relevant contracts. Accordingly, the management did not expect these guarantees to have significant impact on the financial statements.

For the year ended 31 March 2022

### 37. EVENTS AFTER THE REPORTING DATE

The Hong Kong Legislative Council has, on 9 June 2022, passed the Employment and Retirement Schemes Legislation (Offsetting Arrangement) (Amendment) Bill 2022 (the "Bill") to abolish the MPF offsetting mechanism. It is envisaged that the cancellation of mechanism will not come into effect until 2025 at the earliest.

The abolishment of the MPF offsetting mechanism will not have retrospective effect, and the Bill will not change the rate and maximum payment of statutory severance payments or long service payments, which is currently calculated as 2/3 of the employee's last monthly wages (capped at HK\$22,500), and subject to the maximum limit of HK\$390,000.

The Group has already commenced an assessment of the impact of the Bill to the Group. The Group is not yet in a position to state whether the abolishment of the MPF offsetting mechanism will result in substantial change to the Group's financial statements.

# **FINANCIAL SUMMARY**

The consolidated results, assets and liabilities of the Group for last five financial years as extracted from the financial statements of the Groups are summarised below:

# **RESULTS**

	Year ended 31 March				
	2022 HK\$'000	2021 HK\$'000	2020 HK\$'000	2019 HK\$'000	2018 HK\$'000
Revenue	71,978	70,241	67,227	58,045	53,703
Profit/(Loss) before income tax Income tax expense	5,478 (1,430)	9,357 (1,498)	11,903 (2,337)	8,246 (1,638)	(447) (2,633)
Profit/(Loss) for the year attributable to owners of the Company	4,048	7,859	9,566	6,608	(3,080)
Total comprehensive income attributable to		,	,	0,000	
owners of the Company	4,048	7,859	9,566	6,608	(3,100)

# **ASSETS AND LIABILITIES**

		As at 31 March			
	2022 HK\$'000	2021 HK\$'000	2020 HK\$'000	2019 HK\$'000	2018 HK\$'000
Total assets	110,324	112,010	104,887	91,188	88,645
Total liabilities	16,815	18,958	16,405	10,076	14,054
Total equity	93,509	93,052	88,482	81,112	74,591